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1. INTRODUCTION 
ATHEROSCLEROSIS AND HYPERLIPIDEMIA1-3 
Atherosclerosis, a disease which affects large and medium size arteries, is 
now a leading cause of death in many developed countries. The lesion 
characteristic of atherosclerosis is a localised plaque in the intima and is 
composed of cholesterol esters, proliferation of smooth muscle, deposition of 
fibrous proteins and calcification. Such plaques; 
 Narrow the arterial lumen causing distal ischemia. 
 Ulcerate in to the arterial lumen, with thrombosis of artery and 
distal  
      embolization; or 
 Weaken the arterial wall, leading to formation of aneurysms. 
The cause of atherosclerosis is not known although several factors have been 
blamed in the pathogenesis of atherosclerosis. A lot of experimental and 
epidemiological evidence suggests a relationship between atherosclerosis 
and elevated level of plasma lipid. 
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Table 1.1 Serum lipid levels (mg/dl) and associated risk of Ischemic 
heart disease 
                     Serum lipid levels (mg/dl) and the risk of IHD* 
          Lipid      Desirable 
level 
       (Low risk) 
Borderline level 
(Moderate risk) 
Abnormal level 
(High risk) 
Total 
cholesterol 
LDL cholesterol  
HDL cholesterol 
Triglycerides  
      < 200 
      <130 
       >60 
       <200 
     200-240 
      130-160 
       40-60 
       200-400 
     >240 
     >160 
      <40 
      >400 
* The risk increases further with other risk factors such as smoking, diabetes 
and hypertension 
 In the management of hyperliproteinemia, weight reduction, appropriate 
modification of diet, abstinence from alcohol, and specific treatment of 
causative disease, if any such as hypothyroidism and diabetes mellitus, are 
much more important than lipid-lowering drugs. 
Drug therapy is indicated in those: 
 In whom the dietary measures are not successful. 
 Who find the dietary restrictions irksome; and  
 Who are at high risk of pancreatitis. 
The main classes of drug used clinically are:  
 Statins: HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A)          
                   reductase inhibitors 
 Fibrates 
 Bile acid binding resins.     
Chapter-1                                                                                                      Introduction                           
                                                                                                     
Dept. of Pharmaceutical Science, Saurashtra University, Rajkot, Gujarat.   3 
Statins: HMG-CoA reductase inhibitors 
 Lovastatin (Mevacor , AltocorTm ); lovastatin extended release (Atoprev) 
 Simvastatin (Zocor); simvastatin + ezetimibe (vytorin) 
 Pravastatin (Pravachol) 
 Fluvastatin (Lescol, Lescol XL)  
 Atorvastatin (Lipitor)  
 Rosuvastatin (Crestor) 
Mechanism of action of Statins 
 
Fig. 1.1 Hypercholesterolemia favors entry of LDL particles into 
subendothelial space at lesion-prone arterial sites. Monocyte chemotactic 
protein-1 (MCP-1) and oxidized-LDL act as chemoattractants to direct 
accumulation of monocytes and their migration to the subendothelial space, 
where monocytes undergo phenotypic transformation into 
macrophages. Concurrently, oxigen free radicals modify LDL. Oxidatively 
modified LDL is taken up by nondownregulating macrophage receptors to 
form lipid-rich foam cells. Foam cells develop into fatty streaks, precursor of 
atherosclerotic plaques. Statins exihibit pleiotropic effects on many 
components of atherosclerosis that accompany hypercholesterolemia, 
including platelet coagulation abnormalities, abnormal endothelial function, 
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and determinants of plaque thrombogenicity such as plaque inflammation and 
proliferation13. 
Major Secondary Prevention Trials with Statins1, 4: 
1. Scandinavian simvastatin survival study (4S) 
2. cholesterol and Recurrent Events (CARE) 
3. Long-Term Intervention with Pravastatin in Ischemic Disease 
(LIPID) 
Because patients with established CHD are at very high risk of recurrent 
CHD, the following studies (Table No. 1.2) demonstrate the reduction in 
cardiovascular morbidity and mortality and total mortality. 
Table 1.2 Major Secondary Prevention Trials with Statins4: 
stud
y 
perso
ns 
durati
on 
Statin 
(dose/
day) 
Baselin
e 
LDL-C 
(mg/dl) 
LDL-
C 
chang
e 
Major  
Coron
ary 
Event
s 
Coron
ary 
Mortal
ity 
Total 
Mortal
ity 
stroke 
4S 4444 5.4 
yrs 
Simva
statin 
10/40 
mg 
188 -35% -35% -42% -30% -27% 
CA
RE 
4159 5 yrs Prava
statin 
40 mg 
139 -27% -25% -24% -9% -31% 
LIPI
D 
9014 5 yrs Prava
statin  
40 mg 
150 -25% -29% -24% -23% -19% 
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4.   The heart protection study4  
This study showed that simvastatin (40 mg daily) improved outcome in 
a     broadly defined high-risk population, including people with normal/low 
plasma LDL cholesterol, and that simvastatin was extremely safe. 
                           Lovastatin and simvastatin are members of new class of drug used in 
the treatment of hypercholesterolemia. Being prodrugs, they hydrolyze in vivo 
to their corresponding -hydroxyacids which are potent inhibitor of HMG-CoA 
reductase and, thus, of de novo cholesterol synthesis. As the primary site of 
cholesterol synthesis and regulation, the liver is the target organ for HMG-
CoA reductase inhibitors. Lovastatin and simvastatin were more efficiently 
extracted by the liver, which is the target organ for both compounds, than their 
corresponding - hydroxyacids with subsequent minimization of systemic 
burden. These suggest that, compared to a conventional dosage form, a 
sustained/controlled-release dosage form of lovastatin and simvastatin might 
provide similar or better efficacy. 5-7 
 All statins, acts in the liver to demonstrate its lipid-lowering action. It is 
also noteworthy that plasma concentrations of atorvastatin acid and its 
metabolites do not correlate with the reduction in LDL cholesterol, indicating 
that there is a poor pharmacokinetic–pharmacodynamic relationship. This 
issue has adequately been discussed by Lennernas7. Therefore, to improve 
the therapeutic efficacy of atorvastatin, it is imperative that the effective 
concentration of atorvastatin be increased in the liver instead of the plasma. 
Thus, in the case of atorvastatin, increase in the bioavailability does not 
guarantee improved pharmacodynamics or therapeutic efficacy. Finally, the 
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ideal delivery strategy for Atorvastatin would be one that would decrease its 
intestinal and hepatic metabolism and improve its targeting to liver8. 
      An ideal dosing scheme would provide therapeutic levels of inhibitor to the 
liver at a rate that result in a hepatic extraction ratio approaching unity, there 
by minimizing the systemic HMG-CoA reductase levels. In practice, this may 
be accomplished by a portal drug infusion. 
         Hence in the present work, a multi-unit granular dosage form is 
prepared in the form of capsule, containing swellable hydrogel forming 
polymer and gas forming agent to float and retard the drug release from the 
formulation, floating bioadhesive tablet, high density tablet and mucoadhesive 
tablet. 
1.1 Modified Release Oral Drug Delivery Systems  
 The oral route represents nowadays the predominant and most 
preferable route for drug delivery. Unlike the majority of parentral dosage 
forms, it allows ease of administration by the patient and it’s the natural, and 
therefore a highly convenient way for substances to be introduced into the 
human body.  
Oral drug delivery systems (DDS) are divided into immediate release and 
modified release systems. Immediate release DDS are intended to 
disintegrate rapidly, and exhibit instant drug release. They are associated with 
a fast increase and decrease, and hence fluctuations in drug plasma levels, 
which leads to reduction or loss in drug effectiveness or increased incidence 
of side effects. Administration of the DDS several times per day is therefore 
necessary to compensate the decrease in drug plasma concentration due to 
metabolism and excretion.  
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Modified release systems, on the other hand, have been developed to 
improve the pharmacokinetic profiles of active pharmaceutical ingredients 
(APIs) and patient compliance, as well as reducing side effects12. Oral 
modified release delivery systems are most commonly used for  
 1) Delayed release (e.g., by using an enteric coating) 
  2) Extended release (e.g., zero-order, first-order, biphasic release, etc.)  
 3) Programmed release (e.g., pulsatile, triggered, etc.) and 
  4) Site specific or timed release (e.g., for colonic delivery or gastric 
retention). Extended, sustained or prolonged release drug delivery systems 
are terms used synonymously to describe this group of controlled drug 
delivery devices, with predictability and reproducibility in the drug release 
kinetics13. Delayed release dosage forms are distinguished from the ones 
mentioned above as they exhibit a pronounced lag time before the drug is 
released. Oral extended release dosage forms offer the opportunity to provide 
constant or nearly constant drug plasma levels over an extended period of 
time following administration. Extended release DDS include single-unit, such 
as tablets or capsules, and multiple-unit dosage forms, such as minitablets, 
pellets, beads or granules, either as coated (reservoir) or matrix devices14.  
 Extended release DDS offer several advantages compared to 
conventional DDS15 including:  
I. Avoiding drug level fluctuations by maintenance of optimal therapeutic 
plasma and tissue concentrations over prolonged time periods, avoiding sub-
therapeutic as well as toxic concentrations, thus minimizing the risk of failure 
of the medical treatment and undesirable side effects;  
II. Reducing the administered dose while achieving comparable effects;  
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III. Reduced frequency of administration leading to improved patients’ 
compliance and subsequently improved efficacy of the therapy and cost 
effectiveness;  
IV. Targeting or timing of the drug action. Hence, it is highly desirable to 
develop sustained DDS releasing the drug at predetermined rates to achieve 
optimal drug levels at the site of action.  
 On the other hand, drugs administered as sustained or extended 
release oral dosage form should comply with the following parameters:  
I. Maintain a constant plasma level over prolonged time periods;  
II. Have a broad therapeutic window to avoid health hazard to the patient in 
case of undesirable burst release of the nominal dose16.  
The maximum achievable sustained drug release is subject to inter individual 
variations, with an average gastrointestinal (GI) transit time of around 24 h in 
humans (Davis et al., 1984). The transit time is affected by age, gender, body 
mass index and the state of health of the individual as well as his emotional 
state and composition of meals. In addition, drugs affecting gastric motility, 
such as opioid analgesics or metoclopramide, have to be taken into account.  
 Numerous oral sustained drug delivery systems have been developed 
to prolong drug release. The key point in this respect is that the API has to be 
absorbed well throughout the whole gastrointestinal tract (GIT). Generally, the 
absorption of APIs from oral DDS is precluded by several physiological 
difficulties, such as inability to restrain and localize the drug delivery system 
within desired regions of the GIT and the high variable nature of gastric 
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emptying process (Rouge et al., 1996). The gastric emptying process can 
vary from a few minutes to 12 h, depending upon the physiological state of the 
subject and the design of pharmaceutical formulation. This variation, may lead 
to unpredictable bioavailability and times to achieve peak plasma levels, since 
the majority of drugs are preferentially absorbed in the upper part of the small 
intestine (Rouge et al., 1996). In addition, the relatively brief gastric emptying 
time in humans, through the stomach or upper part of the intestine (major 
absorption zone), can result in incomplete drug release from the DDS leading 
to diminished efficacy of the administered dose.  
1.1.1 Gastroretentive Dosage Form (GRDF): 17-19 
Several difficulties are faced in designing controlled release systems 
for better absorption and enhanced bioavailability. One of such difficulties is 
the inability to confine the dosage form in the desired area of the 
gastrointestinal tract. Gastroretentive systems can remain in the gastric region 
for several hours and hence significantly prolong the gastric residence time of 
drugs. Prolonged gastric retention improves bioavailability, reduces drug 
wastage, and improves solubility for drugs that are less soluble in a high pH 
environment.  
 GRDF extend significantly the duration of time over which the drugs may be 
released. They not only prolong dosing intervals, but also increase patient 
compliance beyond the level of existing controlled release dosage form. 
Conventional oral controlled dosage forms suffer from mainly two adversities. 
The short gastric retention time (GRT) and unpredictable gastric emptying 
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time (GET), so GRT and GET are important considerations to formulate a 
controlled release dosage form having required extended GI residence time 
             Dosage form with prolonged GRT, i.e. gastro retentive dosage forms 
(GRDF), will bring about new and important therapeutic options such as10–  
1)  This application is especially effective in sparingly soluble and insoluble 
drugs. It is known that, as the solubility of a drug decreases, the time 
available for drug dissolution becomes less adequate and thus the 
transit time becomes a significant factor affecting drug absorption. To 
overcome this problem, erodible, gastro-retentive dosage forms have 
been developed that provide continuous, controlled administration of 
sparingly soluble drugs at the absorption site.  
2)  GRDF greatly improves the pharmacotherapy of the stomach through 
local drug release, leading to high drug concentration at the gastric 
mucosa. (e.g. Eradicating Helicobacter pylori from the submucosal 
tissue of stomach) making it possible to treat gastric and duodenal 
ulcers, gastritis and oesophagitis, reduce the risk of gastric carcinoma 
and administer non-systemic controlled release antacid formulations 
(calcium carbonate).  
3)  GRDF can be used as carriers for drugs with so-called absorption 
windows. These substances for instance antiviral, antifungal and 
antibiotic agents (sulphonamides, quinolones, penicillins, 
cephalosporins, aminoglycosides, tetracyclines etc.), are absorbed only 
from very specific sites of the GI mucosa.  
 The design of oral control drug delivery systems (DDS) should be 
primarily aimed to achieve more predictable and increased bioavailability. The 
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ideal system should have advantage of single dose for the whole duration of 
treatment and it should deliver the active drug directly at the specific site. 
Control release implies the predictability and reproducibility to control the drug 
release, drug concentration in target tissue and optimization of the therapeutic 
effect of a drug by controlling its release in the body with lower and less 
frequent dose. Under certain circumstances prolonging the gastric retention of 
a delivery system is desirable for achieving greater therapeutic benefit of the 
drug substances. For example, drugs that are absorbed in the proximal part of 
the gastrointestinal tract, and the drugs that are less soluble or are degraded 
by the alkaline pH may benefit from the prolong gastric retention. In addition, 
for local and sustained drug delivery to the stomach and the proximal small 
intestine to treat certain conditions, prolonging gastric retention of the 
therapeutic moiety may offer numerous advantages including improved 
bioavailibility, therapeutic efficacy and possible reduction of the dose size. It 
has been suggested that prolong local availability of antibacterial agents may 
augment their effectiveness in treating H.Pylori related peptic ulcers. 
Gastroretentive Drug delivery systems (GRDDS) 16-19, however are not 
suitable for drugs that may cause gastric lesions, e.g., Nonsteroidal anti-
inflammatory agents. 
1.1.2 Basic physiology of the gastrointestinal tract 
 The complex anatomy and physiology of the GIT, including variations 
in acidity, bile salts, enzyme content, and the mucosal absorptive surface, 
significantly influence the release, dissolution, and absorption of orally 
administered dosage forms. Two distinct patterns of gastrointestinal (GI) 
motility and secretion exist, corresponding to the fasted and fed states. As a 
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result, the BA of orally administered drugs will vary depending on the state of 
feeding. The fasted state is associated with various cyclic events, commonly 
referred to as the migrating motor complex (MMC), which regulates GI motility 
patterns. The MMC is organized into alternating cycles of activity and 
quiescence and can be subdivided into basal (Phase I), preburst (Phase II), 
and burst (Phase III) intervals (Figure 1.1) 1. Phase I, the quiescent period, 
lasts from 30 to 60 min and is characterized by a lack of secretory, electrical, 
and contractile activity. Phase II exhibits intermittent action for 20–40 min 
during which contractile motions increase in frequency and size. Bile enters 
the duodenum during this phase, whereas gastric mucus discharge occurs 
during the latter part of Phase II and throughout Phase III. Phase III is 
characterized by intense, large, and regular contractions, termed 
housekeeper waves, that sweep off undigested food and last 10–20 min. 
Phase IV is the transition period of 0–5 min between Phases III and I. This 
series of electrical events originates in the foregut and continues to the 
terminal ileum in the fasted state, repeating every 2–3 hrs. Feeding sets off a 
continuous pattern of spike potentials and contractions called postprandial 
motility. 
 
Figure 1.2 Motility patterns of the GIT in fasted state 
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 The particular phase during which a dosage form is administered 
influences the performance of peroral CRDDS and GRDDS. When CRDDS 
are administered in the fasted state, the MMC may be in any of its phases, 
which can significantly influence the total gastric residence time (GRT) and 
transit time in the GIT. This assumes even more significance for drugs that 
have an absorption window because it will affect the amount of time the 
dosage form spends in the region preceding and around the window. The less 
time spent in that region, the lower the degree of absorption. Therefore, the 
design of GRDDS should take into consideration the resistance of the dosage 
form to gastric emptying during Phase III of the MMC in the fasted state and 
also to continuous gastric emptying through the pyloric sphincter in the fed 
state. This means that GRDDS must be functional quickly after administration 
and able to resist the onslaught of physiological events for the required period 
of time. 
1.1.3 Gastric emptying and problems 
It is well recognized that the stomach may be used as a depot for Sustained 
release dosage forms, both in human and veterinary applications, stomach is 
anatomically divided in to three parts: Fundus, body and pylorus. The 
proximal stomach made up of the fundus and body region serves as a 
reservoir for ingested materials, while the distal region (antrum) is the major 
site for the mixing motion, acting as a pump to accomplish gastric emptying. 
The process of the gastric emptying occurs both during fasting and fed 
stages. Scintigraphy study involving measurement of gastric emptying rates in 
healthy human subject have revealed that an orally administered Controlled 
release dosage form is mainly subjected to two physiological adversities, 
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a) The short GRT (Gastric Residence Time) 
b) Variable (unpredictable) GET (Gastric Emptying Time) 
Yet another major adversity encountered through the oral route is the first 
pass effect, which leads to reduce systematic availability of a large number of 
a drug. These problems can be exacerbated by alteration in the gastric 
emptying that occur due to factors such as age, race, sex and disease states, 
as they may seriously affect the release of a drug from DDS. It is therefore 
desirable to have a controlled release product that exhibits an extended, GI 
residence and a drug release profile independent of patients’ related 
variables. 
1.1.4 Potential drug candidates for stomach specific drug delivery 
systems 
1. Drugs those are locally active in the stomach e.g. misroprostol, antacids 
 etc. 
2. Drugs that have narrow absorption window in gastrointestinal tract (GIT) 
 e.g. L-dopa, para amino benzoic acid, furosemide, riboflavin etc.  
3. Drugs those are unstable in the intestinal or colonic environment e.g. 
 captopril, ranitidine HCl, metronidazole. 
4. Drugs that disturb normal colonic microbes e.g. antibiotics against 
 Helicobacter  pylori. 
5. Drugs that exhibit low solubility at high pH values e.g. diazepam, 
 chlordiazepoxide, verapamil HCl. 
1.1.5 Drugs those are unsuitable for stomach specific drug delivery 
systems 
1. Drugs that have very limited acid solubility e.g. phenytoin etc. 
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2. Drugs that suffer instability in the gastric environment e.g. erythromycin etc. 
3. Drugs intended for selective release in the colon e.g. 5- amino salicylic 
 acid,  corticosteroids etc. 
2. APPROACHES TO GASTRIC RETENTION or MECHANISTIC ASPECTS 
OF GRDFS 17- 29 
A number of approaches have been used to increase the GRT of a 
dosage form in stomach by employing a variety of concepts. These include – 
Single-unit dosage forms 
a) Floating Systems30 
Floating Drug Delivery Systems (FDDS) have a bulk density lower than 
gastric fluids and thus remain buoyant in the stomach for a prolonged period 
of time, without affecting the gastric emptying rate. While the system is 
floating on the gastric contents, the drug is released slowly at a desired rate 
from the system.  
b) High Density Systems 31, 32  
These systems with a density of about 3 g/cm3 are retained in the 
rugae of the stomach and are capable of withstanding its peristaltic 
movements. A density of 2.6-2.8 g/cm3 acts as a threshold value after which 
such systems can be retained in the lower part of the stomach.  
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Fig 1.3 Intragastric residence positions of floating and nonfloating units. 
. 
c) Bio/Muco-adhesive Systems: 33-36 
Bio/muco-adhesive systems are those which bind to the gastric 
epithelial cell surface or mucin and serve as a potential means of extending 
the GRT of drug delivery system (DDS) in the stomach, by increasing the 
intimacy and duration of contact of drug with the biological membrane.   
d) Swelling and Expanding Systems 37, 38 
These are the dosage forms, which after swallowing; swell to an extent 
that prevents their exit from the pylorus.  These systems may be named as 
“plug type system”, since they exhibit the tendency to remain logged at the 
pyloric sphincter if that exceed a diameter of approximately 12-18 mm in their 
expanded state.  
e) Incorporation of Passage Delaying Food Agents 39-42 
Food excipients like fatty acids e.g. salts of myristic acid change and 
modify the pattern of the stomach to a fed state, thereby decreasing gastric 
emptying rate and permitting considerable prolongation of release. The delay 
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in the gastric emptying after meals rich in fat is largely caused by saturated 
fatty acids with chain length of C10-C14. 
f) Ion-Exchange Resins 43 
Ion exchange resins are loaded with bicarbonate and a negatively 
charged drug is bound to the resin. The resultant beads were then 
encapsulated in a semi-permeable membrane to overcome the rapid loss of 
carbon dioxide. Upon arrival in the acidic environment of the stomach, an 
exchange of chloride and bicarbonate ions take place. As a result of this 
reaction carbon dioxide was released and trapped in the membrane thereby 
carrying beads towards the top of gastric content and producing a floating 
layer of resin beads in contrast to the uncoated beads, which will sink quickly. 
g) Osmotic Regulated Systems 44, 45 
It is comprised of an osmotic pressure controlled drug delivery device 
and an inflatable floating support in a bio-erodible capsule. In the stomach the 
capsule quickly disintegrates to release the intra-gastric osmotically controlled 
drug delivery device. The inflatable supports inside forms a deformable hollow 
polymeric bag that contains a liquid that gasify at body temperature to inflate 
the bag. The osmotic controlled drug delivery device consists of two 
components – drug reservoir compartment and osmotically active 
compartment. 
h) pH-Independent formulation 44 
             Most drugs are either weak acids or weak basics and hence pH 
dependent release is observed in body fluids. However buffers can be added 
to such formulations to help in maintaining a constant microenvironmental pH 
to obtain pH independent drug release. 
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g) Fluid filled floating chamber19 
  These are the dosage forms includes incorporation of a gas-filled 
floation chamber into a microporous component that houses a drug reservoir. 
Apertures or openings are present along the top and bottom walls through 
which the gastrointestinal tract fluid enters to dissolve the drug. The other two 
walls in contact with the fluid are sealed so that the undissolved drug remains 
therein. 
h) Multiple-unit dosage forms46.47 
  The purpose of designing multiple-unit dosage form is to develop a 
reliable formulation that has all the advantages of a single-unit form and also 
is devoid of the above mentioned disadvantages of single-unit formulations. 
Microspheres have high loading capacity and many polymers have been used 
such as albumin, gelatine, polymethecrylate, polyacrylamine. Spherical 
polymeric microsponges, also referred to as “microballoons” have been 
prepared. 
2.1 INTRODUCTION TO STOMACH SPCIFIC DOSAGE FORM 48-51 
The floating drug delivery system (FDDS) also called Hydrodynamically 
Balanced Drug Delivery System (HBS) 51. FDDS is an oral dosage forms 
(capsule or tablet) designed to prolong the residence time of the dosage form 
within the GIT. It is a formulation of a drug with gel forming hydrocolloids 
meant to remain buoyant on stomach contents. Drug dissolution and release 
from dosage retained in the stomach fluids occur at the pH of the stomach 
under fairly controlled condition. 
The formulation of the dosage form must comply with major criteria for HBS, 
like 
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1) It must have sufficient structure to form a cohesive gel barrier. 
2) It must maintain an overall specific gravity less than that of gastric 
content. 
 3)  It should dissolve slowly enough to serve as a ‘Reservoir’ for the   
delivery system. 
TYPES OF FLOATING DRUG DELIVERY SYSTEMS (FDDS) 
Based on the mechanism of buoyancy, two distinctly different 
technologies have been utilized in development of FDDS, which are 17,18, 23 
A. Effervescent System, and 
B. Non- Effervescent System. 
A.  EFFERVESCENT SYSTEM:  
 These are the matrix types of systems prepared with the help of 
swellable polymers such as methylcellulose and chitosan and various 
effervescent compounds, eg, sodium bicarbonate, tartaric acid, and citric acid. 
They are formulated in such a way that when in contact with the acidic gastric 
contents, CO2 is liberated and entrapped in swollen hydrocolloids, which 
provides buoyancy to the dosage forms.   
I. Gas Generating systems  
II. Volatile Liquid/Vacuum Containing Systems. 
I. Gas – Generating Systems: 13 
1. Intra Gastric Single Layer Floating Tablets or Hydrodynamically 
Balanced Sysem (HBS) 44, 49 
 These are formulated by intimately mixing the CO2 generating agents 
and the drug within the matrix tablet.   These have a bulk density lower than 
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gastric fluids and therefore remain floating in the stomach for a prolonged 
period.  
 
Fig. 1.4 IntraGastric Single Layer Floating Tablet. 
 
2.  Intra Gastric Bi-layer Floating Tablets 52 
      These are also compressed tablet containing two layers i.e. 
i. Immediate release layer and  
ii. Sustained release layer.  
These are as formulated by intimately mixing the CO2 generating agents and 
the drug within the matrix tablet.  
3. Multiple Unit type floating pills 22-24 
 The system consists of sustained release pills as ‘seeds’ surrounded 
by double layers. The inner layer consists of effervescent agents while the 
outer layer is of swellable membrane layer. When the system is immersed in 
dissolution medium at body temp, it sinks at once and then forms swollen pills 
like balloons, which float as they have lower density. This lower density is due 
to generation and entrapment of CO2 within the system.  
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Fig.1.5 (a) A multi-unit oral floating dosage system. (b) Stages of floating 
mechanism: (A) penetration of water; (B) generation of CO2 and 
floating; (C) dissolution of drug. Key: (a) conventional SR pills; (b) 
effervescent layer; (c) swellable layer; (d) expanded swellable 
membrane layer; (e) surface of water in the beaker (370C). 
II. Volatile Liquid / Vacuum Containing Systems 44, 23 
1. Intra-gastric Floating Gastrointestinal Drug Delivery System: 
 These system can be made to float in the stomach because of 
floatation chamber, which may be a vacuum or filled with air or a harmless 
gas, while drug reservoir is encapsulated inside a micro-porous compartment. 
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Fig. 1.6 Intra Gastric Floating Gastrointestinal Drug Delivery Device 
2. Inflatable Gastrointestinal Delivery Systems: 
In these systems an inflatable chamber is incorporated, which contains 
liquid ether that gasifies at body temperature to cause the chamber to inflate 
in the stomach. These systems are fabricated by loading the inflatable 
chamber with a drug reservoir, which can be a drug impregnated polymeric 
matrix, encapsulated in a gelatin capsule. After oral administration, the 
capsule dissolves to release the drug reservoir together with the inflatable 
chamber. The inflatable chamber automatically inflates and retains the drug 
reservoir compartment in the stomach. The drug continuously released from 
the reservoir into the gastric fluid.  
 
Fig. 1.7 Inflatable Gastrointestinal Delivery System 
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3. Intra-gastric Osmotically Controlled Drug Delivery System:   
 It is comprised of an osmotic pressure controlled drug delivery device 
and an inflatable floating support in a biodegradable capsule. In the stomach, 
the capsule quickly disintegrates to release the intra-gastric osmotically 
controlled drug delivery device. The inflatable support inside forms a 
deformable hollow polymeric bag that contains a liquid that gasifies at body 
temperature to inflate the bag. The osmotic pressure controlled drug delivery 
device consists of two components; drug reservoir compartment and an 
osmotically active compartment.  
 The drug reservoir compartment is enclosed by a pressure responsive 
collapsible bag, which is impermeable to vapour and liquid and has a drug 
delivery orifice. The osmotically active compartment contains an osmotically 
active salt and is enclosed within a semipermeable housing. In the stomach, 
the water in the GI fluid is continuously absorbed through the semipermeable 
membrane into osmotically active compartment to dissolve the osmotically 
active salt. The osmotic pressure thus created acts on the collapsible bag and 
in turn forces the drug reservoir compartment to reduce its volume and 
activate drug release through the delivery orifice.  
 The floating support is also made to contain a bioerodible plug that 
erodes after a predetermined time to deflate the support. The deflated drug 
delivery system is then emptied from the stomach. 
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Fig. 1.8 Intragastric Osmotically Controlled Drug Delivery System 
B. NON EFFERVESCENT SYSTEMS: 
 The Non-effervescent FDDS is based on mechanism of swelling of  
 
 Fig.1.9 Working principle of Non-effervescent type of FDDS    
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polymer or bioadhesion to mucosal layer in GI tract. The most commonly used 
excipients in non-effervescent FDDS are gel forming or highly swellable 
cellulose type hydrocolloids, hydrophilic gums, polysaccharides and matrix 
forming material such as polycarbonate, polyacrylate, polymethacrylate, 
polystyrene as well as bioadhesive polymer such as Chitosan and Carbopol. 
 
ADVANTAGES OF FDDS 13 
Advantages of FDDS can be mainly classified in to four categories. 
A) Sustained drug delivery 
 Administration of a prolonged release floating dosage form will result in 
dissolution in the gastric fluid. The drug solution will also be available 
for absorption from small intestine after gastric emptying. It is therefore 
expected that a drug will be fully absorbed from the floating dosage 
form. 
 Medicaments like aspirin cause irritation to the stomach wall when they 
come into contact with it, hence FDDS are particularly advantageous 
and convenient for the administration of such drug, since they remain 
buoyant in the GI fluid and do not adhere to the walls. 
B) Site specific drug delivery  
 When there is vigorous intestinal movement and a short transit time as 
might occur in certain type of diarrhea, poor absorption is expected 
under such circumstances. It may be advantageous to keep the 
formulation in floating condition in stomach to get a relatively better 
response. 
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 The FDDS are advantageous for drugs absorbed through the stomach 
e.g. ferrous salt and for drugs meant for local action in stomach e.g. 
antacids. 
 FDDS are not restricted to medicament, which are principally absorbed 
from the stomach. Since it has been found that these are equally 
efficacious with medicaments, which are absorb from the intestine e.g. 
Chlorpheniramine maleate. 
C) Pharmacokinetic advantages  
 Maximizing absorption and improving absolute bioavailability of 
delivered drugs, which are absorbed mainly in upper GI tract. 
 
 Site-specific absorption and longer GRT could possibly increase the 
bioavailability of drugs from FDDS e.g. Loop diuretics 
 FDDS can reduce fluctuations in the plasma level of drugs due to 
delayed gastric emptying. 
D) Miscellaneous  
 Ease of administration and better patient compliance. 
 Simple and conventional equipment for manufacture.  
DISADVANTAGES OF FDDS: 
 Gastric retention is influenced by many factors such as gastric motility, 
pH and presence of food. These factors are never constant and hence 
the buoyancy cannot be predicted exactly or accurately. 
 Drugs that cause irritation and lesion to gastric mucosa are not suitable 
to be formulated as floating drug delivery systems. 
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 Gastric emptying of floating forms in supine subjects may occur at 
random and become highly dependent on the diameter. Therefore, 
patients should not be dosed with floating forms just before going to 
bed.  
 High variability in gastric emptying time due to variations in emptying 
process. 
 Drugs such as nifedipine which undergoes first-pass metabolism, may 
not be desirable. 
 Unpredictable bioavailability. 
APPLICATIONS OF FDDS 
 
 Because of the increased GRT, FDDS is beneficial in treatment of 
gastric and duodenal ulcer. 
 Floating granules of Indomethacin are superior to the conventional 
Indomethacin containing dosage form for maintaining desired plasma 
level of drugs. 
 According to recent studies administration of diltiazem floating tablet 
might be more effective compared to conventional tablet in treatment of 
hypertension. 
 Due to prolonged GRT, it is used to eradicate H .pylori, causative 
organism for chronic gastritis and peptic ulcer. 
 FDDS containing 5-fluorouracil is beneficial in treatment of stomach 
neoplasm. 
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 Tacrine, in the form of FDDS, provide better drug delivery system with 
reduced GI side effects in Alzheimer’s patients. 
 Madopar®HBS- containing L-dopa and benserazide here drug is 
released and absorbed over a period of 6-8 hr and maintains 
substantial plasma concentration for Parkinson’s patients. 
 Cytotec®-containing misoprostol, a synthetic prostaglandin-E1 analog, 
for prevention of gastric ulcer caused by non-steroidal antiinflammatory 
drugs (NSAIDS). 
Marketed Products of FDDS: 
Table 1.3 Marketed Products of FDDS 
BRAND NAME DRUG Clinical Importance Dosage form 
Madopar® Levodopa   
Benserazide 
Parkinsonism Capsule 
Cytotec® Misoprostal Gastric ulcer Capsule 
Valrelease® Diazepam Sedative –hypnotic Capsule 
Conviron Ferrous 
sulphate 
Pernicious anaemia Capsule 
Liquid Gavison® Al hydroxide  
 Mg carbonate 
Heart burn Liquid 
alginate 
preparation 
Topalkan® Al-Mg antacid Antacid Liquid 
alginate 
preparation 
Cifran OD® Ciprofloxacin Urinary tract infection Tablet 
Oflin OD® Ofloxacin Genital Urinary, 
respiratory, Gastro-
intestinal infection 
Tablet 
Prolopa® Propranolol Hypertension Tablet 
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BIOADHESIVE OR MUCOADHESIVE DRUG DELIVERY SYSTEMS52: 
Bioadhesive drug delivery systems are used as a delivery device within the 
human to enhance drug absorption in a site-specific manner. In this approach, 
bio adhesive polymers are used and they can adhere to the epithelial surface 
in the stomach. Thus, they improve the prolongation of gastric retention. The 
basis of adhesion in that a dosage form can stick to the mucosal surface by 
different mechanism. 
These mechanisms are: 
1. The wetting theory, which is based on the ability of bioadhesive polymers to 
spread and develop intimate contact with the mucous layers. 
2. The diffusion theory, which proposes physical entanglement of mucin 
strands the flexible polymer chains, or an interpenetration of mucin strands 
into the porous structure of the polymer substrate. 
3. The absorption theory, suggests that bioadhesion is due to secondary 
forces such as Vander Waal forces and hydrogen bonding. 
4. The electron theory, which proposes attractive electrostatic forces between 
the glycoprotein mucin net work and the bio adhesive material. 
Materials commonly used for bioadhesion are poly acrylic acid, chitosan, 
cholestyramine, sodium alginate, hydroxypropyl methylcellulose (HPMC), 
sucralfate, tragacanth, dextrin, polyethylene glycol (PEG) and polylactic acids 
etc. Even though some of these polymers are effective at producing 
bioadhesive, it is very difficult to maintain it effectively because of the rapid 
turnover of mucus in the gastrointestinal tract (GIT). 
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2. OBJECTIVES 
 
Oral administration is the most convenient and preferred means of drug 
delivery to the systemic circulation. In recent years scientific and technological 
advancements have been made in the research and development of rate 
controlled oral drug delivery system by overcoming physiological constituents, 
such as short residence time and unpredictable gastric emptying time.   
 This goal can be achieved by the development of stomach specific 
drug delivery system which increases the gastric residence time. 
OBJECTIVE OF THE STUDY:- 
Following are the objectives of the present study: 
          The primary objective of this study is to formulate and evaluate a 
suitable gastroretentive drug delivery system for a model short half-life 
HMG-CoA reductase inhibitors and comparing the drug release profile for 
prepared different dosage form and for better management of 
hyperlipidaemia. 
 
1. To carry out pre-formulation studies for the possible drug/polymer/ 
excipient interactions by IR/DSC. 
2. To design and develop gastro-retentive dosage forms like Floating 
mucoadhesive tablet, mucoadhesive high density tablet, 
mucoadhesive Floating capsule, mucoadhesive tablets. 
3. Screening of excipients for the envisaged dosage form. 
4. Standardizing the process/formulation parameters to manufacture a 
reproducible dosage form. 
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5. Evaluating its physicochemical parameters and optimization of dosage 
form by following experimental design methodology for statistical 
validation. 
6. To carry out short term stability studies on the optimized formulation as 
per ICH guidelines at 30 ± 20C (65 ± 5 %RH) and 40 ± 20C (75 ± 5 
%RH). 
7. Release profile characterization of the final optimized formulation and 
determine kinetics and mechanism of release. 
8. The pharmacodynamic efficacy of the optimized and stable dosage 
form would be taken up in experimental animal model to establish a 
meaningful In Vitro In Vivo correlation. 
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3. REVIEW OF LITERATURE 
SIMVASTATIN: - 
1. DESCRIPTION: 3-5 
 1.1 Nomenclature: 
 Generic Name         : Simvastastin 
 Chemical Name      : [(1S,3R,7R,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-                                                    
 6-oxo-oxan-2-yl] ethyl]-3-7-dimethyl-1,2,3,7,8, 
                                         8a-hexahydronaphthalen-1-yl] 2, 
                                         2- dimethylbutanoate 
 Trade Names       : Cholestat, coledis, Simovil, Simvastatin,   
            Simvastatina, Simvastatine, Sinvacor. 
 1.2 Formula:  
 Empirical Formula  :    C25H38O5  
 Structural Formula      : 
O
O
O
OO
H
 
  SIMVASTATIN   
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 1.3 Physical and chemical properties: 
 Molecular weight : 418.566 g/mol 
 Color : White or almost-white  
 Nature : Crystalline powder 
 Odour  : Odourless 
 Melting point  : 135-138 C 
 Specific rotation  : Between +285 and +300 (t=20C) 
 LogP  :  4.937 
 Solubility  : Practically insoluble in water; freely soluble  
   in Alcohol, in chloroform, and in methyl   
   alcohol; sparingly soluble in propylene  
   glycol; very Slightly soluble in petroleum 
   spirit. 
2. PHARMOCOKINETICS: 2, 3, 9-10 
2.1. Absorption: - 
               Simvastatin is absorbed from the gastrointestinal tract after oral               
administration and is hydrolyzed to its active -hydroxyacid form. 
simvastatin undergoes extensive first-pass metabolism in the liver, its 
primary site of action.  
2.2. Bioavailability:  
Less than 5% of the oral dose has been reported to reach the circulation 
as active metabolite. 
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2.3 Distribution:  
Both simvastatin and its -hydroxyacid metabolite are about are 95% 
bound to plasma proteins. 
2.4. Elimination:  
It is mainly excreted in the faeces via the bile as metabolite. About 10 to 
15% is recovered in the urine, mainly in inactive forms. 
3.   PHARMACOLOGY: 
3.1. Therapeutic Category: - 
 Anticholesteremic Agents, HMG-CoA Reductase Inhibitors, Antilipemic 
agent  
3.2. Mechanism of action: 3, 10 
Competitively inhibit 3-hydroxy-3-methyle –glutaryl-coenzyme A (HMG-
CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA 
to mevalonate.  This conversion is an early rate-limiting step in 
cholesterol biosynthesis.  
3.3   Therapeutic/clinical Uses:  
 Secondary prevention of myocardial infarction and stroke in 
patients who have symptomatic atherosclerotic disease.  
 Primary prevention of arterial disease in patients who are at high 
risk because of elevated serum cholesterol concentration, 
especially if there other risk factors for atherosclerosis. 
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 In severe drug resistant dyslipidemia (e.g. heterozygous familial 
hypercholesterolaemia), a bile acid binding resin is added to 
treatment with a statin.                       
3.4    Adverse Effects:  
Myopathy, rhabdomyolysis, headache, skin rashes, dizziness, blurred 
vision. 
3.5    Toxicity:  
Simvastatin is considered to be unsafe in patients with Porphyria 
because it has been shown to be Porphyrinogenic.  
3.6 Drug interaction:  
 3A4 substructure: simvastatin, atorvastatin, lovastatin    
 3A4inhibitors: azole antifungls (fluconazole, ketoconazole), 
grapefruit juice, macrolide antibiotics (erythromycin), protease 
inhibitors, nefazodone,    fluvoxamine, verapamil, amiodarone    
cyclosporins.                                           
 Drug interaction that increase risk for myopathy: gemofibrozil, 
fenofibrate &/or niacin (at least 1 g/day) in combination with a 
statin. 
Contraindication: - 
Concomitant administration of drugs that inhibit the cytochrome P450 
isoenzyme CYP3A4, such as ciclosporin, itraconazole, ketoconazole, 
erythromycin, clarithromycin, nefazodone, might produce high plasma 
levels of simvastatin, thus increasing the risk of myopathy.   
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Use with caution in patients who consumes substantial quantities of 
alcohol, who have history of liver disease, or have signs suggestive of 
liver disease. All stains have been associated with myalgia, myopathy 
(i.e., muscle pain, tenderness, or weakness with creatine phosphokinase 
[CPK]), and rhabdomyolysis. Uncomplicated myalgia has been reported 
with drugs in this class.   
4. DOSAGE FORM AND DOSE   
4.1. Dosage Form:  
Tablets  
4.2. Dose:  
   Initial dose of 5 mg to 10 mg in the evening; an initial dose of 20 mg may 
be used in patients with ischemic heart disease. Maximum up to 80 mg 
once a day in the evening.  
Patients with homozygous familial hypercholesterolaemia may be 
treated with 40 mg once a daily in the evening, or 80mg daily in three 
divided doses of 20 mg, 20 mg, and an evening dose of 40 mg. 
5. METHOD OF ANALYSIS:  
 Elemental analysis 
 Spectroscopy like-IR, NMR, Mass and UV-Visible spectroscopy 
 Thin Layer Chromatography 
 High Performance Liquid Chromatography 
 Structural details by X-ray Diffraction 
 Thermal methods  
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6. STORAGE:  
        Store under nitrogen in airtight containers. Protect from light. 
ATORVASTATIN3, 9-11: - 
1. DESCRIPTION: 3 
 1.1 Nomenclature: 
 Generic Name      :    Atorvastatin 
 Chemical Name   : (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-
 phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol- 
 1-yl]-3,5-dihydroxyheptanoic acid 
 Trade Names    :    Atogal, Atorpic, Cardyl, Faboxim, Hipolixan,  
           Lipitor, Lipotropic, Lipovastatinklonal, Liprimar. 
 1.2 Formula:  
 Empirical Formula  :    C33H35FN2O5  
 Structural Formula: 
 
  ATORVASTATIN   
 1.3 Physical and chemical properties: 
 Molecular weight : 558.639 g/mol 
 Color : White or almost-white  
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 Nature : Crystalline powder 
 Odour  : Odourless 
 Melting point  : 159.2-160.7C 
 Specific rotation  : Between +285 and +300 (t=20C) 
 LogP  :  5.7 
 Solubility  : Practically insoluble in water; freely soluble  
   in Alcohol, in chloroform, and in methyl  
   alcohol; sparingly soluble in propylene  
   glycol; very Slightly soluble in petroleum  
   spirit. 
2. PHARMOCOKINETICS:2, 3, 9-11 
3.1 Absorption: - 
               Atorvastatin is rapidly absorbed after oral administration with maximum 
plasma concentrations achieved in 1 to 2 hours. Atorvastatin undergoes 
extensive first-pass metabolism in the liver, its primary site of action.  
3.2 Bioavailability:  
The absolute bioavailability of atorvastatin is approximately 14%.  
3.3 Distribution:  
Atorvastatin is highly protein bound (≥98%) with a blood/plasma 
concentration ratio of 0.25 indicating a low red blood cell distribution. 
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3.4 Elimination:  
It is primarily eliminated via hepatic biliary excretion with less than 2% of 
atorvastatin recovered in the urine. Bile elimination follows hepatic 
and/or extra-hepatic metabolism.  
4.   PHARMACOLOGY: 
     4.1 Therapeutic Category: - 
Anticholesteremic Agents, HMG-CoA Reductase Inhibitors, Antilipemic 
agent  
4.2   Mechanism of action: 3, 10 
Competitively inhibit 3-hydroxy-3-methyle –glutaryl-coenzyme A (HMG-
CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA 
to mevalonate.  This conversion is an early rate-limiting step in 
cholesterol biosynthesis.  
 
4.3   Therapeutic/clinical Uses:  
 Secondary prevention of myocardial infarction and stroke in 
patients who have symptomatic atherosclerotic disease.  
 Primary prevention of arterial disease in patients who are at high 
risk because of elevated serum cholesterol concentration, 
especially if there other risk factors for atherosclerosis. 
 In severe drug resistant dyslidaemia (e.g. heterozygous familial 
hypercholesterolaemia), a bile acid binding resin is added to 
treatment with a statin.         
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 Myocardial infarction and stroke prophylaxis in patients with type 
II diabetes.               
4.4   Adverse Effects:  
Myopathy, rhabdomyolysis, headache, skin rashes, dizziness, blurred 
vision. 
4.5   Toxicity:  
Side effects may include myalgia, constipation, asthenia, abdominal 
pain, and nausea. Other possible side effects include myotoxicity 
(myopathy, myositis, rhabdomyolysis) and hepatotoxicity.  
4.6   Drug interaction:  
 3A4 substructure: simvastatin, atorvastatin, lovastatin    
 3A4inhibitors: azole antifungls (fluconazole, ketoconazole), 
grapefruit juice, macrolide antibiotics (erythromycin), protease 
inhibitors, nefazodone, fluvoxamine, verapamil, amiodarone    
cyclosporins.                                           
 Drug interaction that increase risk for myopathy: gemofibrozil, 
fenofibrate &/or niacin (at least 1 g/day) in combination with a 
statin. 
Contraindication: - 
Concomitant administration of drugs that inhibit the cytochrome P450 
isoenzyme CYP3A4, such as ciclosporin, itraconazole, ketoconazole, 
erythromycin, clarithromycin, nefazodone, might produce high plasma 
levels of simvastatin, thus increasing the risk of myopathy.   
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Use with caution in patients who consumes substantial quantities of 
alcohol, who have history of liver disease, or have signs suggestive of 
liver disease. All stains have been associated with myalgia, myopathy 
(i.e., muscle pain, tenderness, or weakness with creatine phosphokinase 
[CPK]), and rhabdomyolysis. Uncomplicated myalgia has been reported 
with drugs in this class.   
5. DOSAGE FORM AND DOSE   
5.1  Dosage Form:  
Tablets  
5.2   Dose:  
   Initial dose of 5 mg to 10 mg in the evening; an initial dose of 20 mg may 
be used in patients with ischemic heart disease. Maximum up to 80 mg 
once a day in the evening. Patients with homozygous familial 
hypercholesterolaemia may be treated with 40 mg once a daily in the 
evening, or 80mg daily in three divided doses of 20 mg, 20 mg, and an 
evening dose of 40 mg. 
6. METHOD OF ANALYSIS:  
 Elemental analysis 
 Spectroscopy like-IR, NMR, Mass and UV-Visible spectroscopy 
 Thin Layer Chromatography 
 High Performance Liquid Chromatography 
 Structural details by X-ray Diffraction 
 Thermal methods  
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6. STORAGE:  
        Store under nitrogen in airtight containers. Protect from light. 
HYDROXYPROPYLMETHYLCELLULOSE 53, 54 
1. DESCRIPTION:  
1.1. Nomenclature: - 
 Non-proprietary names :  JP: Hydroxypropylmethylcellulose 
                                                 BP:  Hypromellose 
                                                 Ph Eur:  Methylhydroxypropylcellulosum 
                                                 USP :  Hypromellose 
 Chemical Name :  Cellulose, 2-hydroxypropyl methyl ether 
 Synonyms :  Methyl hydroxypropyl cellulose, Propylene             
                                                                     glycol ether of methylecellulose,                                                                       
      Methylcellulose,Methylcellulose propylene 
                                                              Glycolether, Methocel, Metolose, E464,  
      Pharmacoat, Culminal MHPC. 
1.2  Formula: - 
 Structural Formula : 
OR
CH
2
OR
O
OO
O
O
OR
OR
OR
CH
2
OR
Where R is H, CH
3
 or CH
3
-CH(OH)-CH
2  
1.3 Physical and chemical properties:  
 Molecular weight         : 10,000 - 15,00,000 
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 Color                             : White to creamy-white  
 Nature                           : Fibrous or granular  powder 
 Odour       : Odourless 
 Taste        : Tasteless 
 Density        : 0.3-1.3 g/ml 
 Specific gravity        : 1.26 
  Solubility        : Soluble in cold water, practically insoluble                                                         
in Chloroform, ethanol (95%) and ether but                                                    
Soluble in mixture of ethanol and                                                   
Dichloromethane 
 Viscosity                         : HPMC K4M     :  3,000-5600 mPa s 
                                           HPMC K100M:   80,000-1,20,000 mPas 
 Melting point                   :Browns at 190-200 C, chars at 225-230 C, 
                                           Glass transition temperature is 170-180 C 
 
2.   FUNCTIONAL CATEGORY: - 
 Coating agent, film-forming, rate-controlling polymer for sustained release,    
 stabilizing    agent, suspending agent, tablet binder, viscosity-increasing   
 agent. 
3. APPLICATION: - 
 In oral product HPMC is primarily used as tablet binder, in film coating 
and as an extended release tablet matrix. Concentration between 2-
5% w/w may be used as a binder in either wet or dry granulation 
Chapter – 3                                                                                             Review of literature 
Dept. of Pharmaceutical Science, Saurashtra University Rajkot, Gujarat. 44 
process. High viscosity grade may be used to retard the release of 
water-soluble drug from a matrix. 
 HPMC is widely used in oral and topical pharmaceutical formulation. 
 Concentration of 0.45-1% w/w may be added as a thickening agent to 
vehicle for eye drop and artificial tear solution. 
 HPMC is used as an adhesive in plastic bandage and as a wetting 
agent for hard contact lenses. It is widely used in cosmetics and food 
products. 
 In addition, HPMC is used as an emulsifier, suspending agent and 
stabilizing agent in topical gels and ointments. As a protective colloid, it 
can prevent droplets and particle from coalescing or agglomerating 
thus, inhibiting the formation of sediments. 
4   STABILITY AND STORAGE:  
 It is stable although it is slightly hygroscopic. The bulk material should 
be stored in an airtight container in a cool and dry place. Increased in 
temperature reduces the viscosity of the solution. 
 
5.   SAFETY:  
It is generally regarded as a non-toxic and nonirritant material so it is widely 
used in many oral and topical pharmaceutical formulations. Excessive 
consumption of HPMC may have laxative effect. 
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 POLYETHYLENE OXIDE53, 54 
1. DESCRIPTION:  
    1.1 Nomenclature: - 
 Non-proprietary names :  USP :  Polyethylene oxide 
     Chemical Name :  Polyethylene oxide 
 Synonyms : Polyox; polyoxiante; polyoxirane;  
      polyoxyethylene 
1.2 Formula : (CH2CH2O)n 
1.3 Physical and chemical properties:  
 Molecular weight : 1,00,000 - 70,00,000 
 Color : White to creamy-white  
 Nature : Granular  powder 
 Odour  : Slight ammoniacal odor 
 Taste  : Tasteless 
 Density  : 1.3 g/ml (True) 
 Solubility  : Soluble in water and a number of common 
   organic solvents such as acetonitrile,  
   chloroform, and methylene chloride. It is  
   insoluble in aliphatic hydrocarbons, 
   ethylene glycol, and most alcohols 
 Viscosity  : 30 -10000 mPs 
 Melting point  : 65–70C,                                                     
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2.   FUNCTIONAL CATEGORY: - 
     Mucoadhesive; coating agent; tablet binder; thickening agent. 
4. APPLICATION: - 
 Polyethylene oxide used as a tablet binder at concentrations of 5–85%.  
 The higher molecular weight grades provide delayed drug release via 
the hydrophilic matrix approach. 
 Polyethylene oxide has also been shown to facilitate coarse extrusion 
for  tableting as well as being an aid in hot-melt extrusion.  
 Polyethylene oxide has been shown to be an excellent mucoadhesive 
polymer. Low levels of polyethylene oxide are effective thickeners, 
although alcohol is usually added to waterbased formulations to 
provide  improved viscosity stability. 
 Polyethylene oxide can be radiation crosslinked in solution to produce 
a hydrogel that can be used in wound care applications 
 Polyethylene oxide films demonstrate good lubricity when wet. This 
property has been utilized in the development of coatings for medical 
devices.  
5.   STABILITY AND STORAGE:  
 Store in tightly sealed containers in a cool, dry place. Avoid exposure to     
            high   temperatures since this can result in reduction in viscosity. 
6.   SAFETY:  
 Animal studies suggest that polyethylene oxide has a low level of toxicity 
regardless of the route of administration. It is poorly absorbed from the 
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gastrointestinal tract but appears to be completely and rapidly eliminated. 
The resins are neither skin irritants nor sensitizers, and they do not cause 
eye irritation. 
 
CARBOMER53, 54 
1. DESCRIPTION:  
1.1.  Nomenclature: - 
 Non-proprietary names : BP :  Cabomers 
                                              Ph Eur :  Carbomers 
                                               USPNF :  Carbomer 
  Synonyms :  Acrypol; Acritamer; acrylic acid polymer;        
carbomera;Carbopol;polyacrylicacid;carboxyvinyl polymer;Pemulen; 
Tego Carbomer carboxy  polymethylene. 
             Formula: - 
 Structural Formula : 
  
1.2  Physical and chemical properties:  
 Molecular weight          : 7*105 to 4*109       
 Color                              : White 
 Nature                            : fluffy, hygroscopic powder 
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 Odour       : slight characteristic odor 
 Viscosity       : 20.5-54.5 poise (0.2%) 
   305-394 poise (0.5%) 
 Density        : 0.3 gm/cm3 
 Specific gravity        : 1.41 
 Solubility        :  Swellable in water and glycerin and, after 
neutralization, in ethanol (95%). Carbomers  do not dissolve but merely 
swell to a remarkable extent, since they are three-dimensionally 
crosslinked microgels. 
 Melting point               :Decomposition occurs within 30 min at 260 C, 
                                      Glass transition temperature is 100-105 C. 
2.   FUNCTIONAL CATEGORY: - 
   Bioadhesive material; controlled-release agent; emulsifying agent; 
emulsion  stabilizer;  rheology modifier; stabilizing agent; suspending agent; 
tablet binder. 
3. APPLICATION: - 
 Carbomers are used in liquid or semisolid pharmaceutical formulations 
as rheology modifiers. Formulations include creams, gels, lotions and 
ointments for use in ophthalmic, rectal, topical and vaginal 
preparations.  
 In tablet formulations, carbomers are used as controlled release 
agents and/or as binders. In contrast to linear polymers, higher 
viscosity does not result in slower drug release with carbomers. Lightly 
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crosslinked carbomers (lower viscosity) are generally more efficient in 
controlling drug release than highly crosslinked carbomers (higher 
viscosity). In wet granulation processes, water, solvents or their 
mixtures can be used as the granulating fluid. The tackiness of the wet 
mass may be reduced by including talc in the formulation or by adding 
certain cationic species to the granulating fluid. 
 The presence of cationic salts may accelerate drug release rates and 
reduce bioadhesive properties.  
 Carbomer polymers have also been investigated in the preparation of 
sustained-release matrix beads as enzyme inhibitors of intestinal 
proteases in peptide-containing dosage forms, as a bioadhesive for a 
cervical patch and for intranasally administered microspheres, in 
magnetic granules for site-specific drug delivery to the esophagus, and 
in oral mucoadhesive controlled drug delivery systems.  
 Carbomers copolymers are also employed as emulsifying agents in the 
preparation of oil-in-water emulsions for external administration. 
Carbomer 951 has been investigated as a viscosity-increasing aid in 
the preparation of multiple emulsion microspheres. 
  Carbomers are also used in cosmetics. Therapeutically, carbomer 
formulations have proved efficacious in improving symptoms of 
moderate-to-severe dry eye syndrome. 
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 4.   STABILITY AND STORAGE:  
      Carbomer powder should be stored in an airtight, corrosion resistant    
container and protected from moisture. The use of glass, plastic, or resin-lined      
containers is recommended for the storage of formulations containing carbomer. 
5.   SAFETY:  
    Carbomers are generally regarded as essentially nontoxic and 
nonirritant materials; there is no evidence in humans of hypersensitivity reactions 
to carbomers used topically. 
Incompatibilities 
Carbopol is incompatible with phenol, cationic polymers, strong acids and high 
concentrations of electrolytes, and is discolored by resorcinol. Exposure to light 
causes oxidation, which is reflected in a decrease in viscosity. 
Safety 
Acute oral doses of carbopol-934P to rats, mice and guinea pigs produce LD50 
values of 4.3, 4.6 and 2.5 g/kg, respectively. In dogs, no fatalities were noted with 
doses as high as 8g/kg. No primary irritation or any evidence of sensitivity or 
allergic reaction in humans following topical application of dispersions containing 
carbopol-934P has been observed. Carbopol-934P in contact with the eye is very 
irritating. 
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   RIVIEW OF LITERATURE ON DRUG  
McClelland GA et al6 (1991) an extended-release osmotic dosage form was 
designed for gastrointestinal delivery of the water soluble tromethamine salt of 
the β-hydroxyacid form of simvastatin, a potent HMG-CoA reductase inhibitor 
and cholesterol lowering agent. The cholesterol lowering efficacy and systemic 
plasma drug level resulting from peroral administration of this dosage form, 
relative to the powder-filled capsule oral bolus, were evaluated in dogs. A twofold 
improvement in cholesterol lowering efficacy was realized with the controlled 
release dosage form that was accompanied by a drug AUC and Cmax that were 
67 and 16%, respectively, of those achieved with the bolus dosage form. These 
results suggest that extended release dosage forms have the potential for a 
dose-sparing advantage in the administration of HMG-CoA reductase inhibitors 
for the treatment of hypercholesterolemia.  
Cheng H, et al7 (1993) designed seven controlled-release dosage forms for 
gastrointestinal delivery of Lovastatin or simvastatin, two potent HMG-CoA 
reductase inhibitors for the treatment of hypercholesterolemia. The in vivo 
performance for these formulations was evaluated in dogs and healthy 
volunteers in terms of the cholesterol lowering efficacy and/or systemic 
concentration of HMG-CoA reductase inhibitors. Results from the present and 
previous studies suggest that, through the controlled release of HMG-CoA 
reductase inhibitors, sustained lower plasma concentration of HMG-CoA 
reductase inhibitors may result in an equal or better therapeutic efficacy. 
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Ballantyne CM et al55 (2003) previous studies have shown that effects on high-
dencity lipoprotein cholesterol may differ among statins. And in this study 
Simvastatin (80 mg) increased HDL-C and apo A-I significantaly more than did 
Atorvastatin ((80 mg) in patients with hypercholesterolemia. This advantage was 
observed regardless of HDL-C level at baseline or the presence of the metabolic 
syndrome.  
Sobal G et al56 (2005) investigated the influence of simvastatin on oxidation of 
native and modified LDL as well as high density lipoprotein.(HDL), which plays 
protective role in atherosclerosis. the influence of simvastatin on lag time 
(protection from oxidation) by diene conjugation was also investigated. At the 
highest concentration of simvastatin (1.6 µg/ml), they found a prolongation of lag 
time from 73 min to 99 min for native LDL, glycoxidated LDL 60 min to 89 min 
and for HDL 54 min to 64 min. these data shows that simvastatin besides its 
lipid-lowering action has also significant antioxidative properties. 
Pandya P et al 57 (2008) enhanced the solubility and dissolution of poorly 
aqueous soluble drug simvastatin (SIM) using hydrophilic, low viscosity grade 
polymer hydroxypropyl methylcellulose (HPMC K3LV). The co-solvent 
evaporation method was developed for efficient encapsulation of hydrophobic 
drug in polymer micelles of HPMC K3LV. Spray drying and rotaevaporation 
method were applied for solvent evaporation. In vivo study was conducted on 
healthy albino rats (Wister strain), and formulations were administered by oral 
route. The dissolution rate was remarkably increased in co-solvent-evaporated 
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mixtures compared to SIM. Co-solvent-evaporated mixtures showed better 
reduction in total cholesterol and triglyceride levels than the SIM. 
Maurya D et al 58 (2008) enhanced the solubility and dissolution rate of 
atorvastatin calcium (ATR) by a solid dispersion technique using poly- (ethylene 
glycol) 6000 (PEG 6000). Microwave energy was used to prepare an enhanced 
release dosage form of the poorly water soluble drug ATR with PEG 6000 as a 
hydrophilic carrier. An in-vivo study was performed to determine the lipid-
lowering efficacy (cholesterol, high density lipoprotein and triglyceride) of the 
solid dispersions using a Triton-induced hypercholesterolemia model in rats. An 
increase in the solubility of ATR was observed with increasing concentration of 
PEG 6000. The optimized ratio for preparation of solid dispersions of ATR with 
PEG 6000 was 1: 12 w/w by conventional fusion and the microwave induced 
fusion method. The in-vitro study showed that solid dispersions increased the 
solubility and dissolution rate of ATR, and thus may improve its bioavailability 
compared with plain ATR. The solid dispersion formulation prepared by the 
microwave induced fusion method significantly (P < 0.05) reduced serum lipid 
levels in phases I and II (18 h and 24 h) of the Triton test compared with plain 
ATR. 
Khan F et al 59 (2011) prepared stabilized gastro-retentive floating tablets of ATC 
to enhance bioavailability. A 32 factorial design used to prepare optimized 
formulation of ATC. The selected excipients such as docusate sodium enhanced 
the stability and solubility of ATC in gastric media and tablet dosage form. The 
best formulation (F4) consisting of hypromellose, sodium bicarbonate, 
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polyethylene oxide, docusate sodium, mannitol, crosscarmellose sodium, and 
magnesium stearate, gave floating lag time of 56 ± 4.16 s and good matrix 
integrity with in vitro dissolution of 98.2% in 12 h. After stability studies, no 
significant change was observed in stability, solubility, floating lag time, total 
floating duration, matrix integrity, and sustained drug release rates, as confirmed 
by DSC and powder X-ray diffraction studies. In vivo pharmacokinetic study 
performed in rabbits revealed enhanced bioavailability of F4 floating tablets, 
about 1.6 times compared with that of the conventional tablet (Storvas® 80 mg 
tablet).  
Lakshmi NV et al 60 (2011) studied the effect of polyethylene glycol 4000 (PEG 
4000) and polyethylene glycol 6000 (PEG 6000) on in vitro dissolution of 
Atorvastatin Calcium (ATC) from solid dispersions. Formulated a physical 
mixtures and solid dispersions (dropping method) using 1:1, 1:2 and 1:3 ratios of 
drug and carriers (PEG 4000 & PEG 6000). PEG 6000 in 1: 3 drug to carrier ratio 
exhibited the highest drug release (89.65%) followed by PEG 4000 (80.03%) in 
the same ratio formulated as solid dispersions using dropping method. The FT-IR 
shows the complexation and there were no interactions. Finally solid dispersion 
of Atorvastatin: PEG 6000 prepared as 1:3 ratio by dropping method showed 
excellent physicochemical characteristics. 
Mohammed A et al61 (2011) chitosan–atorvastatin (CH–AT) conjugate efficiently 
synthesized through amide coupling reaction. The formation of conjugate was 
confirmed by 1H NMR and FT-IR spectrometry. Nano-sized conjugate with a 
mean size of 215.3 ± 14.2 nm was prepared by the process of high pressure 
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homogenization (HPH). Scanning electron microscopy (SEM) revealed that CH–
AT nano-conjugate possess smooth surface whereas X-ray diffraction (XRD) 
spectra demonstrated amorphous nature of nano-conjugate. CH–AT nano-
conjugate showed solubility enhancement of nearly 4-fold and 100-fold compared 
to CH–AT conjugate and pure AT, respectively. The plasma-concentration time 
profile of AT after oral administration of CH–AT nano-conjugate (2574 ± 95.4 
ng/mL) to rat exhibited nearly 5-fold increase in bioavailability compared with AT 
suspension (583 ± 55.5 ng/mL). 
Rao M et al62 (2010) formulated surface solid dispersions (SSD) of simvastatin 
which improve the aqueous solubility and dissolution rate to facilitate faster onset 
of action. SSDs of simvastatin with two different superdisintegrants in three 
different drug–carrier ratios were prepared by a coevaporation method. PXRD 
study demonstrated that there was a significant decrease in crystallinity of pure 
drug present in surface solid dispersions, which resulted in an increased 
dissolution rate of simvastatin. 
Taízia DS et al63 (2010) prepared solid dispersions (SD) of SIM with inert carriers 
to improve the release profile. SIM SD with polyethylene glycol (PEG 6000) or 
polyvinylpyrrolidone (PVP K15) in 1:1, 1:2, 1: 3, 1:4, and 1:5 ratios were prepared 
and their stability and dissolution properties were investigated. Drug release from 
all SD was significantly improved when compared to their corresponding physical 
mixture or SIM alone. The tablets gradually released SIM with a final quantity 
greater than 80% in 60 minutes. 
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Shen HR et al64 (2006) prepared self-microemulsifying drug delivery systems 
(SMEDDS) containing atorvastatin to improve its bioavailability. SMEDDS is a 
mixture of lipid, surfactant, and cosurfactant, which are emulsified in aqueous 
medium under gentle digestive motility in the gastrointestinal tract. Droplet size, 
zeta-potential and long-term physical stability of the formulation was investigated. 
The release of atorvastatin from SMEDDS capsules was studied using the 
dialysis bag method in 0.1 M HCl and phosphate buffer (pH 7.4), compared with 
the release of atorvastatin from a conventional tablet. A pharmacokinetic study 
was performed in 6 beagle dogs after oral administration of 6mg kg−1 
atorvastatin. The bioavailability of atorvastatin SMEDDS capsules was 
significantly increased compared with that of the conventional tablet. SMEDDS 
capsules consisting of Labrafil, propylene glycol and Cremophor RH40 provided 
the greatest bioavailability.  
Michael AB et al65 (2003) studied a multicenter, randomized, double-blind, 
parallel-dose conducted in 917 hypercholesterolemic patients to compare the 
efficacy of 80 mg/d simvastatin versus 80 mg/d atorvastatin on HDL-C and 
apolipoprotein (apo) A-I for 24 weeks. Prespecified subgroups analyzed were 
patients with low HDL-C levels and with the metabolic syndrome. Simvastatin 
increased HDL-C and apo A-I values significantly more than did atorvastatin for 
the mean of weeks 6 and 12 (8.9% vs 3.6% and 4.9% vs -0.9%, respectively) 
and the mean of weeks 18 and 24 (8.3% vs 4.2% and 3.7% vs -1.4%). These 
differences were observed across both baseline HDL-C subgroups (<40 mg/dL, 
≥40 mg/dL) and in patients with the metabolic syndrome. Low-density lipoprotein 
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cholesterol and triglyceride reductions were greater with atorvastatin. 
Consecutive elevations >3* the upper limit of normal in alanine aminotransferase 
(ALT) and/or aspartate aminotransferase (AST) occurred in significantly fewer 
patients treated with simvastatin than with atorvastatin (2/453 [0.4%] vs 13/464 
[2.8%]), with most elevations observed in women taking atorvastatin (11/209 
[5.3%] vs 1/199 [0.5%] for simvastatin).  
REVIEW OF LITERATURE OF GASTRORETENTIVE DOSAGE  FORM 
 
 Sheth PR et al66 (1978) formulated sustained release capsules such that they 
are hydrodynamically balanced so that, upon contact with gastric fluid the 
formulation acquires and maintain a bulk density of less than one thereby remain 
buoyant in the fluid and remaining so until substantially all of the active ingredient 
is released. The formulations comprise adjuvant materials with specific gravity <1 
and hydrocolloids. e.g. cellulose derivatives. The % release from capsule 
containing chlordiazopoxide into simulated gastric fluid (pH 1.2) after 1,2,3,5, and 
7 hr are reported 39, 61, 86, 94, and 100% respectively. 
 Ikura et al67 (1988) developed a dosage form in the form of a pilule such as 
subtilized granules and normal granules or a tablet. And they described that 
pilule and tablet of excessively large size, since they are expected to disintegrate 
and disperse and then complete releasing the drug while they pass the site of 
absorption. It is therefore preferable to make the in the form of a pilule whose 
particle size ranging form 0.5 to 2 mm. this invention was prepared by thoroughly  
mixing the active drug with lower alkyl ether of cellulose and polyacrylic acid or 
its salt, and one or more foaming agent, lubricant, binder, and vehicle. 
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 Timmermans J et al68 (1991) described apparatus for floating dosage form. The 
apparatus and method are particularly suitable for determining a change in 
chemical and /or physical properties a material exposed to a fluid and for 
measurements such as of the floating force produced by buoyant pharmaceutical 
dosage form. 
 Krogel I et al69 (1999) developed and evaluated floating drug delivery system 
based on effervescent core and a polymeric coating. The mechanical properties 
(puncture strength and elongation) of acrylic (Eudragit RS, RL and NE) and 
cellulose (cellulose acetate, ethyl cellulose) polymer, which primarily determined 
the type of delivery system, a polymer coating with a high elongation value and 
high water low carbon dioxide permeability was selected (Eudragit RL/ acetyl 
tributyl citrate 20%w/w) in order to initiate the effervescent reaction and the 
floating process rapidly. HPMC was also added in the core to retard drug 
release. The composition and hardness of the tablet core and the composition 
and hardness of the coating could control the time of flotation.                           
 Li S et al70 (2003) investigated the effect of formulation variables on the calcium 
release and floating properties of the delivery system by using 2x3 factorial 
designs by using different grades of Hydroxypropylmethylcellulose (K100LV and 
K4M) and carbopol. They reported that by increasing the HPMC viscosity the 
release rate decreases and floating properties improved as the viscosity of the 
polymer is increased. Carbopol (CP934) incorporation was found to compromise 
the floating capacity of floating and release of calcium. 
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 Gohel MC et al71 (2004) developed a in vitro dissolution method to evaluate a 
carbamazepine floating drug delivery system. A 100 ml glass beaker was 
modified by adding a side arm at the bottom of the beaker so that the beaker can 
hold 70 ml of 0.1 N HCL dissolution medium and allow collection of samples. The 
performance of the modified dissolution apparatus was compared with USP 
dissolution apparatus. The drug release followed zero-order kinetics in the 
proposed method. 
 Streubel A et al72 (2003) developed a physicochemically characterize single 
unit, floating controlled drug delivery systems consisting of polypropylene foam 
powder, matrix forming polymers, drug and filler. The highly porous foam powder 
provided low density and, thus, excellent in vitro floating behavior of the tablets. 
All foam powder containing tablets remained floating for at least 8 h in 0.1 N HCL 
at 37 C. The tablet eroded upon contact with the release medium, and the 
relative importance of drug diffusion, polymer swelling and tablet erosion for the 
resulting release patterns varied significantly with the type of the matrix former. 
 Chavanpatil M et al73 (2005) designed the sustained release formulation, with 
floating and swelling features in order to prolong the gastric retention time of the 
drug delivery systems. Psyllium husk, HPMC K100M, crospovidone and its 
combination were used to get sustained release profile over a period of 24 h. it 
was found that in vitro drug release rate increased with increasing amount of 
crospovidone.  
 Baumgartner S et al74 (2000) prepared the floating matrix tablets with high dose 
of a freely soluble drug. A tablet containing HPMC, drug and different additives 
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were compressed. The investigation showed that tablet composition and 
mechanical strength have the greater influence on the floating propertied and 
drug release. With the incorporation of a gas-generating agent, beside optimum 
floating time, 30 sec and duration of floating >8 hr., the drug release was also 
increased. The drug release was sufficiently sustained (more than 8 hr). 
 Bodmeier R et al75 (1999) developed a multifunctional drug delivery system 
based on HPMC – matrix tablets placed within an impermeable polymeric 
cylinder (open at both ends). Depending on the configuration of the device, 
extended release, floating or pulsatile drug delivery systems could be obtained. 
Release behavior was investigated as a function of HPMC content, HPMC 
viscosity, position of the matrix within the polymeric cylinder, addition of various 
fillers and agitation speed of release medium. The release was independent of 
the agitation rate, the position of the tablet within the cylinder and length of the 
cylinder. 
 Gerogiannis VS et al76 (1993) examined the floating and swelling characteristics 
of several excipients used in controlled release technology. The floating behavior 
was evaluated with resultant weight measurements, while a gravimetric method 
was employed for studying their swelling. The results indicated that higher 
molecular weight polymers had slower rates of polymer hydration and usually 
followed by enhanced floating behavior. 
 Wei Z et al77 (2001) developed a new kind of two-layer floating tablet for gastric    
retention with cisapride as a model drug, sodium bicarbonate was used as an 
effervescent agent in floating layer and the amount of 
Chapter – 3                                                                                             Review of literature 
Dept. of Pharmaceutical Science, Saurashtra University Rajkot, Gujarat. 61 
hydroxypropylmethylcellulose in drug loading layers controls the in vitro drug 
release of cisapride. The in vitro drug dissolution in the simulated gastric fluid is 
more as compared to that of simulated intestinal fluid because cisapride has 
greater solubility in acid pH. Finally they concluded that this kind of new dosage 
form could be used as a general model for the design of other tablets for gastric 
retention, which has separate regulating of buoyancy and drug release. 
 Talwar N et al78 (2000) prepared a pharmaceutical composition comprising a 
drug, a gas generating component, a swelling agent, a viscolying agent and 
optionally a gel-forming polymer. The swelling agent belonged to a class of 
compounds known as superdisintegrants (e.g. cross linked PVP, NaCMC). The 
viscolyzing agent initially and the gel forming polymer thereafter form a hydrated 
gel matrix which entrap the gas, in the stomach or upper part of the small 
intestine (spatial control). At the same time the hydrated gel matrix created a 
tortuous diffusion path for the drug, resulting in sustained release of the drug 
(temporal control). 
 Chen GL et al79 (1998) studied the in vitro performance of floating sustained 
release capsule of verapamil. Capsules filled with mixture of verapamil, HPC and 
effervescent material are proposed to provide floating and sustained release for 
over 10 hrs. The effects of weight filled in the capsule, amount of HPC and the 
addition of effervescent material on the dissolution kinetics were studied. They 
concluded that the release of verapamil from the capsule followed Higuchi 
release model. However, when effervescent material was added, the system 
showed a zero-order release 
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BS Dave et al80 (2004) prepared a gastroretentive drug delivery system of 
ranitidine hydrochloride. A 32 full factorial design was applied to systemically 
optimize the drug release profile. The results of the full factorial design indicated 
that a low amount of citric acid and a high amount of stearic acid favors 
sustained release of ranitidine hydrochloride from a gastroretentive formulation. 
No significant difference was observed between the desired release profile and 
batches F2, F3, F6, and F9. Batch F9 showed the highest f2 (f2 = 75) among all 
the batches, and this similarity is also reflected in t50 (~214 minutes) and t80 
(~537 minutes) values.  
Shishu N., et al81 (2007) developed and evaluated of single unit floating tablets 
of 5-FU which, after oral administration, are designed to prolong the gastric 
residence time, increase drug bioavailability and target the stomach cancer. A 
floating drug delivery system (FDDS) was developed using gas-forming agents, 
like sodium bicarbonate, citric acid and hydrocolloids, like hydroxylpropyl 
methylcellulose (HPMC) and Carbopol 934P. The results of the in vitro release 
studies showed that the optimized formulation could sustain drug release for 24 h 
and remain buoyant for 16 h.  
Shah SS et al82 (2010) developed a system that permits the drug release to be 
changed freely while maintaining pH-independent drug release (model drug was 
Domperidone). Powder mixture of drug and HPMC K4M, eudragit L100, sodium 
bicarbonate (as gas-generating agent) and other excipients were mixed and 
directly compressed using single-punch tablet compression machine. The linear 
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regression analysis and model fitting showed that all these formulations followed 
Higuchi model, which had a higher value of correlation coefficient (r). 
Tadros M et al83 (2010) developed a gastroretentive controlled release drug 
delivery system with swelling, floating, and adhesive properties. Swelling ability, 
floating behaviour, adhesion period and drug release studies were conducted in 
0.1 N HCl (pH 1.2) at 37 ± 0.5°C. Drug release profiles of all formulae followed 
non-Fickian diffusion. Statistical analyses of data revealed that tablets containing 
HPMC K15M (21.42%, w/w), Na alginate (7.14%, w/w) and NaHCO3 (20%, w/w) 
(formula F7) or CaCO3 (20%, w/w) (formula F10) were promising systems 
exhibiting excellent floating properties, extended adhesion periods and sustained 
drug release characteristics. Abdominal X-ray imaging of formula F10, loaded 
with barium sulfate, in six healthy volunteers revealed a mean gastric retention 
period of 5.50 ± 0.77 h. 
Zate S et al84 (2010) developed and evaluated the gastroretentive mucoadhesive 
sustained release tablet of Venlafaxine hydrochloride which releases the drug in 
a sustained manner over a period of 12 hours, by using Carbopol 971P in 
combination with eudragit RS-PO and ethyl cellulose as a mucoadhesive and 
release retardant respectively. Sustained release tablets were prepared by direct 
compression and were evaluated for bioadhesion time, swelling index and matrix 
erosion, and in vitro drug release. The tablets of batch F3 and F6 had high 
swelling behaviors but release of drug is very less and batch F2 having 
considerable swelling index and in vitro drug release (99.85%). From the 
experiments they concluded that use of carbopol as a release retardant and 
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adhesive polymer is very effective; and also it act as strong release retardant in 
combination with hydrophobic polymers. 
Bhisel K et al85 (2010) developed gastroretentive drug delivery systems 
(GRDDS) of Ketoconazole, which is having narrow absorption window in 
gastrointestinal tract. A 32 factorial design was used in formulating the buoyant 
capsule with hydroxypropyl methyl cellulose (HPMC K15 M) and lactose as 
independent variables. Floating time, swelling index, drug release were the three 
dependent variables. The floating tablet formulation was developed by taking the 
optimized capsule formulation as base point. These tablets were evaluated for 
floating lag time, in vitro floating time and drug release properties. The in vivo 
buoyancy time for tablets and capsules were evaluated by X-ray studies. In vivo 
study showed that the optimum tablet and capsule formulation were retained in 
stomach for more than eight hours. The percent drug release of capsule 
formulation was found to be 80.33% and that of tablet formulation was found to 
be 80.16% in 8 hours. 
Prajapati S et al86 (2011) prepared a floating matrix tablet containing domperidone 
as a model drug. Polyethylene oxide (PEO) and hydroxypropyl methylcellulose 
(HPMC) were evaluated for matrix-forming properties. A simplex lattice design 
was applied to systemically optimize the drug release profile. The amounts of 
PEO WSR 303, HPMC K15M and sodium bicarbonate were selected as 
independent variables and floating lag time, time required to release 50% of drug 
(t50) and 80% of drug (t80), diffusion coefficient (n) and release rate (k) as 
dependent variables. The amount of PEO and HPMC both had significant 
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influence on the dependent variables. concluded that the content of PEO had 
dominating role as drug release controlling factor, but using suitable 
concentration of sodium bicarbonate, one can tailor the desired drug release 
from hydrophilic matrixes. The linear regression analysis and model fitting 
showed that all these formulations followed Korsmeyer and Peppas model, which 
had a higher value of correlation coefficient (r).  
Chandira RM et al87 (2010) formulated floating tablets of Itopride hydrochloride 
using an effervescent approach for gastroretentive drug delivery system. Floating 
tablets were fabricated; using direct compression method containing Itopride 
hydrochloride, polymers HPMC K100M, HPMC K15M and Carbopol 934 P, along 
with gas generating agent sodium bicarbonate and citric acid. The addition of 
Carbopol aided in the reduction of the drug dissolution due to their hydrophobic 
nature. The concentration of these agents was also optimized to get desired 
controlled release of drug. The floating tablet formulations were evaluated for 
physical characterization, assay, swelling index, in‐vitro drug release, hardness, 
friability and weight variation. The drug release pattern of this optimized 
formulation was found to be non‐fickian diffusion mechanism. 
Patel JK et al88 (2010) formulated and evaluated of floating-bioadhesive tablets 
to lengthen the stay of glipizide in its absorption area. Effervescent tablets were 
made using chitosan (CH), hydroxypropyl methylcellulose (HPMC), 
carbopolP934 (CP), polymethacrylic acid (PMA), citric acid, and sodium 
bicarbonate. The type of polymer had no significant effect on the floating lag 
time. All tablets floated atop the medium for 23-24 hr. Increasing carbopolP934 
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caused higher bioadhesion than chitosan (p < 0.05). All formulations showed a 
Higuchi, non-Fickian release mechanism. Tablets with 10% effervescent base, 
80% CH/20% HPMC, or 80% CP/20% PMA seemed desirable.  
Dias RJ et al89 (2010) designed and optimized an oral controlled release 
acyclovir mucoadhesive tablet, in term of its drug release and mucoadhesive 
strength. A 32 full factorial design was employed to study the effect of 
independent variables like Carbopol-934P and HPMC K100M, which significantly 
influences like swelling index, ex-vivo mucoadhesive strength and in-vitro drug 
release. Tablets were prepared by direct compression and evaluated for 
mucoadhesive strength and in-vitro dissolution parameters. Both these polymers 
had a significant effect on the mucoadhesive strength of the prepared tablet. 
Jagdale SC et al90 (2009) developed a gastroretentive drug delivery system of 
propranolol hydrochloride. Hydroxypropyl methylcellulose (HPMC) K4 M, HPMC 
E 15 LV, hydroxypropyl cellulose (HPC; Klucel HF), xanthan gum, and sodium 
alginate (Keltose) were evaluated for their gel forming abilities. They were 
evaluated for physical properties, in vitro release as well as in vivo behavior. 
floating tablets were formulated with HPMC K4 M and HPC. 
Khan F et al91 (2009) prepared and evaluated of gastroretentive floating tablet of 
theophylline. Two hydrophilic cellulose derivatives, Methocel K100M and 
Methocel K15MCR were evaluated for their gel forming and release controlling 
properties. Sodium bicarbonate and citric acid were incorporated as gas 
generating agents. Tablets were prepared by direct compression technique. 
Formulations were evaluated for in vitro buoyancy and drug release study. It was 
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found that polymer content and amount of floating agent significantly affected the 
mean dissolution time, percentage drug release after 8 hours, release rate 
constant and diffusion exponent.  
Sungthongjeen S et al92 (2008) Floating multi-layer coated tablets were 
designed based on gas formation. The system consists of a drug-containing core 
tablet coated with a protective layer (hydroxypropyl methylcellulose), a gas 
forming layer (sodium bicarbonate) and a gas-entrapped membrane, 
respectively. Eudragit RL 30D was chosen as a gas-entrapped membrane due to 
its high flexibility and high water permeability.  
Javed A et al93 (2007) developed a hydrodynamically balanced system for 
celecoxib as single-unit floating capsules. The capsules were prepared by 
physical blending of celecoxib and the polymer in varying ratios. The formulation 
was optimized on the basis of in vitro buoyancy and in vitro release in citrate 
phosphate buffer pH 3.0 (with 1% sodium lauryl sulfate). Capsules prepared with 
polyethylene oxide 60K and Eudragit RL100 gave the best in vitro percentage 
release and was used as the optimized formulation. For gamma scintigraphy 
studies, celecoxib was radiolabeled with technetium-99m by the stannous 
reduction method. Gamma imaging was performed in rabbits to assess the 
buoyancy of the optimized formulation. The optimized formulation remained 
buoyant during 5 hours of gamma scintigraphic studies in rabbits. 
Krishna SS et al94 (2006) prepared mucoadhesive dosage form which extend 
the GI residence time and control the release of rosiglitazone achieve controlled 
plasma level of the drug which is especially useful after 8 to 12 weeks of 
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monotherapy using conventional dosage forms. The optimized formulation 
showed a mucoadhesive strength >40 gm-f, and a mucoadhesion time >12 hours 
with release profile closer to the target release profile and followed Non-Fickian 
diffusion mediated release of rosiglitazone maleate. 
Singh B et al95 (2006) designed oral controlled release mucoadhesive 
compressed hydrophilic matrices of atenolol and to optimized the drug release 
profile and bioadhesion using response surface methodology. A central 
composite design for 2 factors at 3 levels each was employed to systematically 
optimize drug release profile and bioadhesive strength. Carbopol 934P and 
sodium carboxymethylcellulose were taken as the independent variables. 
Compressed matrices exhibited non-Fickian drug release kinetics approaching 
zero-order, as the value of release rate exponent (n) varied between 0.6672 and 
0.8646, resulting in regulated and complete release until 24 hours. Both the 
polymers had significant effect on the bioadhesive strength of the tablets, 
measured as force of detachment against porcine gastric mucosa (P < 0.001). 
Srivastava AK et al96 (2005) developed floating matrix tablets of atenolol to 
prolong gastric residence time and increase drug bioavailability. The tablets were 
prepared by direct compression technique, using polymers such as 
hydroxypropyl methylcellulose (HPMC K15M, K4M), guar gum (GG), and sodium 
carboxymethylcellulose (SCMC), alone or in combination, and other standard 
excipients. Tablets were evaluated for physical characteristics viz. hardness, 
swelling index, floating capacity, thickness, and weight variation. In vitro release 
mechanism was evaluated by linear regression analysis. GG- and SCMC-based 
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matrix tablets showed significantly greater swelling indices compared with other 
batches. The tablets exhibited controlled and prolonged drug release profiles 
while floating over the dissolution medium.  
Chowdary KPR et al97 (2003) formulated mucoadhesive tablets of diltiazem as 
matrix tablets employing sodium carboxymethylcellulose (Sodium CMC), 
hydroxyl propyl methyl cellulose (HPMC) and ethyl cellulose. Non-Fickian release 
was observed from most of the formulations. A two layered tablet formulation, an 
immediately releasing layer consisting of diltiazem and croscarmellose sodium, 
(a superdisintegrant) and a matrix consisting of diltiazem, sodium CMC and ethyl 
cellulose as a second maintenance layer, gave release close to the theoretical 
sustained release (SR) needed for diltiazem. 
Abubakr ON et al98 (2000) prepared captopril floating tablets using two viscosity 
grades of hydroxypropylmethylcellulose (HPMC 4000 and 15000 cps) and 
Carbopol 934P. Drug release best fit both the Higuchi model and the Korsmeyer 
and Peppas equation, followed by first order kinetics. While tablet hardness and 
stirring rate had no or little effect on the release kinetics, tablets hardness was 
found to be a determining factor with regard to the buoyancy of the tablets. 
Rosa M et al99(1994) developed utilizing both the concepts of adhesiveness and 
of flotation, in order to obtain a unique drug delivery system which could remain 
in the stomach for a much longer period of time. The bioadhesive property of the 
tablets was determined using rabbit tissue and a modified tensiometer. The new 
oral controlled-release system shows, at least in vitro, good characetristics in 
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relation to three parameters: controlled release of the drug, bioadhesiveness in 
the stomach and intestine of rabbits and buoyancy in an acid medium. 
Shoufeng Li et al100 (2001) composite Box-Wilson design for the controlled 
release of calcium was used with 3 formulation variables: X1 (hydroxypropyl 
methylcellulose [HPMC] loading), X2 (citric acid loading), and X3 (magnesium 
stearate loading). Twenty formulations were prepared, and dissolution studies 
and floating kinetics were performed on these formulations. All 3 formulation 
variables were found to be significant for the release properties (P < 0.05), while 
only HPMC loading was found to be significant for floating properties. 
Experimentally, calcium was observed to release from the optimized formulation 
with n and T50% values of 0.89 (± 0.10) and 3.20 (± 0.21) hours, which showed 
an excellent agreement.  
Barata P et al101 developed high-density, gastro retentive controlled delivery 
system of ranitidine. Four layer tablets containing 150 mg of ranitidine were 
prepared by manual compression, resulting in a final system consisted by a 
mucoadhesive layer, a high-density layer, a ranitidine sustained release layer 
and a ranitidine immediate release layer. The high density layer was obtained by 
mixing barium sulfate with HPMC K 100 M (90:10). Ranitidine immediate release 
layer (75 mg) was prepared by mixing ranitidine with 22 mg of lactose and 3 mg 
of sodium croscarmellose. Tablets density was determined at appropriate time to 
ensure that it would always be above 2.5 g/cm3. The immediate release layer 
disintegrated within 5 minutes and using a 25% level of HPMC K 100 M it is 
possible to sustain ranitidine release for 6 hours, thus obtaining the desired 
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release profile. Despite of the swelling of the hydrophilic polymer the system 
density remained always above 2.5 g/cm3. It was observed that the addition of 
the mucoadhesive and of the high density layer significantly (p<0.05) increased 
tablets gastric retention time and ranitidine relative bioavailability.  
RIVIEW OF LITERATURE ON POLYMER 
Milen D et al102 (1999) studied Verapamil hydrochloride release from tablets 
based on high molecular weight poly(ethylene oxide) (PEO). The drug release 
proceeds as a controlled diffusion (n = 0.44–0.47), which rate is dependent on 
the molecular weight of PEO. The introduction of hydrophilic polymers with pH 
dependent solubility (Eudragit L, Eudispert hv and Carbopol 934) at 
concentrations of 10/50% with respect to PEO amount keeping constant the ratio 
drug: matrix insures relatively complete release both in alkali medium and under 
the conditions of the Half-change test. Meanwhile drug release kinetics also 
changes — the release of all models studied runs as a typical abnormal diffusion 
(a = 0.66–0.87), i.e. like a diffusion-relaxation controlled process. The decrease 
in drug concentration leads not only to retarded release of the drug sample but 
also to changes in the kinetics of the process. At lower drug concentrations on 
the matrix from a typical abnormal diffusion it turns into a relaxation controlled 
diffusion (n10% = 1). 
 
Muhammad AM et al103 (2011) prepared propranolol hydrochloride-loaded 
matrix tablets using guar gum, xanthan gum, and hydroxypropylmethylcellulose 
(HPMC) as rate-retarding polymers. Guar gum alone was unable to control drug 
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release until a 1:3 drug/gum ratio, where the release pattern matched a Higuchi 
profile. Matrix tablets incorporating HPMC provided near zero-order release over 
12 h and erosion was a contributing mechanism. Combinations of HPMC with 
guar or xanthan gum resulted in a Higuchi release profile, revealing the 
dominance of the high viscosity gel formed by HPMC. As the single rate-
retarding polymer, xanthan gum retarded release over 24 h and the Higuchi 
model best fit the data. When mixed with guar gum, at 10% or 20% xanthan 
levels, xanthan gum was unable to control release. However, tablets containing 
30% guar gum and 30% xanthan gum behaved as if xanthan gum was the sole 
rate-retarding gum and drug was released by Fickian diffusion.  
Seyed AM et al104 (2004) investigated the effect of hydroxyl group containing 
tablet excipients on the duration of adhesion of mucoadhesive polymers, discs 
containing Carbopol 934 (C934), polycarbophil (PC), sodium carboxymethyl 
cellulose, hydroxypropylmethyl cellulose (HPMC), tragacanth and sodium 
alginate (Na alg.), either alone or in the presence of various amounts of 
excipients were prepared. All the excipients examined reduced the duration of 
adhesion and the relative durability of the polymer containing discs. HPMC discs 
despite showing the longest duration of mucoadhesion, suffered the greatest 
reduction in adhesive properties in the presence of excipients which were 
examined. The least reduction in the duration of adhesion was observed with PC 
and C934. Among the excipients tested, spray-dried lactose produced the 
greatest reduction in the duration of adhesion, followed by polyethylene glycol 
6000 and pregelatinized starch.  
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Parka JS et al105 (2010) evaluated gelling behavior and drug release profiles of 
PEG, various contents of the polymers were investigated through a robust 
experimental design method. When exposed to an aqueous environment, the 
PEO–PEG matrix hydrated slowly and swelled, causing a thick gel layer to form 
on the surface, the thickness of which increased significantly depending on the 
PEG contents. The optimal settings of PEO and PEG were 94.26 and 140.04 mg, 
respectively (PEG rate of 148.57%). Moreover, as the amount of PEG increased, 
the release rate also increased. When the formulation contained more than 150% 
of PEG, most of the drug loaded in the tablet was released in about 12 h. When 
the amount of PEG was less than 100%, the drug release rate was sustained 
significantly.  
Sarojini S et al106 (2010) investigated the floating tablets containing theophylline 
as a model drug. Formulations were optimized for type of filler and different 
concentration of polyethylene oxide. Sodium bicarbonate was used as a gas 
generating agent. A 32 randomized factorial design was employed in formulating 
gastric floating drug delivery system (GFDDS) with content of PEO (X1) and ratio 
of starch 1500 to lactose as filler( X2 ) were selected as independent variables. 
Study revealed that type of filler had significant effect on release of drug and 
floating property from different concentration of PEO. Lactose gave higher drug 
release with release mechanism towards zero order compared to starch 1500 
which gave slow release with release mechanism towards diffusion based. 
Optimized formulations were studied for effect of hardness on floating properties 
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and dissolution medium on drug release. Hardness of tablet had major influence 
on floating lag time which might be due to decreased porosity. 
Panigrahy RN et al107 (2011) developed combined bioadhesive-floating oral drug 
delivery system exhibiting a unique combination of bioadhesion and floatation to 
prolong residence in the stomach using Acyclovir, as a model drug. The in vitro 
drug release, buoyancy lag-time, bioadhesive strength and swelling index were 
evaluated. The in vitro drug release from the tablet was controlled by the amount 
of HPMC K-15 and other bioadhesive polymers. The release of Acyclovir from 
the tablets followed the Higuchi matrix model. The swelling properties were 
increased with increasing polymer concentration and contributed to the drug 
release from the tablet matrix.  
Hongtao Li et al108 (2008) investigated the effect of drug solubility on polymer 
hydration and drug dissolution from modified release matrix tablets of 
polyethylene oxide (PEO). Tablet dissolution was tested using the USP 
Apparatus II, and the hydration of PEO polymer during dissolution was recorded 
using a texture analyzer. A multiple linear regression model could be used to 
describe the relationship among drug dissolution, polymer ratio, hydrogel 
formation and drug solubility; the mathematical correlation was also proven to be 
valid and adaptable to a series of study compounds.  
Mahalingam R et al109 (2009) prepared compacts bioadhesive gastroretentive 
delivery system to deliver water soluble and water insoluble compounds in the 
stomach. Compacts with 90:10, 75:25, and 60:40 of polyvinylpyrrolidone (PVP) 
and polyethylene oxide (PEO) were evaluated for swelling, dissolution, 
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bioadhesion, and in vitro gastric retention. Compacts containing higher PEO 
showed higher swelling (111.13%) and bioadhesion (0.62±0.03 N/cm2), and 
retained their integrity and adherence onto gastric mucosa for about 9 h under in 
vitro conditions. 
Shoufeng Li et al110 (2003) investigated the effect of formulation variables on 
drug release and floating properties of the delivery system. Hydroxypropyl 
methylcellulose (HPMC) of different viscosity grades and Carbopol 934P 
(CP934) were used in formulating the Gastric Floating Drug Delivery System 
(GFDDS) employing 2 × 3 full factorial design. It was found that both HPMC 
viscosity, the presence of Carbopol and their interaction had significant impact on 
the release and floating properties of the delivery system. The decrease in the 
release rate was observed with an increase in the viscosity of the polymeric 
system.  
RIVIEW OF LITERATURE ON STATASTICAL DESIGN   
Dandu R et al111(2009) prepared 11 formulation and process variables at two 
levels chosen and randomly assigned to the Plackett-Burman DOE: Ciprofloxacin 
(unseived vs seived below mesh 35), Avicel® (PH102 vs PH101), Klucel® (EFX 
vs JF), pregelatinized starch (partially gelatinized vs fully gelatinized), Aerosil® 
(0% vs 0.25%), Magnesium stearate (vegetable vs animal), mixing time (5 min vs 
20 min), roll pressure (80 bar vs 140 bar), feed screw speed to roll speed ratio (5 
vs 7), fine granulator (50 rpm vs 25 rpm), and compression force (12kN vs 16kN). 
Weight variation, tablet hardness, and disintegration time of the resultant tablets 
was evaluated to elucidate “main effects” among these 11 variables - using only 
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12 experiments These results demonstrate the feasibility of applying Plackett-
Burman DOE to identify the “main effects” in pharmaceutical manufacturing 
design space with a far fewer number of experiments.  
Krzysztof W et al112 (2011) seven factors of wet granulation process were 
investigated for criticality. Low and high levels of each factor represented 
maximal and minimal settings of wide operational ranges. Granulates were 
produced in line with Plackett-Burman experimental matrix, blended with extra-
granular excipients and compressed into tablets. The high shear granulation 
factors, i.e. quantity of binding solution, rotational speed of impeller and wet 
massing time were considered of critical importance. Operational ranges of the 
parameters were optimized. 
El-Malah Y et al113 (2006) Studied the effect of seven factors – POLYOX 
molecular weight (X1) and amount (X2); Carbopol (X3), lactose (X4), sodium 
chloride (X5), citric acid (X6); compression pressure (X7) – on (1) the release of 
theophylline from hydrophilic matrices, demonstrated by changes in dissolution 
rate, and (2) their impact on the release exponent [n] indicative of the drug 
transport mechanism through the diffusion matrix. This objective was 
accomplished utilizing the Placket–Burman screening design. Theophylline 
tablets were prepared according to a 7-factor–12-run statistical model and 
subjected to a 24-h dissolution study in phosphate buffer at pH 7.2. The primary 
response variable, Y4, was the cumulative percent of theophylline dissolved in 12 
h. The regression equation for the response was Y4 = 66.2167−17.5833X1 
−3.3833X2 −9.366X3 −1.1166X4 −0.6166X5 + 2.6X6 −2.783X7. This polynomial 
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model was validated by the ANOVA and residual analysis. The results showed 
that only two factors (X2 and X3) had significant effect (p-value < 0.10) on 
theophylline release from the hydrophilic polymer matrix. Factors (X2 and X7) 
had significant effect (p-value < 0.10) on [n], the exponent. 
Jain SP et al114(2010)  focused on exploiting Plackett–Burman design to screen 
the effect of nine factors—poly (ethylene oxide) molecular weight (X1), poly 
(ethylene oxide) amount (X2), ethylcellulose amount (X4), drug solubility (X5), 
drug amount (X6), sodium chloride amount (X7), citric acid amount (X8), 
polyethylene glycol amount (X9), and glycerin amount (X11) on the release of 
drugs from the extended release extrudates, i.e., release rate and release 
mechanism. The experiments were carried out according to a nine-factor 12-run 
statistical model and subjected to an 8-h dissolution study in phosphate buffer pH 
6.8. The significance of the model was indicated by the ANOVA and the residual 
analysis. Poly (ethylene oxide) amount, ethylcellulose amount and drug solubility 
had significant effect on the T90 values whereas poly (ethylene oxide) amount 
and ethylcellulose amount had significant effect on the n value. 
Sastry SV et al115 (1998) prepared bilayered osmotically controlled 
Gastrointestinal Therapeutic System of atenolol using cellulose acetate 
pseudolatex by polymer emulsification method. Various factors such as orifice 
size, coating thickness, amount and nature of polymeric excipients, and amount 
of osmotic agent influence the drug release from GITS. Studied a 7-factor, 12-run 
Plackett–Burman screening design was evaluate the formulation variables for 
atenolol GITS coated with CA pseudolatex. The variables studied were orifice 
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size, %coating weight gain, amounts of sodium chloride, Polyox N80 and 303, 
and Carbopol 934P and 974P on drug release. The screening design has 
revealed that orifice size, %coating weight gain and amount of Carbopol 934P 
have prominent influence on in-vitro atenolol release. The response variable was 
cumulative percent atenolol released (Y) in 24 h with constraints on percent 
release at 2, 6, 12 and 18 h. The polynomial equation obtained was Y24=149.82-
0.13X1- 0.34X2+0.06 X3-0.13X4-0.23X5-76.25X6-2.46 X7. The results indicated 
that the drug release under constrained conditions was influenced by the factors 
with decreasing order of importance as %coating weight gain>Carbopol 
934P>Polyox N80>Carbopol 974P>Polyox 303>amount of sodium 
chloride>orifice size. 
Zhang Y et al116(2010) described the (1) development of a software program, 
called DDSolver, for facilitating the assessment of similarity between drug 
dissolution data; (2) to establish a model library for fitting dissolution data using a 
nonlinear optimization method; and (3) to provide a brief review of available 
approaches for comparing drug dissolution profiles. DDSolver is a program which 
is capable of performing most existing techniques for comparing drug release 
data, including exploratory data analysis, univariate ANOVA, ratio test 
procedures, the difference factor f1, the similarity factor f2, the Rescigno indices, 
the 90% confidence interval (CI) of difference method, the multivariate statistical 
distance method, the model-dependent method. Sample runs of the program 
demonstrated that the results were satisfactory, and DDSolver could be served 
as a useful tool for dissolution data analysis. 
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4. METHODOLOGY 
 The following materials that were either AR/LR grade or the best 
possible pharma grade available were used as supplied by the manufacturer.  
MATERIALS USED: 
   Table 4.1 List of material used     
Sr. No. Materials Manufacture 
DRUG 
1. SIMVASTATIN Biocon limited, Banglore, India., DRL 
Hyderabad,  
2. ATORVASTATIN Alembic Pharma Vadodara 
EXCIPIENTS 
2. Cross carmelose sodium FMC Ireland. 
3. HPMC K4M 
Aqualon, USA, Colorcon Asia Pvt 
Ltd.  
4. HPMC K100M 
Aqualon, USA, Colorcon Asia Pvt 
Ltd. 
5. Gaur Gum Loba chem. India. 
6. Polyox® WSR 303 Colorcon Asia Pvt Ltd. Goa. 
7. Carbopol 934P SD Fine Chem. Mumbai. 
8. 
Micro crystalline cellulose 
101  
FMC, Ireland. 
9. Sodium bicarbonate Colorcon, Goa. 
10. Mg Al silicate Signet, Mumbai. 
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11. Sodium starch glycolate Colorcon, Goa. 
12. PVP K 30 Aqualon, USA. 
13. Hydrochloric Acid Ranbaxy chemical. 
14. Titanium Dioxide Merck ltd. Mumbai. 
 
DETAILS OF INSTRUMENTS USED: 
   Table 4.2 List of instruments used      
Sr. 
No 
Instruments Manufacture 
1. Electronic Weighing Balance Shimadzu Corporation, Japan. 
2. Bulk density apparatus  Erweka, GmbH, Germany 
3.  Hardness tester Dolphin India, Mumbai 
3. Sieve Techno Instruments comp, Bangalore 
4. Dissolution apparatus  Electrolab, India, Veego lab India. 
5. 
UV/visible 
Spectrophotometer 
UV-1700 UV/VIS, Shimadzu 
Corporation, Japan. 
6. 
FTIR Spectrophotometer 
(Spectrum RXI) 
Perkin Elmer Ltd, USA,  Shimandzu, 
Japan. 
7. 
Rotary tablet compression 
machine 
Hardik Engg. Ahemedabad. 
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METHODOLOGY: 
1.  PREFORMULATION: 
Prior to development of the dosage forms with a new drug candidate, it is 
essential that certain fundamental physical and chemical properties of the 
drug molecule and other derived properties of the drug powder are 
determined. This information will dictate many of the subsequent events 
and possible approaches in formulation development. This first learning 
phase is known as preformulation. 
In this the two sub-phases are: 
 Analytical Involves identification of the active pharmaceutical 
ingredient, evaluating for pharmacopoeial compliance, and 
development of analytical procedures. 
 Formulation, the approved material of certain chemical identity and 
purity can have varied pharmaceutical properties that can have impact 
over formulations and drug release patterns, so any batch-to batch 
variations in these characteristics of the material and their effect on the 
performance of the dosage forms are to be established. 
1.1.     Analytical phase: 
          The Preformulation parameter for Simvastatin and Atorvastatin under 
analytical    
          aspects is, 
1.1.1. UV spectroscopy:  
 The UV spectra were scanned from 200 to 400 nm at medium scanning 
speed, with the solution in 1 cm quartz cell. Solution concentration of 
100 μg/ml was used, and data were obtained in methanol.  
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1.1.2. Infrared spectroscopy:   
           The infrared spectrum of Simvastatin and Atorvastatin were obtained in 
a KBr pellet using IR spectrophotometer. 
1.1.3. Melting point: 
          The melting point of Simvastatin and Atorvastatin were recorded by           
 using Thiele’s   apparatus. 
1.1.4 Calibration curve of Simvastatin: 
Instrument: 
        Shimadzu UV-Visible spectrophotometer-1700 
 Principle: 
  The calibration curve is obtained by dissolving Simvastatin in 0.1N 
Hydrochloric acid + 0.5% SLS. This solution was treated with manganese 
dioxide. Absorbance measured spectrometrically at 238 nm, 247 nm, and 257 
nm against reagent blank. It obeyed Beer's Law in the concentration range of 
2-25 g/ml. 
 Method: 
      Standard stock solution: -  
 The stock solution was freshly prepared by dissolving 20mg 
Simvastatin in 0.1N hydrochloric acid + 0.5% SLS in a 100ml volumetric flask 
(Stock-I) for getting 0.2mg/ml strength. 
      Preparation of Calibration Curve: 
 The aliquots of 0.2 to 4.0 ml of standard Simvastatin solution (stock-I) 
were transferred to series of 20 ml volumetric flask. The volume of each 
volumetric flask was made up to 20ml with 0.1N hydrochloric acid + 0.5% 
SLS. This solution was treated with manganese dioxide. The absorbance of 
solution in each volumetric flask was measured at 238 nm, 247 nm, and 257 
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nm against reagent blank; for standard calibration curves the absorbance was 
taken as absorbance at 247 nm minus the absorbance at 257 nm against 
concentration. 
Calibration Curve of Atorvastatin: 
  The calibration curve is obtained by dissolving Atorvastatin in 0.1N 
Hydrochloric acid + 0.5% SLS. Absorbance measured spectrometrically at 
245 nm against reagent blank. It obeyed Beer's Law in the concentration 
range of 2-26 g/ml. 
 Method: 
      Standard stock solution: 
  The stock solution was freshly prepared by dissolving 50mg 
Atorvastatin in 0.1N hydrochloric acid + 0.5% SLS in a 100ml volumetric flask 
(Stock-I) for getting 0.2mg/ml strength. 
      Preparation of Calibration Curve: 
  The aliquots of 0.2 to 4.0 ml of standard Atorvastatin solution (stock-I) 
were transferred to series of 20 ml volumetric flask. The volume of each 
volumetric flask was made up to 20ml with 0.1N hydrochloric acid + 0.5% 
SLS. The absorbance of solution in each volumetric flask was measured at 
246 nm against reagent blank. 
1.2. Formulation phase: 
 1.2.1.  Preformulation study for selection of polymers: 
 Commonly used pharmaceutical ingredients were screened for the 
purpose of selecting polymers that can impart floating characteristic to the 
granules. These include Hydroxypropylmethylcellulose (K100M, K4M), Cross 
carmellose sodium, sodium starch gycolate, micro crystalline cellulose. The 
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polymers were passed through a BSS #100 sieve. The dissolution medium 
used to study the floating behavior was 0.1N HCl. Powder of each polymer 
(about 100mg) was sprinkled in glass beaker (diameter-6 cm) containing 
100ml of a dissolution medium. The floating characteristics were observed at 
0, 1, 2, 4, 6, 8, 10 and 12 hr. 
2. PREPARATION OF SIMVASTATIN AND ATORVASTATIN 
GASTRORETENTIVE DOSAGE FORMS: 
Procedure for Floating Granules Production: 
 Floating swellable granules containing Simvastatin/Atorvastatin were 
prepared by wet granulation technique using varying concentrations of 
different grades of polymers. Polymers and drugs were mixed homogeneously 
using glass mortar and pastle. PVP K 30 in isopropyl alcohol was used as 
granulating agent. Granules were prepared by passing the wet coherent mass 
through a BSS # 16 sieve. The granules were dried in hot air oven at a 
temperature of 60 C; dried granules were sieved through BSS # 20/44 
sieves. Dried granules after sieving were mixed with sodium bicarbonate used 
as a gas-generating agent. Granules were filled in to the ‘0’ size EHGC using 
hand-filling machine. 
Procedure for Tablets (Floating, Mucoadhesive, High density) 
Production: 
In the present study of gastroretentive floating matrix tablets, direct 
compression method was found the most compatible during the preliminary 
study because the effervescent mixture is not compatible with wet granulation 
method as well as low density approach will not be achieved by dry 
granulation technique.  
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Dry powder of Simvastatin and Atorvastatin, definite amount of polymer 
mixture (having various combinations of HPMC K100M, HPMC K4M, 
Carbopol 934P, Titanium dioxide, Guar gum, Polyox® WSR 303, and 
Magnesium aluminum silicate) and effervescent agent (Sodium bicarbonate) 
along with ducusate sodium as a stabilizing agent, Magnesium stearate (as a 
lubricant) and talc (as a glident) were directly compressed at low pressure 
and/or high pressure in Rotary Tablet Punching Machine. 
2.1. FORMULATION OF FLOATING TABLET*:  
2.1.1 Experimental Design117-119  
Plackett–Burman factorial designs can identify main factors from the 
large number of suspected contributor factors for the desired response 
variables. Therefore, these designs are extremely useful in preliminary studies 
where the aim is to identify formulation variables that can be fixed or 
eliminated in further investigation. The model is of the form:  
Y= β0 + β1 X1+ β2 X2+ β3 X3+ β4 X4+….. βn Xn 
Where Y is the response, β0 is a constant and β1 to βn are the coefficients of 
the response values.  
 The design analyzes the input data and presents a rank ordering of the 
variables with magnitude of effect, and designates signs to the effects to 
indicate whether an increase in factor value is advantageous or not115. Below 
Tables summarizes the formulation variables for screening, and the 
constraints used. A 7-factor 8-run Plackett–Burman screening design was 
generated. 
Docusate sodium was added in all Atorvastatin formulation as stabilizing 
agent.  
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BHA (Butayed Hydroxyl Anisole was added in all Simvastatin formulation as 
Anti oxidizing agent 
 
Table.4.3 Preliminary trial batches prepared by First line of Plackett-
burman design 
RUN Drug 
HPMC 
K100M 
Sod 
Starch 
Glycolate 
 
NaHCo-
3 
PVP 
Mg. 
Stearate 
TALC 
S1 80 64 20 15 8 4 4 
S2 
80 
48 20 30 8 
4 4 
S3 
80 
64 15 30 8 
4 4 
S4 
80 
64 20 30 6 
4 4 
S5 
80 
64 20 15 6 
4 4 
S6 
80 
48 20 15 6 
4 4 
S7 
80 
48 15 15 8 
4 4 
S8 
80 
48 15 30 6 
4 4 
S9 
80 
64 15 15 8 
4 4 
S10 
80 
64 15 30 6 
4 4 
S11 
80 
48 15 15 6 
4 4 
S12 
80 
48 15 15 6 
4 4 
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Table-: 4.4 Formulation design by First line of Plackett-burman design 
for floating tablet. 
RUN 
HPMC 
K100M 
HPMC 
K4M 
POLYOX 
303 
NaHCO3 PVP 
Mg. 
Stearate 
TALC 
SF1/AF1 + + + - + - - 
SF2/AF2 - + + + - + - 
SF3/AF3 - - + + + - + 
SF4/AF4 + - - + + + - 
SF5/AF5 - + - - + + + 
SF6/AF6 + - + - - + + 
SF7/AF7 + + - + - - + 
SF8/AF8 - - - - - - - 
 
 
Table-: 4.5 Formulation by First line of Plackett-burman design for 
floating tablet. 
RUN 
HPMC 
K100M 
HPMC 
K4M 
POLYOX 
303 
NaHCO3 PVP 
Mg. 
Stearate 
TALC 
SF1/AF1 48 48 18 12 16 6 3 
SF2/AF2 32 48 18 24 8 8 3 
SF3/AF3 32 32 18 24 16 6 4 
SF4/AF4 48 32 12 24 16 8 3 
SF5/AF5 32 48 12 12 16 8 4 
SF6/AF6 48 32 18 12 8 8 4 
SF7/AF7 48 48 12 24 8 6 4 
SF8/AF8 32 32 12 12 8 6 3 
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2.2. FORMULATION OF HIGH DENSITY TABLET:  
Table-: 4.6 Formulation design by First line of Plackett-burman design 
for high density tablet. 
RUN 
HPMC 
K100M 
HPMC 
K4M 
POLYOX 
303 
Titanium 
Dioxide 
PVP 
Mg. 
Stearate 
TALC 
SH1/AH1 + + + - + - - 
SH2/AH2 - + + + - + - 
SH3/AH3 - - + + + - + 
SH4/AH4 + - - + + + - 
SH5/AH5 - + - - + + + 
SH6/AH6 + - + - - + + 
SH7/AH7 + + - + - - + 
SH8/AH8 - - - - - - - 
 
Table-: 4.7 Formulation by First line of Plackett-burman design for high 
density tablet. 
RUN 
HPMC 
K100M 
HPMC 
K4M 
POLYOX 
303 
Titanium 
Dioxide 
PVP 
Mg. 
Stearate 
TALC 
SH1/AH1 48 48 12 16 16 6 3 
SH2/AH2 32 48 12 32 8 8 3 
SH3/AH3 32 32 12 32 16 6 4 
SH4/AH4 48 32 6 32 16 8 3 
SH5/AH5 32 48 6 16 16 8 4 
SH6/AH6 48 32 12 16 8 8 4 
SH7/AH7 48 48 6 32 8 6 4 
SH8/AH8 32 32 6 16 8 6 3 
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2.3 FORMULATION OF MUCOADHESIVE TABLET:  
Table-: 4.8 Preliminary trial batches prepared by First line of Plackett-
burman design 
RUN Drug 
HPMC 
K100M 
Carbopol 
934 
 
POLYOX 
303 
Guar 
Gum 
 
Mg. 
Stearate 
TALC 
S13 80 
80 60 15 15 
4 4 
S14 
80 
80 40 20 15 
4 4 
S15 
80 
60 60 20 15 
4 4 
S16 
80 
60 60 20 15 
4 4 
S17 
80 
80 40 20 15 
4 4 
S18 
80 
60 40 15 15 
4 4 
S19 
80 
60 40 20 15 
4 4 
S20 
80 
60 60 15 15 
4 4 
 
Table-: 4.9 Formulation design by First line of Plackett-burman design 
for mucoadhesive tablet. 
RUN 
HPMC 
K100M 
POLYOX 
303  
CARBOPOL 
934P 
Guar 
Gum 
PVP 
Mg. 
Stearate 
TALC 
SM1/AM1 + + + - + - - 
SM2/AM2 - + + + - + - 
SM3/AM3 - - + + + - + 
SM4/AM4 + - - + + + - 
SM5/AM5 - + - - + + + 
SM6/AM6 + - + - - + + 
SM7/AM7 + + - + - - + 
SM8/AM8 - - - - - - - 
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Table-:4.10 Formulation by First line of Plackett-burman design for 
mucoadhesive tablet. 
RUN 
HPMC 
K100M 
POLYOX 
303  
CARBOPOL 
934P 
Guar 
Gum 
PVP 
Mg. 
Stearate 
TALC 
SM1/AM1 30 20 40 20 16 6 3 
SM2/AM2 15 20 40 40 8 8 3 
SM3/AM3 15 10 40 40 16 6 4 
SM4/AM4 30 10 20 40 16 8 3 
SM5/AM5 15 20 20 20 16 8 4 
SM6/AM6 30 10 40 20 8 8 4 
SM7/AM7 30 20 20 40 8 6 4 
SM8/AM8 15 10 20 20 8 6 3 
 
2.4. FORMULATION OF FLOATING CAPSULE:  
Table-:4.11 Formulation design by First line of Plackett-burman design 
for floating capsule. 
RUN 
C.C 
Sod 
HPMC 
K4M 
MCC 
101 
VEEGUM 
EUDRAGIT 
RS  
HPMC 
K100M 
NaHCO3 
SC1/AC1 + + + - + - - 
SC2/AC2 - + + + - + - 
SC3/AC3 - - + + + - + 
SC4/AC4 + - - + + + - 
SC5/AC5 - + - - + + + 
SC6/AC6 + - + - - + + 
SC7/AC7 + + - + - - + 
SC8/AC8 - - - - - - - 
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Table-:4.12 Formulation by First line of Plackett-burman design for 
floating capsule. 
RUN 
C.C 
Sod 
HPMC 
K4M 
MCC 
101 
VEEGUM 
EUDRAGIT 
RS  
HPMC 
K100M 
NaHCO3 
SC1/AC1 37.5 50 10 25 50 25 12.5 
SC2/AC2 25 50 10 37.5 25 37.5 12.5 
SC3/AC3 25 25 10 37.5 50 25 25 
SC4/AC4 37.5 25 5 37.5 50 37.5 12.5 
SC5/AC5 25 50 5 25 50 37.5 25 
SC6/AC6 37.5 25 10 25 25 37.5 25 
SC7/AC7 37.5 50 5 37.5 25 25 25 
SC8/AC8 25 25 5 25 25 25 12.5 
*SF, AF, SH, AH, SM, AM, SC, AC were Formulation Code. 
 (+ ) = High level amount 
(–)  = Low level amount 
Docusate sodium was added in Atorvastatin formulation as stabilizing agent.  
All quantities given are in mg. 
BHA (Butayed Hydroxyl Anisole was added in all Simvastatin formulation as 
Anti oxidizing agent 
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3. EVALUATION OF GASTRORETENTIVE DOSAGE FORM: - 
  Evaluation was performed to assess the physicochemical properties 
and release characteristics of the developed formulations. 
3.1. TABLET THICKNESS: 
Thickness of tablets was important for uniformity of tablet size. 
Thickness was measured using Vernier Calipers on 3 randomly selected 
samples.  
3.2. TABLET HARDNESS: 
The resistance of tablet for shipping or breakage, under conditions of 
storage, transportation and handling, before usage, depends on its hardness. 
The hardness of tablet of each formulation was measured by Monsanto 
hardness tester. 
3.3. FRIABILITY: 
Friability is the measure of tablet strength. Roche friabilator was used 
for testing the friability using the following procedure. Friability was done as 
per USP specification. 
       %Friability = (Initial wt. of tablets – Final wt. of tablets) x 100 
                                        Initial wt. of tablets 
3.4. WEIGHT VARIATION: 
Twenty tablets were weighed individually and the average weight was 
determined. The % deviation was calculated and checked for weight variation 
as per USP. The average weight of 20 tablets was calculated for each 
formulation. 
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3.5. TEST FOR CONTENT UNIFORMITY: 
Tablet and capsule containing 80 mg of drug was dissolved in 200 ml of 0.1N 
HCl with 0.5% SLS (sodium lauryl sulphate) taken in volumetric flask. The 
drug was allowed to dissolve in the solvent and sonicate for 2 to 3 hr. after, 
this solution was treated with manganese dioxide then centrifuge for 10 min, 
filtered it, this filtered solution was measured at 238 nm, 247 nm, and 257 nm 
against reagent blank.  The absorbance taken for calculating concentration 
was absorbance at 247 nm minus the absorbance at 257 nm for simvastatin 
and for Atorvastatin was measured at 246 nm against reagent blank. The 
concentration of Simvastatin/Atorvastatin in mg/ml was obtained by using 
standard calibration curve of the drug. Claimed drug content was 80 mg per 
tablet. Drug content studies were carried out in triplicate for each formulation 
batch. 
3.6. BUOYANCY / FLOATING TEST: 
The time between introduction of dosage form and its buoyancy on the 
simulated gastric fluid and the time during which the dosage form remain 
buoyant were measured. The time taken for dosage form to emerge on 
surface of medium called Floating Lag Time (FLT) or Buoyancy Lag Time 
(BLT) and total duration of time by which dosage form remain buoyant is 
called Total Floating Time (TFT). The lag time was carried out in beaker 
containing 250 ml of 0.1N HCl (pH 1.2) as a testing medium maintained at 37 
°C.  
3.7. MEASUREMENT OF IN VITRO MUCOADHESION TIME/ STRENGTH 
 These were measured by ‘modified balance method. Briefly, a balance 
was taken and its left pan was replaced with a weight to the bottom of which a 
tablet was attached. Both sides were balanced with weight. Rat gastric 
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mucosa having a thick layer of mucus was fixed to a rubber cork, which was 
already attached to the bottom of the beaker containing corresponding 
medium with a level slightly above the mucosa. The weight, which was 
attached to the tablet, was brought into contact with the porcine mucosa, kept 
undisturbed for 5 minutes and then the pan was raised. Weights were 
continuously added on the right side pan in small increments and the weight 
at which the tablet detached from the mucosa was recorded as the 
mucoadhesive strength. For measuring mucoadhesion time a 10-gram weight 
was put on right side pan after raising it and the detachment time was noted. 
The time period throughout which the tablet remained attached to the mucosa 
is mucoadhesion time. 
  The force of adhesion was calculated using following formula; 
 Force of adhesion (N) = Mucoadhesive strength/100 × 9.81 
3.8. IN VITRO SWELLING STUDIES 
The degree of swelling of bio‐adhesive polymers is an important factor 
affecting adhesive. For conducting the study, a tablet was weighed and 
placed in a beaker containing 100 ml of 0.1 N HCl for 24 hrs, the tablets were 
taken out from the beaker and excess water was removed carefully by using 
filter paper. The swelling Index was calculated using the following formula, 
 Swelling Index (SI) = (Wt‐Wo)/Wo X 100 
   Where SI= Swelling index. 
   Wt = Weight of tablets after time at‘t’. 
   Wo = Weight of tablet before placing in the beaker. 
 
3.9. DISSOLUTION STUDIES: 
5.9.1 Dissolution Study of floating capsule: - 
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Apparatus : Dissolution test apparatus (USP XXIII) 
Method : USP type 2 apparatus (paddle) 
    Dissolution medium : 0.1N HCl + 0.5% SLS 
    Volume of DM : 900 ml 
    Temperature : 37 + 0.5 C 
    Speed : 50 rpm 
Procedure:   
The capsule was placed inside the dissolution vessel. 10 ml of sample 
were withdrawn at time intervals of 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24 hr. 
The volume of dissolution fluid adjusted to 900 ml by replacing 10ml of 
dissolution medium after every sample. Each sample was analyzed at 238 
nm, 247 nm, 257 nm using double beam UV and Visible Spectrophotometer 
against reagent blank. The absorbance taken for calculating concentration 
was absorbance at 247 nm minus the absorbance at 257 nm for the 
simvastatin and for Atorvastatin was measured at 246 nm against reagent 
blank. The drug concentration was calculated using standard calibration 
curve. 
3.9.2 Dissolution Study of Tablets: - 
Apparatus : Dissolution test apparatus (USP XXIII) 
Method : USP type 2 apparatus (paddle) 
    Dissolution medium : 0.1N HCl + 0.5% SLS 
    Volume of DM : 900 ml 
    Temperature : 37 + 0.5 C 
    Speed : 50 rpm 
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Procedure:   
The tablet was placed inside the dissolution vessel. 10 ml of sample 
were withdrawn at time intervals of 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24 hr. 
The volume of dissolution fluid adjusted to 900 ml by replacing 10ml of 
dissolution medium after every sample. Each sample was analyzed at 238 
nm, 247 nm, 257 nm using double beam UV and Visible Spectrophotometer 
against reagent blank. The absorbance taken for calculating concentration 
was absorbance at 247 nm minus the absorbance at 257 nm for the 
simvastatin and for Atorvastatin was measured at 246 nm against reagent 
blank. The drug concentration was calculated using standard calibration 
curve. 
4. MECHANISM OF DRUG RELEASE116, 120-122. :  
Various models were tested for explaining the kinetics of drug release. 
To analyze the mechanism of the drug release rate kinetics of the dosage 
form, the obtained data were fitted into zero-order, first order, Higuchi, Hixon-
Crowell model and Korsmeyer-Peppas release model. Drug release rate 
kinetic of dosage form was calculated by using DDSover, A Microsoft Excel 
Add-in. 
 Zero order release rate kinetics: - 
 To study the zero–order release kinetics the release rate data are fitted to the 
following equation. 
          F= Ko.t 
Where ‘F’ is the drug release, ‘K’ is the release rate constant and‘t’ is the 
release time. 
The plot of % drug release versus time is linear. 
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 First order release rate kinetics:  
The release rate date are fitted to the following equation 
      Log (100-F) = kt 
A plot of log % drug release versus time is linear. 
 Higuchi release model: 
To study the Higuchi release kinetics, the release rate data were fitted to the 
following equation, 
      F = k t1/2 
Where ‘k’ is the Higuchi constant.  
In higuchi model, a plot of % drug release versus square root of time is linear. 
 Korsmeyer and Peppas release model: 
The release rate data were fitted to the following equation, 
      Mt /M  = K.t
n 
      Where, Mt /M  is the fraction of drug released, 
      ‘K’ is the release constant, 
      ‘t’ is the release time. 
‘n’ is diffusion exponent, if n is equal to 0.89, the release is zero order. If n is 
equal to 0.45 the release is best explained by Fickian diffusion, and if 0.45 < n 
< 0.89 then the release is through anomalous diffusion or nonfickian diffusion 
(swellable & cylinder   Matrix). 
In this model, a plot of log (Mt/M ) versus log (time) is linear. 
The dissolution data of plackett-burman design batches of 
Simvastatin/Atorvastatin gastroretentive tablets and capsule were fitted to 
Zero-order, First-order, Higuchi, and Korsmeyer-Peppas model to study the 
kinetics of drug release. 
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4.2.3 Optimization of gastroretentive formulation using Plackett-burman 
design 
A statistical model incorporating interactive and polynomial terms was utilized 
to evaluate the responses.  
 Y = β0 + β1X1 + β2X2 + β3X3 + β4X4+ β5X5 + β6X6+β7X7 
Where, Y is the dependent variable, β0 is the arithmetic mean response of the 
eight runs, and βi is the estimated coefficient for the factor Xi. The polynomial 
equation can be used to draw conclusions after considering the magnitude of 
coefficient and the mathematical sign it carries, i.e. positive or negative. The 
high values of correlation coefficient for the dependent variables indicate a 
good fit. The equation may be used to obtain estimate of the response 
because small error of variance was noticed in the replicates. Regression 
analysis was calculated by using the Microsoft Excel. 
4. In Vivo Evaluation Of Gastrointestinal Residence Time 
 in vivo evaluation of gastrointestinal residence time of gastroretentive 
dosage form to confirm the spatial and temporary placement of 
gastroretentive drug delivery system, a variety of techniques have been used 
like string technique, endoscopy, gamma scintigraphy (25-29). Of these 
techniques, X-ray technique was used to determine the gastric residence time 
of the tablets. For in vivo testing, healthy volunteers were selected. Volunteer 
was asked to swallow the placebo tablet with sufficient water after meal in the 
afternoon under the supervision of registered doctor. This was noted as zero 
time reading. The successive images were then recorded at regular intervals 
over a period of 4–8 h. The X-ray of the tablet in the volunteers was recorded 
at intervals of 1, and 8 h.  
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4.1. Tablet Preparation for In Vivo Studies29 
Tablets with diameter 8 mm and 226 mg in weight were prepared. All the 
ingredients used in this study are transparent to X-ray, and therefore, to make 
the tablets X-ray opaque, the incorporation of BaSO4 was necessary. Barium 
sulfate has a high relative density (4.4777 g/cm2) and poor floating properties. 
For in vivo tests, tablets with the following composition were compressed: 40 
mg barium sulfate, and other ingredient as per the formula without the drug. 
Hardness was adjusted to 4.2 kg/cm2. 
5.   STABILITY STUDY: 
Introduction 
          In any rational design and evalution of dosage forms for drugs, stability 
of the active component must be a major criterion in determining their 
acceptance or rejection. Stabitily of the drug can be defined as the ability of a 
particular formulation, in a specific container, to remain within its physical, 
chemical, therapeutic and toxicological specification.  
                                                     OR 
            Stability of a drug can be defined as the time from the date of 
manufacture and the packaging of the formulation, until its chemical or 
biological activity is not less than a predetermined level of labeled potency 
and its physical characteristics have not changed appreciably or deleteriously. 
            The international conference on Harmonization (ICH) guidelines titled 
‘stability testing of New Drug substance and products’(Q1A) describes the 
stability test requirements for drug registration applications in the European 
union, japan and the USA.  
ICH specifies the length of the study and storage conditions, 
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Long-Term Testing: 25 C + 2 C / 60% RH + 5% for 12 months.   
Accelerated Testing:  40 C + 2 C / 75% RH + 5% for 6 months.   
             Stability studies were carried out at 40 C / 75% RH for the selected 
formulation for six months. 
Method 
          The selected formulaton were packegd in air tight plastic container. 
They were then stored at 40 C / 75% RH, forn six month and evaluated for 
their physical appearance, drug content, and drug release at at specific 
interval of time per ICH guidelines. 
6. ANIMAL STUDY: 
      Experimental animals 
Male albino Wister rats weighing between 200-250 gm was used. 
Institutional Animal Ethics Committee approved the experimental protocol; 
animals were maintained under standard conditions in an animal house 
approved by Committee for the Purpose of Control and Supervision on 
Experiments on Animals (CPCSEA). 
Selection of dose and treatment period for models:  
The treatment period consisted of 40 days in all the models. 
The following doses were administered once daily for duration mentioned 
above. 
6.1 Evaluation of Total Cholesterol: 
 Experimental animals 
       Female adult albino rats (Wister strain) weighing between 190-240 gms 
body weighs were selected for the experimental study. They were divided into 
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3 groups, each group consisting of 6 rats and kept under standard laboratory 
conditions.  
Treatment protocol 
Group 1: Control group: Animal of this group received 0.5% Sod. CMC 
solution, p.o. 2.85 ml/Kg daily for forty days. 
Group 2: Pure drug group: Animals of this group received Pure Drug 
(Simvastatin/Atorvastatin), 11.42mg/Kg/day p.o. for forty days. 
Group 3: Optimized Formulation group: Animals of this group received Last        
Optimized Formulation of Simvastatin, 11.42mg/Kg/day, p.o. for forty 
days. 
Blood samples were collected at 18th day and 40th day by retro orbital 
puncture method and serum was used for assay of Total cholesterol. 
Estimation of Total cholesterol: 
Principle: 
Cholesterol esters are hydrolysed by Cholesterol Esterase (CE) to give free 
cholesterol and fatty acids. In subsequent reaction, Cholesterol Oxidase 
(CHOD) oxidizes the 3-OH group of free cholesterol to liberate Cholest-4-en-
3-Peroxide couples with 4-Aminoantipyrine (4-AAP) and phenol to produce 
red Quinoneimine dye. Absorbance of colored dye is measured at 505 nm 
and is proportional to amount of Total Cholesterol concentration in the 
sample.  
6.2 Assay Parameters: 
Mode of reaction                               End point 
Wavelength                                       505 nm (490-510 nm) 
Flow-cell temperature                       37º c 
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Optical path length                            1 cm 
Blanking                                            Reagent blank 
Sample volume                                  10 µl 
Reagent volume                                100 µl 
Incubation time                                 10 min at 37º C or 30 min  
                                                           At room temperature 
Concentration of Standard                 200 mg/dL 
Stability of final colour                     1 hour 
Linearity                                            750 mg/dL 
Units                                                  mg/dL 
Laboratory Procedure: 
 Sample Blank Test 
Total Cholesterol reagent  1000 µL 1000 µL 
Serum    ---  10 µL 
Mixed well and incubated for exactly 10 minutes. Measured the absorbance of 
the sample against respective sample blank at 505 nm.  
Statistical analysis 
The statistical significance was assessed using one-way analysis of variance 
(ANOVA) followed by Dunnett’s comparison test. The values are expressed 
as mean + SEM and p<0.05 was considered significant. 
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  5. RESULT  
1. Preformulation: - 
1.1. Analytical Phase:  
1.1.1. UV spectroscopy:   
 
Fig. 5.1 Simvastatin UV Spectrum 
   In 0.1 N HCl solution of Simvastatin spectral maxima was observed at 238 nm. 
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1.1.2. Infrared spectroscopy:  
Figure 5.2 and 5.3 shows IR spectrum of Simvastatin and drug with all 
excipients which used in formulation having characteristic absorption band 
in the following region. 
The characteristic peaks of drug appear in the spectra of mixture of drug 
and excipient same wave number, indicating no modification or interaction 
between the drug and the excipients. 
    From that it can conclude that the drug has maintained its identity without 
losing its characteristic properties.  
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Fig. 5.2 Simvastatin IR Spectrum 
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Fig. 5.3 Simvastatin+ Excipients IR Spectrum 
 
1.1.3. Melting point:  
Melting point of simvastatin was found to be 135 C which is in accordance 
with the standard melting point of simvastatin. 
Table 5.1 Data of simvastatin melting point 
Parameter Reported Observed 
Melting point 135-138 C 133-136 C 
 
1.1.4 Calibration curve of Simvastatin:  
 The table shows the absorbance value of different concentration of 
simvastatin in 0.1 N HCl at 247 nm minus the 257 nm.  
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The calibration curve was plotted as shown in Fig 5.4 in concentration range 
of 2-12 g/ml after regression analysis of data as shown in table 5.2 the value 
of R2 was found to be 0.9992 which indicate the accuracy of results. 
                   Table 5.2 Data of the standard calibration curve of Simvastatin 
 
Conc. 
g/ml 
Absorbance 
Set1  Set2 Set3 Average 
00 0.000 0.000 0.000 0.000 
2 0.071 0.071 0.071 0.071 
4 0.140 0.139 0140 0.140 
6 0.208 0.208 0207 0.208 
8 0.270 0270 0.271 0.270 
10 0.348 0.348 0.347 0.348 
12 0.419 0.418 0.419 0.419 
Regression output 
Intercept = 0.0000 
Slope      = 0.0347 
 
Correlation coefficient (R2)   = 0.9992 
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Fig. 5.4 Standard curve of Simvastatin   
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1.2. Analytical Phase:  
1.2.1. UV spectroscopy:   
 
Fig. 5.5 Atorvastatin UV Spectrum 
In 0.1 N HCl solution of Atorvastatin spectral maxima were observed at 246 nm. 
1.2.2 Infrared spectroscopy: 
Figure 5.6 and 5.7 shows IR spectrum of Atorvastatin and drug with all 
excipients which used in formulation having characteristic absorption band 
in the following region. 
The characteristic peaks of drug appear in the spectra of mixture of drug 
and excipient same wave number, indicating no modification or interaction 
between the drug and the excipients. 
    From that it can conclude that the drug has maintained its identity without 
losing its characteristic properties.  
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Fig. 5.6 Atorvastatin IR Spectrum 
 
 
 
   Fig. 5.7 Atorvastatin+ Excipient IR Spectrum 
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1.2.3 Melting point:  
Melting point of atorvastatin was found to be 159 C which is in accordance with 
the standard melting point of atorvastatin. 
Table 5.3 Data of atorvastatin melting point 
Parameter Reported Observed 
Melting point 159.2-160.7 C 159-160 C 
 
1.2.4 Calibration curve of Atorvastatin:  
The table shows the absorbance value of different concentration of simvastatin in 
0.1 N HCl at 246 nm. The calibration curve was plotted as shown in Fig 5.8 in 
concentration range of 5-50 g/ml after regression analysis of data as shown in 
table 5.4 the value of R2 was found to be 0.9993 which indicate the accuracy of 
results. 
 Table 5.4 Data of the standard calibration curve of Atorvastatin 
 
 
 
 
 
 
 
 
Conc. 
g/ml 
Absorbance 
Set1  Set2 Set3 Average 
00 00 00 00 00 
5 0.177 0.177 0.177 0.177 
10 0.347 0.348 0.347 0.347 
15 0.510 0.511 0.511 0.511 
20 0.697 0.698 0.697 0.697 
25 0.825 0.825 0.825 0.825 
50 1.687 1.687 1.687 1.687 
Regression output 
Intercept = 0.0000 
Slope      = 0.0338 
 
Correlation coefficient (R2)   = 
0.9993 
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Fig. 5.8 Standard curve of Atorvastatin 
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2. EVALUATION OF GASTRORETENTIVE DOSAGE FORM OF 
SIMVASTATIN : 
 2.1.   EVALUATION OF FLOATING CAPSULE 
  2.1.1 Filling capsule evaluation:    
Table 5.5 The values of various evaluation parameters of the formulations SC 
made at formulation stage 
 
Response 
                      FORMULATION CODE 
SC1 SC2 SC3 SC4 SC5 SC6 SC7 SC8 
Bulk density 
(gm/ml) 
0.333 0.335 0.439 0.380 0.363 0.389 0.391 0.387 
Tapped density 
(gm/ml) 
0.384 0.393 0.537 0.459 0.430 0.448 0.438 0.461 
Angle of repose 
(o) 
29.74 31.32 29.74 32.93 35.92 32.52 33.31 30.46 
Friability (%) 
(granules) 
0.98 0.45 0.89 1.4 0.67 0.62 0.88 0.91 
% Fine 15 12 9 13 11 21 9 16 
Wt variation (%) 2.34 1.56 3.12 3.67 0.93 1.30 0.84 0.06 
TFT  (hr) 24 25 8 8 28 9 22 12 
Drug content (%) 99.17 99.57 102.2 99.55 101.7 97.23 102.6 103.4 
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2.1.2 Dissolution Study or drug release testing of floating Capsule: - 
Table 5.6 Data of the release profile of the SC1 – SC8. 
 
Time 
(Hrs) 
Cumulative drug release (%) 
SC1 SC2 SC3 SC4 SC5 SC6 SC7 SC8 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0.5 12.32 5.19 14.78 18.16 11.61 12.02 8.09 10.45 
1 17.21 10.39 19.48 34.08 20.52 19.90 13.05 20.83 
2 21.14 15.60 28.09 43.88 27.56 28.72 16.50 38.45 
3 34.15 19.20 46.07 55.98 31.47 53.57 18.65 42.19 
4 43.31 23.13 58.80 65.50 37.69 59.11 25.67 51.46 
5 46.65 28.04 72.80 76.12 43.34 70.51 27.30 55.35 
6 61.34 39.45 77.95 89.04 48.58 89.14 32.49 60.58 
7 66.34 44.73 88.94 99.15 52.83 92.55 35.49 69.43 
8 72.32 52.28 97.83 99.95 60.03 97.28 51.10 77.41 
9 75.40 54.34   66.59 103.70 57.51 82.69 
10 81.07 59.98   74.79  67.55 90.61 
12 90.33 71.13   86.48  80.51 100.25 
24 100.25 101.4   99.47  98.19  
Chapter-5  Result 
Dept. of Pharmaceutical Science Saurashtra University Rajkot, Gujarat. 113 
 
Fig. 5.9 In vitro release profile of Designed formulation SC1 –SC8 
 
2.1.3 Mechanism of Drug Release: - 
Table 5.7 R2 & k values of the release profiles of each formulation made at 
formulation stage corresponding to Zero order, First order, and higuchi kinetics. 
Form 
Zero-order First order Higuchi 
R2 ko R
2 k1 R
2 kH 
SC1 0.5231 6.302 0.9858 0.167 0.9433 23.200 
SC2 0.7907 4.808 0.9818 0.086 0.9192 17.077 
SC3 0.1635 7.527 0.9614 0.333 0.8477 28.619 
SC4 0.8845 14.538 0.9689 0.601 0.9833 34.802 
SC5 0.6176 5.842 0.9700 0.178 0.9655 21.270 
SC6 0.9472 13.067 0.9549 0.359 0.9402 32.685 
SC7 0.8295 5.104 0.9343 0.114 0.8734 17.882 
SC8 0.8943 9.512 0.9725 0.195 0.9759 26.893 
NOTE: R
2 
= Coefficient of determination, ko = Zero-order release constant, k1 = First-order 
release constant, kH = Highchi release constant,  
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Table 5.8 R2, n
 
& kKP values of the release profiles of each formulation made at 
formulation stage corresponding to Korsmeyer – peppas models 
Formulation 
Korsmeyer-peppas 
R2 kKP N 
SC1 0.9434 17.077 0.669 
SC2 0.9533 9.262 0.771 
SC3 0.8682 21.039 0.726 
SC4 0.9939 29.671 0.598 
SC5 0.9680 18.206 0.569 
SC6 0.9862 19.920 0.789 
SC7 0.9304 11.178 0.685 
SC8 0.9934 19.554 0.669 
 
2.1.4 Polynomial equation 
Table 5.9 Polynomial equation of the various dependent variables in SC 
Formulation 
Simvastatin 
Floating 
capsule 
kH of  
Higuchi 
Y1=25.503+0.294X1-0.436X2+0.037X3-
0.113X4+0.134X5+0.185X6-0.030X7 
‘n’ of Korse-
Peppas 
Y1=0.621+0.0001X1-0.000878X2+0.022X3 
+0.002X4-0.004X5-0.00045X6+0.001X7 
log(K) Korse-
Peppas- 
Y1=1.3898+0.00422X1-0.0088X2-0.0125X3-
0.0055X4 +0.0068X5+0.0021X6-0.0006X7 
k1 of 1
st order Y1=0.199-0.009X1+0.009X2+0.007X3-
0.005X4-0.005X5-0.008X6+0.001X7 
k0 of  zero 
order 
Y1=7.265+0.226X1-0.226X2-0.165X3-0.055X4 
+0.017X5+0.196X6-0.072X7 
R2 of zero order Y1=0.962+0.014X1-0.001X2-0.040X3-
0.006X4-0.013X5+0.017X6-0.011X7 
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Fig 5.10 Effect of HPMC K4M and Cross carmellose sodium on ‘n’ of 
Korsemeyer-peppas 
 
For tablets of a known geometry (in this case a slab) n = 0.5 means Fickian 
diffusion, 0.5 < n < 1.0 non-Fickian diffusion, and n = 1.0 Case II diffusion. 
Considering the n values calculated for the studied tablets (Table 5.9), almost in 
most cases a non-Fickian mechanism is dominant. In this case the non- Fickian 
or anomalous diffusion shows also a relaxation of the polymeric chains, and 
influences the drug release. Release from initially dry, hydrophilic glassy 
polymers that swell in contact of water and become rubbery show anomalous 
diffusion as a result of the rearrangement of macromolecular chains. The 
thermodynamic state of the polymer and the penetrate concentration are 
responsible for the different types of the diffusion. A third class of diffusion is 
case II diffusion, which is a special case of non-Fickian diffusion. The results of 
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the calculated n (Table 5.9) reveal a non-Fickian type of drug diffusion, which 
means that the process of diffusion and relaxation run at comparable rates.  On 
the basis of polynomial equation for ‘n’ of Korsemeyer-peppas equation Cross 
carmelose sod., HPMC K4M, Veegum, HPC, Klucel HF having positive effect, 
and Veegum have the maximum effect on the ‘n’ value. 
2.1.5 Stability studies: 
Table 5.10 Stability data of optimized SC2 formulation stored at 45 ºC / 75% RH 
   PA- Physical appearance, DT- Disintegration time, % DC- Percent Drug Content. %CDR- 
Percent  cumulative drug Release. ++: same as initial, TFT- Total Floating Time 
 
 
2.1.6 Animal study: 
 
Table 5.11 Total cholesterol level in treated group. 
 
Treatment Total cholesterol level in mg/dL 
0 Day 18th Day 40th Day 
Control 25.85+1.609 25.26+1.668 25.85+1.399 
Pure Drug 25.93+2.003 13.11+1.166 10.55+0.607*** 
Formulation 27.35+3.123 13.46+1.785 10.23+0.951*** 
 
All values are mean  SEM, n = 6. *p<0.05, **p<0.01, ***p<0.001 when compared 
to control group 
 
 
 
Sampling 
interval 
Optimized Formulation 
PA %DC %CDR at 24 
Hr. 
TFT (Hr)  
0 ++ 100.43 89.51 25 
1 Week ++ 101.65 88.52 24 
2  week ++ 101.33 89.64 25 
3 Week ++ 101.95 88.14 24 
4 week ++ 101.23 87.75 25 
2 month ++ 100.56 88.34 25 
3 month ++ 100.34 87.56 25 
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Fig. 5.11 Total cholesterol level in treated group. 
 
2.2.   EVALUATION OF FLOATING TABLET 
 2.2.1 Floating tablet evaluation:    
Table 5.12 The values of various evaluation parameters of the formulations 
made at formulation stage 
Response 
FORMULATION CODE 
SF1 SF2 SF3 SF4 SF5 SF6 SF7 SF8 
Bulk density 
(gm/ml) 
0.435 0.436 0.376 0.388 0.391 0.403 0.431 0.423 
Tapped density 
(gm/ml) 
0.489 0.478 0.434 0.456 0.432 0.487 0.465 0.489 
Angle of repose 28.43 34.1 32.12 28.34 30.34 31.45 32.45 29.65 
Friability (%) 0.23 0.45 0.49 0.73 0.72 0.82 0.48 0.54 
Hardness 
(kg/cm2) 
4-5 4-5 4 4 5 4 4 4 
Wt variation (%) 1.44 1.87 2.52 2.76 0.89 0.54 0.71 0.24 
Floating Lag 
Time (Sec) 
65 209 165 180 90 245 720 1 
*** *** 
*** *** 
Chapter-5  Result 
Dept. of Pharmaceutical Science Saurashtra University Rajkot, Gujarat. 118 
TFT  (hr) 24 24 28 31 30 28 30 24 
Swelling Index 
 (24 Hr) 
572.4 578.5 580.8 559.5 611.6 602.8 602.5 692.5 
Drug content  
(%) 
98.37 98.23 101.3 99.37 100.3 99.34 97.23 100.3 
 
Fig 5.12 Pareto Chart showing the effect on Floating lag time of tablet112,123 
 
Fig 5.13 Pareto Chart showing the effect on Total Floating time of tablet 
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2.2.2 Dissolution Study or drug release testing of floating Tablet: - 
Table 5.13 Data of the release profile of the SF1 – SF8. 
 
Time 
(Hrs) 
Cumulative drug release (%) 
SF1 SF2 SF3 SF4 SF5 SF6 SF7 SF8 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0.5 3.89 2.92 6.16 8.11 8.11 7.46 3.89 10.05 
1 7.14 5.19 11.04 10.07 11.37 11.36 9.73 18.18 
2 11.05 10.07 17.22 23.38 19.17 15.28 16.24 24.05 
3 14.31 13.33 30.88 36.40 28.29 21.15 24.71 38.70 
4 23.42 21.14 42.94 45.24 42.62 34.81 33.51 48.83 
5 34.50 34.48 52.11 53.77 53.41 42.35 48.50 56.40 
6 49.49 48.18 60.01 60.05 63.58 52.81 58.98 64.95 
7 61.59 61.90 69.22 67.64 71.50 59.09 67.54 72.88 
8 75.99 76.63 79.10 74.27 77.82 68.30 77.74 81.79 
9 83.94 81.33 86.08 82.86 85.12 75.26 88.94 89.10 
10 93.53 88.00 92.76 90.18 91.80 82.23 96.27 97.73 
12 97.95 98.24 99.12 93.29 96.21 89.55 100.04 102.48 
24    98.36  99.79   
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Fig 5.14 In vitro release profile of Designed formulation SF1 –SF8 
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2.2.3 Swelling Studies of floating tablets   
Table 5.14 Data of the Swelling index of the SF1 – SF8 
 
 
 
 
 
 
Fig 5.15 Swelling index of the SF1 – SF8 
 
 
Swelling Index (%) 
 
Time 
(Hr) 
SF1 SF2 SF3 SF4 SF5 SF6 SF7 SF8 
1 177.7 182.5 180.3 180.4 183.7 186.3 175.8 213.8 
3 304.3 310.7 320.0 310.4 320.9 324.5 301.2 368.6 
6 361.1 376.7 399.0 376.8 388.8 390.5 367.6 445.2 
12 476.4 489.2 475.2 497.7 488.3 463.2 469.3 545.2 
24 572.4 578.5 580.8 559.5 611.6 602.8 602.5 692.5 
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2.2.4 Mechanism of Drug Release: - 
Table 5.15 R2 & K values of the release profiles of each formulation made at 
formulation stage corresponding to Zero order, First order, and higuchi kinetics. 
Form 
Zero-order First order Higuchi 
R2 ko R
2 k1 R
2 R2 
   SF1 
0.9649 8.583 0.8650 0.220 0.7788 23.116 
SF2 
0.9632 8.408 0.8654 0.210 0.7715 22.594 
SF3 
0.5562 6.683 0.9591 0.254 0.8912 24.516 
SF4 
0.4870 6.492 0.9830 0.183 0.9126 24.016 
SF5 
0.5536 6.693 0.9647 0.219 0.9013 24.564 
SF6 
0.6801 6.068 0.9635 0.209 0.9030 21.891 
SF7 
0.9851 9.272 0.9190 0.219 0.8602 25.402 
SF8 
0.9541 9.878 0.9630 0.249 0.9450 27.625 
NOTE: R
2 
= Coefficient of determination, ko = Zero-order release constant, k1 = First-order 
release constant, kH = Highchi release constant, 
 
Table 5.16 R2, n
 
& kKP values of the release profiles of each formulation made at 
formulation stage corresponding to Korsmeyer – peppas models 
Formulation 
Korsmeyer-peppas 
R2 K N 
SF1 0.9766 8.588 0.964 
SF2 0.9814 7.037 1.054 
SF3 0.9462 14.631 0.752 
SF4 0.9562 16.771 0.685 
SF5 0.9487 16.195 0.703 
SF6 0.9345 14.003 0.703 
SF7 0.9873 11.020 0.923 
SF8 0.9951 20.312 0.660 
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2.2.5 Polynomial equation 
Table 5.17 Polynomial equation of the various dependent variables in SF tablet 
formulation 
Simvastatin  
Floating 
Tablet 
kH of 
 Higuchi 
Y1=42.917-0.076X1-0.037X2-0.395X3-
0.014X4-0.041X5-0.949X6-0.245X7 
‘n’ Of Korse-
Peppas 
Y1=0.226+0.002X1+0.013X2+0.021X3+0.008
X4-0.007X5-0.019X6-0.071X7 
Log(k) of Korse-
Peppas- 
Y1=1.176+0.0033X1+0.0079X2+0.0069X3 
+0.0075X4+0.0114X5-0.0156X6-0.1271X7 
k0 of  
1st order 
Y1=-0.374+0.002X1+0.0004X2-0.001X3 
+0.001X4+0.0003X5+0.015X6-0.010X7 
k1 of  
 zero order 
Y1=19.817-0.019X1+0.060X2-0.108X3-
0.008X4-0.162X5-0.844X6-1.162X7 
R2 of zero order Y1=1.745+0.001X1+0.012X2+0.008X3-
0.003X4-0.032X5-0.097X6-0.149X7 
Floating Lag 
Time (sec) 
Y1=-917.5+11.64X1+7.7X2-
12.79X3+18.18X4-21.09X5-28.37X6-191.1X7 
 
 
Fig.5.16 Effect of HPMC K100M and HPMC K4M on ‘n’ of Kors-peppas 
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Fig. 5.17 Floating Tablet after 1 Hour 
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Fig. 5.18 Floating tablet after 24 Hour 
2.2.6 Stability studies: 
Table 5.18 Stability data of optimized SF8 formulation stored at 45 ºC / 75% RH 
   PA- Physical appearance, DT- Disintegration time, % DC- Percent Drug Content. %CDR-      
Percent cumulative drug Release. ++: same as initial, TFT- Total Floating Time 
Sampling 
interval 
Optimized Formulation 
PA %DC %CDR at 24 Hr. TFT (Hr)  
0 ++ 99.34 98.23 24 
1 Week ++ 99.23 98.56 25 
2  week ++ 99.76 99.67 24 
3 Week ++ 99.12 98.34 24 
4 week ++ 98.78 99.63 24 
2 month ++ 99.67 99.48 24 
3 month ++ 99.21 99.23 24 
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2.3.   EVALUATION OF HIGH DENSITY TABLET  
2.3.1 High Density Tablet Evaluation:   
Table 5.19 The values of various evaluation parameters of the formulations 
made at formulation stage 
Response 
FORMULATION CODE 
SH1 SH2 SH3 SH4 SH5 SH6 SH7 SH8 
Bulk density 
(gm/ml) 
0.367 0.373 0.339 0.360 0.373 0.378 0.389 0.339 
Tapped density 
(gm/ml) 
0.401 0.423 0.378 0.394 0.410 0.418 0.421 0.353 
Angle of repose 28.45 29.24 35.64 38.12 31.56 34.39 29.65 30.91 
Hardness(kg/cm2) 7 7 7 7 7 7-8 7-8 7 
Friability (%) 0.18 0.08 0.18 0.14 0.15 0.15 0.12 0.11 
%Mass Remain at 
24 Hr 
35 40 56 37 43 51 47 33 
Wt variation (%) 1.34 2.03 1.10 1.07 1.43 1.43 1.04 0.2 
Drug content (%) 98.27 97.17 100.1 100.5 101.5 99.63 101.2 100.4 
 
2.3.2 Dissolution Study or drug release testing of High density tablet: - 
Table 5.20 Data of the release profile of the SH1 – SH8. 
 
Time 
(Hrs) 
Cumulative drug release (%) 
SH1 SH2 SH3 SH4 SH5 SH6 SH7 SH8 
0.5 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
1 28.53 23.67 22.05 18.16 12.32 16.21 18.16 12.64 
2 32.81 26.31 25.01 23.38 16.56 26.95 21.11 19.16 
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3 41.31 35.13 31.55 27.65 23.73 31.54 26.02 27.63 
4 48.21 43.31 39.40 33.22 28.00 35.83 31.92 35.15 
5 57.26 52.16 48.57 39.46 35.19 42.39 38.47 42.68 
6 67.90 62.32 54.19 44.73 41.43 48.65 43.42 50.88 
7 73.88 67.97 62.41 49.69 47.36 52.32 48.70 58.13 
8 82.15 70.39 64.49 54.34 50.38 57.95 52.70 65.71 
9 90.11 76.38 71.45 59.32 55.03 62.29 57.68 75.58 
10 98.09 84.66 78.09 63.99 59.04 68.59 61.37 84.18 
12  93.27 84.42 77.10 73.76 80.41 69.94 91.17 
24  97.37 95.30 98.21 99.89 92.90 98.82 97.86 
 
 
 
  
Fig. 5.19 In vitro release profile of Designed formulation SH1 –SH8. 
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2.3.3 Mechanism of Drug Release: - 
Table 5.21 R2 & K values of the release profiles of each formulation made at 
formulation stage corresponding to Zero order, First order and higuchi kinetics. 
Form 
Zero-order First order Higuchi 
R2 ko R
2 k1 R
2 kH 
SH1 0.0891 6.881 0.9622 0.220 0.8737 26.001 
SH2 0.3132 6.352 0.9805 0.166 0.9269 23.665 
SH3 0.4150 5.945 0.9853 0.135 0.9510 21.982 
SH4 0.6040 5.264 0.9814 0.104 0.9700 19.152 
SH5 0.7048 4.927 0.9890 0.090 0.9469 17.734 
SH6 0.5356 5.505 0.9839 0.114 0.9711 20.157 
SH7 0.5435 4.951 0.9792 0.086 0.9726 18.113 
SH8 0.5899 6.055 0.9642 0.161 0.9054 22.041 
NOTE: R
2 
= Coefficient of determination, ko = Zero-order release constant, k1 = First-order 
release constant, kH = Highchi release constant,  
 
Table 5.22 R2, n
 
& kKP values of the release profiles of each formulation made at 
formulation stage corresponding to Korsmeyer – peppas models 
Formulation 
Korsmeyer-peppas 
R2 kKP N 
SH1 0.8990 26.691 0.494 
SH2 0.9319 21.592 0.546 
SH3 0.9518 19.719 0.552 
SH4 0.9737 16.423 0.567 
SH5 0.9638 11.623 0.688 
SH6 0.9716 17.051 0.578 
SH7 0.9734 15.968 0.556 
SH8 0.9122 12.934 0.743 
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2.3.4 Polynomial equation 
Table 5.23 Polynomial equation of the various dependent variables in SH 
Formulation 
 
Simvastatin  
High 
density 
kH of  
Higuchi 
Y1=30.326-0.031X1+0.034X2+0.615X3-0.063X4 
+0.028X5-0.929X6-3.218X7 
‘n’ of  
Korse-Peppas 
Y1=1.238-0.005X1-0.002X2-0.016X3-0.006X4 
-0.004X5+0.004X6+0.006X7 
Log(K) of  
Korse-Peppas- 
Y1=0.82106+0.00423X1+0.00274X2+0.02881X3 
+0.004432X4+0.00378X5-0.024X6-0.073X7 
k0 of  
1st order 
Y1=-0.385+0.004X1-0.004X2-
0.008X3+0.001X4-0.001X5+0.016X6+0.056X7 
k1 of   
zero order 
Y1=9.282-0.011X1+0.005X2+0.145X3-0.013X4 
+0.005X5-0.223X6-0.806X7 
R2 of 
 zero order 
Y1=0.718-0.004X1-0.008X2-0.045X3-0.001X4-
0.005X5+0.065X6+0.151X7 
 
 
 
Fig 5.20 Pareto chart showing the effect of polymer on ‘n’ of Kors-Peppas 
of SH 
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Fig. 5.21 High Density Tablet at 0 Hour 
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Fig. 5.22 High Density Tablet at 27 Hour 
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2.3.5 Stability studies: 
 
Table 5.24 Stability data of optimized SH4 formulation stored at 45 ºC / 75% RH 
 PA- Physical appearance, DT- Disintegration time, % DC- Percent Drug Content. %CDR- 
Percent      cumulative drug Release. ++: same as initial, TFT- Total Floating Time. 
 
 
2.4 EVALUATION OF MUCOADHESIVE TABLET 
2.4.1 Evaluation of Mucoadhesive Tablet. 
Table 5.25 The values of various evaluation parameters of the formulations 
made at formulation stage 
Response 
FORMULATION CODE 
SM1 SM2 SM3 SM4 SM5 SM6 SM7 SM8 
Bulk density 
(gm/ml) 
0.321 0.341 0.339 0.350 0.333 0.410 0.389 0.391 
Tapped density 
(gm/ml) 
0.374 0.383 0.547 0.419 0.360 0.448 0.428 0.422 
Angle of repose 29.34 28.65 30.12 29.67 35.34 38.23 31.48 34.53 
Hardness(Kg/cm2) 4 4 5 5 4 4 4-5 4 
Friability (%) 0.56 0.64 0.78 0.55 0.78 0.63 0.92 0.92 
Wt variation (%) 1.46 1.34 1.1 2.63 5.92 3.40 1.84 0.21 
Swelling Index  
(24 Hr) 
767.9 791.4 797.6 813.4 927.3 884.6 810.3 1045.4 
Sampling 
interval 
Optimized Formulation 
PA %DC %CDR at 24 Hr. 
0 ++ 100.23 92.34 
1 Week ++ 100.45 93.56 
2  week ++ 100.34 92.45 
3 Week ++ 100.12 92.78 
4 week ++ 100.23 93.01 
2 month ++ 100.11 93.42 
3 month ++ 99.34 93.04 
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Mucoadhesive 
Strength 
(gm) 
25 27 23 21 22 23 22 18 
Mucoadhesion 
Time (Hr) 
18 15 19 26 24 21 25 24 
Drug content  (%) 99.17 99.57 102.2 99.55 101.7 97.23 102.6 103.4 
2.4.2 Dissolution Study or drug release testing of mucoadhesive tablet: - 
  Table 5.26 Data of the release profile of the SM1 – SM8. 
Time 
(Hrs) 
Cumulative drug release (%) 
SM1 SM2 SM3 SM4 SM5 SM6 SM7 SM8 
0 0.00  0.00  0.00  0.00  0.00  0.00  0.00  0.00  
0.5 13.29  8.75  12.32  19.13  6.48  7.78  4.86  7.78  
1 17.86  19.80  21.75  21.44  12.33  17.20  9.41  11.69  
2 28.92  23.08  35.74  31.21  17.55  24.05  13.32  16.58  
3 33.20  29.29  40.03  38.74  26.67  30.26  18.87  31.85  
4 36.84  32.92  50.17  46.61  31.91  35.51  23.77  38.73  
5 44.70  38.83  51.26  48.33  36.85  40.46  31.93  44.65  
6 47.07  44.11  53.96  58.49  41.14  46.06  40.10  51.24  
7 51.39  49.39  60.56  62.83  46.10  52.97  48.62  56.21  
8 55.39  51.12  62.32  72.37  50.41  61.84  51.00  61.85  
9 60.70  58.69  70.56  79.02  55.39  66.84  56.95  68.47  
10 66.02  63.03  75.58  84.70  59.72  75.09  64.85  76.72  
12 73.95  69.33  81.90  93.64  68.61  82.71  72.45  84.02  
24 96.76  98.94  98.27  99.03  97.73  99.89  98.96  99.12  
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Fig. 5.23 In vitro release profile of Designed formulation SM1 –SM8. 
 
 
2.4.3 Swelling Studies of floating tablets  
Table 5.27 Data of the Swelling index of the SM1 – SM8 
 
 
 
    Swelling Index(%) 
Time (Hr) SM1 SM2 SM3 SM4 SM5 SM6 SM7 SM8 
1 
132.6 136.2 137.2 141.3 167.8 156.9 140.1 194.5 
3 
311.6 318.6 314.4 328.8 382.0 356.4 323.6 441.2 
6 
328.4 340.5 334.4 349.5 406.0 378.5 345.8 458.2 
12 
535.8 571.4 592.6 520.2 738.8 766.7 586.8 715.2 
24 
767.9 791.4 797.7 813.5 927.3 884.6 810.4 1045.5 
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Fig 5.24 Swelling index of the SM1 – SM8 
 
 
Fig. 5.25 Pareto Chart showing the effect of polymer on Mucoadhesive 
strengh of tablet 
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2.4.4 Mechanism of drug release: - 
 
Table 5.28 R2 & K values of the release profiles of each formulation made at 
formulation stage corresponding to Zero order, First order, and higuchi kinetics.  
Form 
Zero-order First order Higuchi 
R2 ko R
2 k1 R
2 kH 
SM1 0.4545 5.261 0.9614 0.096 0.9800 19.447 
SM2 0.4402 4.832 0.9467 0.079 0.9592 17.900 
SM3 0.1834 5.782 0.9504 0.111 0.9328 21.813 
SM4 0.3782 6.393 0.9687 0.188 0.9438 23.783 
SM5 0.6557 4.791 0.9887 0.081 0.9666 17.405 
SM6 0.6318 5.671 0.9824 0.126 0.9527 20.632 
SM7 0.7485 4.872 0.9790 0.086 0.9102 17.406 
SM8 0.6697 5.871 0.9891 0.167 0.9480 21.278 
NOTE: R
2 
= Coefficient of determination, ko = Zero-order release constant, k1 = First-order 
release constant, kH = Highchi release constant. 
 
Table 5.29 R2, n
 
& kKP values of the release profiles of each formulation made at 
formulation stage corresponding to Korsmeyer – peppas models 
Formulation 
Korsmeyer-peppas 
R2 kKP n 
SM1 0.9821 19.005 0.515 
SM2 0.9611 15.885 0.563 
SM3 0.9593 21.710 0.517 
SM4 0.9485 23.817 0.501 
SM5 0.9720 11.778 0.685 
SM6 0.9570 14.705 0.659 
SM7 0.9364 8.720 0.810 
SM8 0.9564 12.779 0.737 
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2.4.5 Polynomial equation 
Table 5.30 Polynomial equation of the various dependent variables in SM 
Formulation 
 
Simvastatin 
Mucoadhesive 
Tablet 
kH of 
Higuchi 
Y1=21.903+0.048X1-0.384X2-0.001X3 
+0.027X4+0.163X5+0.028X6-1.288X7 
‘n’ of Kors-
Peppas 
Y1=1.034-0.0003X1+0.004X2-0.006X3-
0.003X4-0.017X5+0.022X6+0.089X7 
log(k) of   
Kors-Peppas 
Y1=-0.348-0.00096X1 +0.00628X2 
+0.00138X3+0.00007X4-0.00058X5 
+0.00165X6+0.0316X7 
k1  
of 1st order 
Y1=-0.348-0.001X1+0.006X2+0.006X3 
+0.000073X4-0.001X5+0.002X6+0.032X7 
k0 of 
  zero order 
Y1=7.243+0.015X1-0.099X2-0.005X3+ 
0.004X4+0.031X5+0.012X6-0.310X7 
R2 of zero order Y1=0.892+0.004X1+0.011X2-0.009X3 
-0.008X4-0.026X5+-0.006X6+0.069X7 
Mucoadhesive 
strength 
Y1=15.5+0.017X1+0.275X2+0.188X3 
+0.063X4+0.031X5-0.625X6-0.250X7 
 
2.4.6 In vivo studies 
 
in vivo evaluation of gastrointestinal residence time of gastroretentive dosage 
form to confirm the spatial and temporary placement of gastroretentive drug 
delivery system. X-ray technique was used to determine the gastric residence 
time of the tablets. 
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(a)        (b) 
  
 
  (c) 
            Fig. 5. 26 X-ray images shows the placing of placebo table, (a) At 5 
Min. (b) 3 hr (c) 12 hr 
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2.4.7 Stability studies: 
 Table 5.31 Stability data of optimized SM5 formulation stored at 45 ºC / 75% RH 
 
 
   PA- Physical appearance, DT- Disintegration time, % DC- Percent Drug Content. %CDR- 
Percent  cumulative drug Release. ++: same as initial, TFT- Total  Floating Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sampling 
interval 
Optimized Formulation 
PA %DC %CDR at 
24 Hr. 
Mucoadhesion 
Time (Hr) 
Mucoadhesive 
Strength 
(gm) 
0 ++ 101.84 81.34 24 21.98 
1 Week ++ 101.65 83.45 24 21.83 
2  week ++ 101.45 85.31 24 22.03 
3 Week ++ 101.69 83.56 24 21.45 
4 week ++ 101.34 84.83 24 22.10 
2 month ++ 101.45 83.40 24 21.49 
3 month ++ 101.23 84.98 24 21.45 
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3. EVALUATION OF GASTRORETENTIVE DOSAGE FORM OF 
ATORVASTATIN : 
3.1. EVALUATION OF FLOATING CAPSULE 
3.1.1 Filling capsule evaluation: 
Table 5.32 the values of various evaluation parameters of the formulations made 
at formulation stage 
Response 
FORMULATION CODE 
AC1 AC2 AC3 AC4 AC5 AC6 AC7 AC8 
Bulk density 
(gm/ml) 
0.346 0.324 0.367 0.327 0.378 0.339 0.398 0.388 
Tapped density 
(gm/ml) 
0.401 0.398 0.478 0.445 0.480 0.427 0.456 0.487 
Angle of repose 
(o) 
28.34 33.45 28.34 35.98 33.45 33.45 33.23 29.34 
Friability (%) 
(granules) 
0.11 0.21 0.39 0.34 0.23 0.63 0.49 0.86 
% Fine 12 15 15 16 18 20 13 21 
Wt variation (%) 2.21 1.46 2.13 2.56 1.23 1.34 0.68 0.23 
TFT  (hr) 
20 26 8 7 21 7 18 9 
Drug content (%) 99.1 99.4 99.3 101.2 102.7 99.8 100.6 101.3 
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3.1.2 Dissolution Study or drug release testing of floating Capsule: - 
  Table 5.33 Data of the release profile of the AC1 – AC8. 
Time 
(Hrs) 
Cumulative drug release (%) 
AC1 AC2 AC3 AC4 AC5 AC6 AC7 AC8 
0 0.00  0.00  0.00  0.00  0.00  0.00  0.00  0.00  
0.5 9.65  3.66  11.65  17.97  12.65  15.64  8.31  12.98  
1 14.37  13.00  21.70  27.73  17.38  23.05  13.42  19.38  
2 19.44  18.73  24.48  40.53  26.46  30.84  17.01  29.80  
3 29.86  23.83  32.27  51.73  30.60  45.32  19.28  38.95  
4 41.68  30.28  39.44  63.67  37.43  55.22  26.55  45.49  
5 48.90  34.78  48.98  72.01  45.29  66.17  28.31  54.40  
6 57.15  44.29  62.56  81.72  50.19  75.52  33.73  63.01  
7 66.12  47.86  72.22  88.16  58.79  85.26  36.92  74.01  
8 69.81  55.44  82.27  95.96  67.76  94.71  53.07  81.73  
9 80.17  66.39  94.69  104.47  78.12  101.54  59.82  90.17  
10 82.60  72.74  102.20   84.86   70.32  98.64  
12 92.70  75.80    92.31   83.85  103.17  
24 102.19  98.20    104.13   99.20   
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Fig. 5.27 In vitro release profile of Designed formulation AC1 –AC8. 
 
3.1.3 Mechanism of Drug Release: - 
 
Table 5.34 R2 & K values of the release profiles of each formulation made at 
formulation stage corresponding to Zero order, First order, and higuchi kinetics.  
For
m 
Zero-order First order Higuchi 
R2 ko R
2 k1 R
2 kH 
AC1 0.5926 6.366 0.9792 0.176 0.9315 23.267 
AC2 0.6538 5.195 0.9749 0.095 0.9170 18.828 
AC3 0.4832 7.004 0.9266 0.219 0.8787 25.843 
AC4 0.0107 7.720 0.9697 0.318 0.8561 29.555 
AC5 0.6220 6.295 0.9631 0.169 0.9401 22.903 
AC6 0.1834 7.426 0.9635 0.278 0.8664 28.155 
AC7 0.8318 5.312 0.9276 0.157 0.8721 18.599 
AC8 0.4112 6.988 0.9599 0.264 0.9069 25.994 
NOTE: R
2 
= Coefficient of determination, ko = Zero-order release constant, k1 = First-order 
release constant, kH = Highchi release constant. 
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Table 5.35 R2, n
 
& kKP values of the release profiles of each formulation made at 
formulation stage corresponding to Korsmeyer – peppas models 
Formulation 
Korsmeyer-peppas 
R2 kKP n 
AC1 0.9344 14.318 0.757 
AC2 0.9263 9.709 0.812 
AC3 0.8788 17.850 0.688 
AC4 0.9026 27.257 0.604 
AC5 0.9445 17.306 0.642 
AC6 0.8857 22.767 0.659 
AC7 0.9303 11.503 0.690 
AC8 0.9083 19.324 0.678 
 
3.1.4 Polynomial equation 
Table 5.36 Polynomial equation of the various dependent variables in AC 
Formulation 
 
Atorvastatin 
Floating 
Capsule 
kH of 
Higuchi 
Y1=28.33+0.120X1-0.260X2-0.048X3 
-0.150X4+0.100X5+0.115X6-0.043X7 
‘n’ of 
 Kors-Peppas 
Y1=0.688-0.002X1+0.002722X2+0.015X3 
+0.001X4-0.001X5-0.002X6-0.003X7 
Log(K)  
of kors-peppas 
Y1=1.363+0.005X1-0.009X2-0.013X3 
-0.006X4+0.004X5+0.005X6+0.001X7 
k1 of 
 1st order 
Y1=-0.341-0.004X1+0.005X2+0.007X3 
+0.002X4-0.001X5-0.001X6+0.001X7 
k0 of  
 zero order 
Y1=7.772+0.027X1-0.060X2-0.016X3 
-0.037X4+0.025X5+0.019X6-0.005X7 
R2 of  
zero order 
Y1=0.594-0.011X1+0.016X2+0.002X3 
+0.003X4-0.004X5-0.017X6+0.009X7 
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3.1.5 Stability studies: 
Table 5.37 Stability data of optimized AC2 formulation stored at 45 ºC / 75% RH 
 
   PA- Physical appearance, DT- Disintegration time, % DC- Percent Drug Content.  %CDR- 
Percent     cumulative drug Release. ++: same as initial, TFT- Total  Floating Time  
 
 
3.1.6 Animal study: 
 
Table 5.38 Total cholesterol level in treated group 
 
Treatment Total cholesterol level in mg/dL 
0 Day 18th Day 40th Day 
Control 27.71+3.20 
 
27.82+3.68 27.15+3.48 
Pure Drug 
28.8+1.93 12.5+1.68 9.2+0.96 
Formulation 26.08+4.49 12.8+2.32 7.95+1.01 
 
All values are mean  SEM, n = 6. *p<0.05, **p<0.01, ***p<0.001 when compared 
to control group 
 
Sampling 
interval 
Optimized Formulation 
PA %DC %CDR at 24 Hr. TFT (Hr)  
0 ++ 102.34 101.2 20 
1 Week ++ 102.45 100.45 21 
2  week ++ 102.67 99.45 22 
3 Week ++ 101.45 99.82 22 
4 week ++ 101.53 99.83 21 
2 month ++ 101.83 99.64 21 
3 month ++ 102.77 99.62 21 
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Fig. 5.28 Total cholesterol level in treated group. 
 
3.2. EVALUATION OF FLOATING TABLET  
 3.2.1 Floating tablet evaluation: 
Table 5.39 The values of various evaluation parameters of the formulations AF 
made at formulation stage 
Response 
FORMULATION CODE 
AF1 AF2 AF3 AF4 AF5 AF6 AF7 AF8 
Bulk density 
(gm/ml) 
0.323 0.345 0.382 0.389 0.364 0.383 0.399 0.401 
Tapped density 
(gm/ml) 
0.364 0.391 0.437 0.421 0.401 0.418 0.438 0.442 
Angle of repose(o) 
27.34 29.45 32.45 33.67 29.95 34.76 32.86 31.78 
Hardness(Kg/cm2) 
4 4 4 4 4 4-5 4 4 
Friability (%) 
0.28 0.25 0.29 0.76 0.63 0.73 0.21 0.92 
Wt variation (%) 
1.83 2.06 1.74 1.93 1.98 2.20 4.04 1.74 
*** *** 
*** 
*** 
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Floating Lag Time 
(Sec) 
78 167 112 195 110 185 550 3 
TFT  (hr) 
28 21 28 17 29 28 30 21 
Swelling Index  
(24 Hr) 
571.6 578.3 580.3 556.1 614.3 602.8 604.3 691.6 
Drug content (%) 99.17 99.57 102.2 99.55 101.7 97.23 102.6 103.4 
 
Fig 5.29 Pareto chart showing the effect of polymer on floating lag time of 
AF 
 
Fig 5.30 Pareto chart showing the effect of polymer on Total floating time of 
AF 
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3.2.2 Dissolution Study or drug release testing of Floating Tablet: - 
Table 5.40 Data of the release profile of the AF1 – AF8. 
Time 
(Hrs) 
Cumulative drug release (%) 
AF1 AF2 AF3 AF4 AF5 AF6 AF7 AF8 
0 0.00  0.00  0.00  0.00  0.00  0.00  0.00  0.00  
0.5 5.99  4.66  8.32  9.65  3.00  11.65  9.99  12.65  
1 8.69  7.68  13.69  13.70  7.67  15.38  13.70  20.71  
2 10.73  12.38  19.09  19.43  13.71  20.45  25.43  29.47  
3 17.12  14.45  26.52  24.53  19.11  31.88  32.89  35.96  
4 21.87  19.52  34.99  32.99  29.20  38.71  41.39  45.48  
5 29.64  27.28  43.50  41.83  37.68  44.59  50.27  61.04  
6 36.80  32.76  48.07  52.37  48.87  57.14  64.20  69.03  
7 45.32  38.60  53.66  62.98  63.78  63.78  74.53  78.39  
8 52.89  46.13  58.94  69.64  75.78  72.12  81.93  86.81  
9 59.84  54.04  68.91  79.68  86.85  80.16  90.36  91.94  
10 69.15  62.98  76.94  85.10  96.31  88.92  98.51  103.42  
12 83.50  72.65  81.68  97.21  102.16  94.39  102.37   
24 99.27  98.76  89.11  102.73  103.37  104.55      
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Fig. 5.31 In vitro release profile of Designed formulation AF1 –AF8. 
 
3.2.3 Swelling Studies of floating tablets   
 
Table 5.41 Data of the Swelling index of the AF1 – AF8 
 
 
 
 
 
 Swelling Index (%) 
Time (hr) AF1 AF2 AF3 AF4 AF5 AF6 AF7 AF8 
1 174.5 180.4 182.5 178.3 185.3 187.3 178.3 206.9 
3 304.3 310.4 315.5 311.4 321.6 324.3 301.0 369.6 
6 360.4 378.3 398.3 376.3 389.4 392.5 369.3 445.7 
12 480.3 490.3 477.3 498.4 492.2 462.5 470.2 547.8 
24 571.6 578.3 580.3 556.1 614.3 602.8 604.3 691.6 
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Fig 5.32 Swelling index of the AF1 –AF8 
3.2.4 Mechanism of Drug Release: - 
Table 5.42 R2 & K values of the release profiles of each formulation made at 
formulation stage corresponding to Zero order, First order, and higuchi kinetics. 
Form 
Zero-order First order Higuchi 
R2 ko R
2 k1 R
2 kH 
AF1 0.8204 5.226 0.9451 0.115 0.8661 18.324 
AF2 0.8189 4.637 0.9578 0.081 0.8709 16.277 
AF3 0.5944 5.553 0.9826 0.110 0.9294 20.282 
AF4 0.6604 6.319 0.9488 0.195 0.8998 22.842 
AF5 0.6797 6.511 0.8959 0.204 0.8286 23.313 
AF6 0.6100 6.473 0.9643 0.190 0.9256 23.590 
AF7 0.9726 9.777 0.9425 0.260 0.9153 27.145 
AF8 0.9721 10.902 0.9505 0.232 0.9347 28.576 
NOTE: R
2 
= Coefficient of determination, ko = Zero-order release constant, k1 = First-order 
release constant, kH = Highchi release constant. 
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Table 5.43 R2, n
 
& kKP values of the release profiles of each formulation made at 
formulation stage corresponding to Korsmeyer – peppas models 
Formulation 
Korsmeyer-peppas 
R2 kKP n 
AF1 0.9232 8.397 0.830 
AF2 0.9259 7.426 0.837 
AF3 0.9326 13.569 0.687 
AF4 0.9120 13.302 0.768 
AF5 0.8542 6.527 1.143 
AF6 0.9301 15.640 0.712 
AF7 0.9903 14.991 0.797 
AF8 0.9945 19.410 0.693 
 
3.2.5 Polynomial equation 
 
Table 5.44 Polynomial equation of the various dependent variables in AF 
Formulation 
 
Atorvastatin 
Floating tab 
kH of  
Higuchi 
Y1=48.183+0.054X1-0.160X2-0.975X3-
0.151X4-0.338X5-1.038X6+2.077X7 
‘n’ Of Korse-
Peppas 
Y1=0.089-0.004X1+0.012X2-0.014X3-
0.006X4+0.012X5+0.057X6+0.053X7 
log(k) of  
Korse-Peppas- 
Y1=2.167+0.005X1-0.015X2-0.012X3 
+0.002X4-0.017X5-0.065X6-0.065X7 
+0.028X7 
 
k0 of  
1st order 
Y1=-0.3841-0.0021X1+0.0010X2+0.0164X3 
+ 0.0020X4+0.0044X5+0.0058X6-0.0351X7 
k1 of  
 zero order 
Y1=25.632+0.003X1-0.048X2-0.484X3 
-0.059X4-0.256X5-0.940X6+0.307X7 
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R2 of 
 zero order 
Y1=1.643-0.014X1+0.009X2-0.004X3-
0.010X4 -0.011X5-0.142X6+0.212X7 
Floating Lag Time 
(sec) 
Y1=-732+9.62X1+6.40X2-13.64X3+ 
13.5X4 -12.81X5-10.75X6+128.5X7 
 
3.2.6 In vivo studies 
 
in vivo evaluation of gastrointestinal residence time of gastroretentive dosage 
form to confirm the spatial and temporary placement of gastroretentive drug 
delivery system. X-ray technique was used to determine the gastric residence 
time of the tablets. 
                 
(a)        (b) 
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  (c) 
 
Fig. 5.33 X-ray image shows the placing of placebo table, (a) At 5 Min. (b) 3 hr 
(c) 8 hr  
3.2.7 Stability studies: 
 
Table 5.45 Stability data of optimized AF1 formulation stored at 45 ºC / 75% RH 
   PA- Physical appearance, DT- Disintegration time, % DC- Percent Drug Content. %CDR- 
Percent  cumulative drug Release. ++: same as initial, TFT- Total Floating Time. 
 
Sampling 
interval 
Optimized Formulation 
PA %DC %CDR at 24 Hr. TFT (Hr)  
0 ++ 99.40 84.34 24 
1 Week ++ 99.57 85.84 24 
2  week ++ 99.23 89.95 24 
3 Week ++ 99.10 88.47 24 
4 week ++ 99.64 88.83 26 
2 month ++ 99.42 83.78 22 
3 month ++ 99.43 85.21 24 
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3.3   EVALUATION OF HIGH DENSITY TABLET 
3.3.1 High Density Tablet Evaluation:    
Table 5.46 The values of various evaluation parameters of the formulations 
made at formulation stage 
Response 
FORMULATION CODE 
AH1 AH2 AH3 AH4 AH5 AH6 AH7 AH8 
Bulk density 
(gm/ml) 
0.382 0.362 0.385 0.401 0.373 0.384 0.399 0.381 
Tapped density 
(gm/ml) 
0.424 0.402 0.435 0.485 0.412 0.412 0.450 0.421 
Angle of repose 36.89 32.74 32.77 37.76 27.67 29.49 30.54 31.96 
Friability (%) 1.57 1.83 1.43 0.21 0.23 0.32 0.42 0.49 
Wt variation (%) 1.43 2.95 3.39 3.85 1.39 1.94 0.57 1.93 
Hardness(Kg/cm2) 6-7 6-7 7-8 7-8 7-8 7-8 7-8 7-8 
Drug content (%) 99.17 99.57 102.2 99.55 101.7 97.23 102.6 103.4 
%Mass remain 35 40 56 23 46 56 45 17 
 
3.3.2 Dissolution Study or drug release testing of high density tablet: - 
         Table 5.47 Data of the release profile of the AH1 – AH8. 
Time 
(Hrs) 
Cumulative drug release (%) 
AH1 AH2 AH3 AH4 AH5 AH6 AH7 AH8 
0 0.00  0.00  0.00  0.00  0.00  0.00  0.00  0.00  
1 5.33  11.98  3.66  14.98  4.33  8.65  5.99  16.31  
2 8.68  21.04  7.68  31.70  6.35  12.03  8.69  25.72  
3 16.05  27.14  10.71  47.19  8.38  24.08  13.06  34.18  
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4 22.47  34.28  14.77  56.10  11.09  33.20  15.46  42.69  
5 29.58  45.45  20.17  62.40  16.48  42.37  17.88  54.24  
6 35.40  53.36  27.94  70.73  18.56  46.93  20.64  63.20  
7 48.24  61.31  33.09  74.78  23.66  60.17  24.75  68.20  
8 57.16  67.30  38.93  82.84  26.45  69.48  29.54  76.56  
9 70.79  72.33  47.79  87.62  30.92  78.18  33.70  83.63  
10 80.83  78.38  55.04  99.08  36.75  85.93  35.88  98.40  
12 94.91  87.79  65.33  103.94  41.94  97.38  44.72   
24 101.42  103.57  86.98   84.13  102.23  89.60    
 
 
Fig. 5.34 In vitro release profile of Designed formulation AH1 –AH8. 
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3.3.3 Mechanism of Drug Release: - 
 
Table 5.48 R2 & K values of the release profiles of each formulation made at 
formulation stage corresponding to Zero order, First order, and higuchi kinetics.  
Form 
Zero-order First order Higuchi 
R2 ko R
2 k1 R
2 kH 
AH1 0.7830 5.733 0.8869 0.153 0.8062 20.067 
AH2 0.6436 6.119 0.9779 0.148 0.9369 22.182 
AH3 0.9124 4.320 0.9420 0.078 0.8177 14.766 
AH4 0.2200 7.172 0.9744 0.280 0.9019 26.943 
AH5 0.9547 3.028 0.9822 0.042 0.8365 10.309 
AH6 0.6638 6.238 0.9314 0.193 0.8674 22.457 
AH7 0.9442 3.229 0.9911 0.046 0.8767 11.121 
AH8 0.9804 9.917 0.9557 0.237 0.9198 26.044 
NOTE: R
2 
= Coefficient of determination, ko = Zero-order release constant, k1 = First-order 
release constant, kH = Highchi release constant. 
 
Table 5.49 R2, n
 
& kKP values of the release profiles of each formulation made at 
formulation stage corresponding to Korsmeyer – peppas models 
Formulation 
Korsmeyer-peppas 
R2 kKP n 
AH1 0.8730 4.362 1.228 
AH2 0.9468 11.693 0.827 
AH3 0.9431 3.649 1.102 
AH4 0.9136 17.538 0.768 
AH5 0.9771 3.586 0.945 
AH6 0.8880 7.491 1.052 
AH7 0.9886 5.335 0.808 
AH8 0.9953 15.362 0.776 
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3.3.4 Polynomial equation 
 
Table 5.50 polynomial equations of the various dependent variables in AH 
Formulation 
 
Atorvastatin 
High 
density 
kH of  
Higuchi 
Y1=57.814+0.114X1-0.415X2+0.211X3-
0.060X4-0.304X5+1.237X6-9.145X7 
‘n’ of  
Kors-Peppas 
Y1=0.380+0.003X1+0.002X2+0.038X3-0.008X4 
+0.018X5-0.040X6+0.077X7 
log(k) of  
Kors-Peppas- 
Y1=-0.313+0.001235X1+0.00079X2+0.017X3-
0.003498X4+0.007X5-0.016X6+0.041X7 
k1 of 
 1st order 
Y1=0.631+0.003X1-0.006X2-0.001X3-0.001X4-
0.002X5+0.019X6-0.115X7 
k0 of  
 zero order 
Y1=27.333-0.016X1-0.149X2-0.039X3-0.064X4-
0.164X5-0.080X6-3.031X7 
R2 of  
zero order 
Y1=1.643-0.014X1+0.009X2-0.004X3-0.010X4-
0.011X5-0.142X6+0.212X7 
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Fig 5.35 Pareto chart showing the effect of polymer on ‘n’ of Kors-Peppas 
of AH 
3.3.5 In vivo studies 
 
 
(a)     (b)    (c) 
 
Fig. 5.36 X-ray image shows the placing of placebo table, (a) At 5 Min. (b) 3 hr 
(c) 6 hr  
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3.3.6 Stability studies: 
Table 5.51 Stability data of optimized AH7 formulation stored at 45 ºC / 75% RH 
 
 
   PA- Physical appearance, DT- Disintegration time,  % DC- Percent Drug Content. %CDR- 
Percent  cumulative drug Release. ++: same as initial, TFT- Total  Floating Time 
 
 
3.4.   EVALUATION OF MUCOADHESIVE TABLET 
3.4.1 Mucoadhesive Tablet Evaluation:    
Table 5.52 The values of various evaluation parameters of the formulations AM 
made at formulation stage 
Response 
FORMULATION CODE 
AM1 AM2 AM3 AM4 AM5 AM6 AM7 AM8 
Bulk density 
(gm/ml) 
0.333 0.335 0.439 0.380 0.363 0.389 0.391 0.387 
Tapped density 
(gm/ml) 
0.384 0.393 0.537 0.459 0.430 0.448 0.438 0.461 
Angle of repose 29.74 31.32 29.74 32.93 35.92 32.52 33.31 30.46 
Friability (%) 0.98 0.45 0.89 1.4 0.67. 0.62 0.88 0.91 
Sampling 
interval 
Optimized Formulation 
PA %DC %CDR at 24 Hr. 
0 ++ 101.33 86.81 
1 Week ++ 102.04 83.32 
2  week ++ 101.44 85.74 
3 Week ++ 101.56 85.64 
4 week ++ 101.54 87.55 
2 month ++ 101.89 88.94 
3 month ++ 100.93 88.12 
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Wt variation (%) 2.34 1.56 3.12 3.67 0.93 1.30 0.84 0.06 
Hardness 
(Kg/cm2) 
4-5 4 4 4-5 5 4-5 4-5 4-5 
Swelling Index 
(24 Hr) 
767.9 791.4 797.6 813.4 927.3 884.6 810.3 1045.4 
Mucoadhesive 
Strength 
25.2 27 23 20.8 22 23 22.3 18 
Mucoadhesion 
Time (Hr) 
27 15 20 26 14 24 25 24 
Drug content (%) 99.77 98.23 101.6 98.4 99.5 97.43 102.2 99.8 
3.4.2 Dissolution Study or drug release testing of mucoadhesive tablet: - 
Table 5.53 Data of the release profile of the AM1 – AM8. 
 
Time 
(Hrs) 
Cumulative drug release (%) 
AM1 AM2 AM3 AM4 AM5 AM6 AM7 AM8 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0.5 11.65 8.65 9.99 19.30 7.66 10.65 7.66 3.66 
1 17.37 19.02 13.70 25.07 16.35 20.36 16.35 12.34 
2 28.45 22.45 22.43 31.87 19.77 29.79 24.76 25.38 
3 33.27 30.23 28.55 41.36 26.87 37.61 33.89 33.51 
4 37.45 35.06 35.36 46.91 30.68 40.82 38.40 39.02 
5 44.64 39.25 42.21 50.17 39.50 45.70 43.60 43.57 
6 49.88 47.12 48.10 60.76 43.05 52.94 47.84 45.80 
7 54.14 51.37 56.68 69.41 44.61 59.55 51.43 48.38 
8 56.43 56.31 62.65 77.11 49.51 65.87 53.37 56.30 
9 59.40 63.27 71.31 83.85 55.11 73.21 56.32 60.93 
10 64.05 69.60 80.35 88.96 56.74 80.60 58.95 62.92 
12 69.39 76.97 88.78 96.43 59.70 85.69 63.26 70.25 
24 99.05 101.01 100.90 
102.6
1 
98.32 103.46 98.23 99.59 
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Fig. 5.37 In vitro release profile of designed formulation AM1 –AM8. 
 
 
  3.4.3 Swelling Studies of floating tablets   
 
Table 5.54 Data of the Swelling index of the AM1 – AM8 
  
 
 
    Swelling Index(%) 
Time (Hr) 
AM1 AM2 AM3 AM4 AM5 AM6 AM7 AM8 
1 
133.4 135.5 138.3 140.3 165.3 157.2 140.3 193.3 
3 
311.6 315.0 310.4 330.3 382.5 360.2 330.4 449.4 
6 
328.7 345.5 340.4 355.3 402.4 380.3 350.3 475.3 
12 
535.9 563.3 595.4 524.4 745.3 770.4 599.1 734.9 
24 
771.3 800.4 801.5 815.3 950.2 884.2 818.4 1050.6 
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 Fig 5.38 Swelling index of the AM1 –AM8 
 
 
 
Fig. 5.39 Pareto Chart showing the effect of polymer on Mucoadhesive 
strengh of tablet of AM 
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Fig. 5.40 Pareto Chart showing the release retardant effect of polymer on 
tablet of AM 
3.4.4 Mechanism of Drug Release: - 
Table 5.55 R2 & K values of the release profiles of each formulation made at 
formulation stage corresponding to Zero order, First order, and higuchi kinetics. 
Form 
Zero-order First order Higuchi 
R2 ko R
2 k1 R
2 kH 
AM1 0.3907 5.157 0.9553 0.090 0.9771 19.176 
AM2 0.5800 5.343 0.9823 0.102 0.9637 19.549 
AM3 0.6767 5.990 0.9739 0.147 0.9387 21.660 
AM4 0.3501 6.688 0.9644 0.213 0.9384 24.936 
AM5 0.4486 4.465 0.9315 0.068 0.9662 16.544 
AM6 0.4750 6.018 0.9809 0.142 0.9574 22.239 
AM7 0.1628 4.631 0.8662 0.071 0.9209 17.536 
AM8 0.5190 5.094 0.9737 0.089 0.9648 18.781 
NOTE: R
2 
= Coefficient of determination, ko = Zero-order release constant, k1 = First-order 
release constant, kH = Highchi release constant. 
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Table 5.56 R2, n
 
& kKP values of the release profiles of each formulation made at 
formulation stage corresponding to Korsmeyer – peppas models 
Formulation 
Korsmeyer-peppas 
R2 kKP n 
AM1 0.9831 18.233 0.532 
AM2 0.9646 15.536 0.609 
AM3 0.9488 14.272 0.709 
AM4 0.9449 24.587 0.526 
AM5 0.9680 13.963 0.588 
AM6 0.9580 18.755 0.586 
AM7 0.9490 15.605 0.575 
AM8 0.9648 11.071 0.767 
 
 
3.4.5 Polynomial equation 
 
Table 5.57 Polynomial equation of the various dependent variables in AM 
Formulation 
 
Atorvastatin  
Mucoadhesive 
tablet 
kH of  
Higuchi 
Y1=26.113+0.123X1-0.370X2+0.060X3 
 +0.087X40.132X5-0.764X6-1.115X7 
‘n’ Of  
Korse-Peppas 
0.725-0.0076X1-0.007X2+0.00024X3 
-0.001X4-0.006X5+0.034X6+0.006X7 
log(K)  
of Kors-Peppas- 
Y1=-0.23065-0.00184X1+0.00650X2-
0.00049X3-0.00179X4-0.00361X5 
+0.01617X6 +0.01655X7 
k1 of 
 1st order 
Y1=-0.231-0.002X1+0.006X2-0.00049X3 
-0.002X4-0.004X5+0.016X6+0.017X7 
 
Chapter-5  Result 
Dept. of Pharmaceutical Science Saurashtra University Rajkot, Gujarat. 164 
k0 of  
 zero order 
Y1=7.078+0.027X1-0.105X2+0.020X3 
+0.024X4+0.038X5-0.205X6-0.295X7 
R2 of zero order Y1=0.825-0.014X1-0.011X2+0.008X3 
-0.001X4+0.004X5-0.013X6-0.019X7 
Mucoadhesive 
strength 
Y1=14.4+0.022X1+0.293X2+0.189X3 
+0.061X4+0.022X5-0.538X6-0.175X7 
 
 
 
3.4.6 Stability studies:  
Table 5.58 Stability data of optimized AM1 formulation stored at 45 ºC / 75% RH 
 
 
Note: PA- Physical appearance, DT- Disintegration time, % DC- Percent Drug Content.  %CDR- 
Percent cumulative drug Release. ++: same as initial, TFT- Total Floating Time 
 
 
 
 
 
 
 
 
 
Sampling 
interval 
Optimized Formulation 
PA %DC %CDR at 24 
Hr. 
Mucoadhesion 
Time (Hr) 
Mucoadhesive 
Strength 
(gm) 
0 ++ 99.45 99.77 27 35.23 
1 Week ++ 99.39 99.23 27 33.67 
2  week ++ 99.5 98.45 27 34.59 
3 Week ++ 99.34 99.84 28 35.93 
4 week ++ 99.89 99.52 28 34.82 
2 month ++ 99.11 98.51 27 35.83 
3 month ++ 98.49 98.23 26 34.73 
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6. DISCUSSION 
Oral drug delivery system represents one of the frontier areas of controlled 
drug delivery system. Such a dosage form has major advantage of patient 
compliance. Gastroretentive drug delivery system belongs to oral controlled drug 
delivery system group, which are capable of retain in the stomach.. The release 
rate will be controlled depending upon the type and concentration of the polymer, 
which swells, leads to diffusion and erosion of the drug. 
The main objective of the present research work is to formulate a multi-
unit granular dosage form dispense, in the form of capsule, mucoadhesive 
floating tablet, Mucoadhesive tablet and high density tablet. It also aims at 
studying the effects of formulation variable on the release, floating properties, 
mucoadhesive properties, retention time of gastroretentive drug delivery system. 
To achieve the above objectives, various formulations were prepared by 
using data of trial batches, First line of Plackett-burman design. Simvastatin and 
Atorvastatin were identified and checked for purity by melting point, UV-Visible 
scanning and IR spectroscopy.  
The Preformulation study constitutes standardization of the analytical procedure 
for the estimation of the drug content from the formulations. Standard calibration 
curve of Simvastatin and Atorvastatin were prepared using 0.1 N HCl + 0.5% 
SLS and then this solution was treated with manganese dioxide 10mg/ml and the 
absorbance was noted for different concentration at 238 nm, 247 nm, 257 nm for 
simvastatin and 246 nm for atorvastatin. This method has good reproducibility, 
correlation between the concentration and the absorbance was found to be 
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0.9992, with slope = 0.0347 for simvastatin and correlation between the 
concentration and the absorbance was found to be 0.9993, with slope = 0.0338 
for atorvastatin. 
The same procedure was applied to the estimation of drug from the 
prepared gastroretentive dosage form. Docusate sodium was used in all the 
formulation of atorvastatin as stabilizing agent and BHA (Butylated 
hydroxyanisole) was used in all the formulation of simvastatin as anti oxidizing 
agent. 
The next step in the Preformulation study was the preparation and in vitro 
evaluation of the gastroretentive dosage form containing simvastatin and 
atorvastatin by considering the various formulation variables (such as drug to 
polymer ratio, and polymer to polymer ratio). 
Floating capsule of simvastatin and atorvastatin 
Initial trials were taken to check the floating characteristics, gel forming 
capacity, extent of swelling and buoyancy of different polymers like sodium 
starch glycolate, cross carmellose sodium, HPMC K4M, HPMC K100M. Trial 
batch was prepared by using HPMC K4M, cross carmellose sodium, Mg. Al. 
silicate (Veegum), MCC 101, HPC LH 11, Eudragit RS, with NaHCO3. These 
prepared formulations were evaluated mainly for percent weight variation, 
percent drug content, floating lag time and In vitro release pattern. At that time 
proper floating lag time with 45 to 50% CDR at 4 hrs of the formulation was 
obtained. 
After Preformulation study, the formulations of floating capsule containing 
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simvastatin/atorvastatin were done by taking into consideration the formulation 
variables like HPMC K4M, cross carmellose sodium, Mg. Al. silicate (Veegum), 
MCC 101, HPMC K100M, Eudragit RS, with NaHCO3 using “First line of Plackett-
burman design”. By applying this design eight formulations were prepared and 
parameters like weight variation, drug content floating lag time, Total floating time 
and in vitro drug release of prepared floating capsule were evaluated. 
The mechanism of release, followed by the above formulations was 
determined by finding the R2 value and release constant for each kinetic model 
viz. Zero-order, First-order, Higuchi, Korsmeyer-Peppas and diffusion coefficient 
of korsmeyer-peppas model corresponding to the release data of each 
formulation. For most of the simvastatin formulations the R2 value of First order 
and korsmeyer-peppas model is very near to 1 than the R2 values of other kinetic 
models.  Thus it can be inferred that the drug release follows First order and 
korsmeyer-peppas mechanism. The n values of Korsmeyer-Peppas model of all 
formulations are 0.569 to 0.789. It indicate the almost in most cases a non-
Fickian mechanism is dominant. Whereas in atorvastatin formulation R2 value of 
First order and korsmeyer-peppas model is very near to 1 than the R2 values of 
other kinetic models.  Thus it can be inferred that the drug release follows first 
order and korsmeyer-peppas mechanism. The n values of Korsmeyer-Peppas 
model of all formulations are 0.604 to 0.814. It indicate the almost in most cases 
a non-Fickian mechanism is dominant 
The linear model generated for ‘n’ value of Korsmeyer-Peppas was found to be 
insignificant with an F-value of 29.02 (p<0.05) and R2 value of 0.9864. From the 
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polynomial equation of simvastatin concluded that the polymer having the 
significant effect on the “n” value of Korsemeyer-Peppas constant (Y1) = 
0.621+0.0001X1-0.000878X2+0.022X3+0.002X4-0.004X5-0.00045X6+0.001X7. 
From the above equation conclude that HPMC K4M (X2), EUDRAGIT RS (X5) 
and HPMC K100M (X6) had negative effect so that we can conclude that 
polymers were responsible for the diffusion of drug and drug release is by 
swelling and erosion and polynomial equation of atorvastatin for ‘n’ value of 
Korsmeyer-Peppas was found to be significant with an F-value of 1.173 (p<0.05) 
and R2 value of 0.8756 concluded that the polymer having the significant effect 
on the “n” value of Korsemeyer-Peppas coefficient (Y1) = 0.688-0.002X1 
+0.00272X2 +0.015X3 +0.001X4-0.001X5-0.002X6-0.003X7 From the equation 
Cross Carmelose sodium (X1), EUDRAGIT RS (X5) and HPMC K100M (X6) had 
negative effect means the polymers were responsible for the diffusion of drug. 
From the eight formulation of simvastatin, the formulation number SC2 
was chosen as it had 71% release at 12 hr and near to 100% release at 24 hr, 
and total floating time (TFT) 25 hr, which gives the first order release kinetic. And 
from the eight formulation of Atorvastatin, the formulation number AC2 was 
chosen as it had 75.80% release at 12 hr and near to 98.2% release at 24 hr, 
and total floating time (TFT) 26 hr, which gives the first order release kinetic.  
The final optimized formulation were kept for stability study at 40ºC / 75% 
RH condition and after every week drug content and drug release were 
estimated. After 3 month of stability data there was no significant change in drug 
content and drug release. 
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            Carry out the animal studies for the above optimized formulation. The 
Total cholesterol was estimated in treated animal group. Animal study data 
shows the there was significant difference in control and formulation treated 
group but there was insignificant difference in pure drug and formulation treated 
group. 
Floating tablet of Simvastatin and Atorvastatin 
Initial trials were taken to check the floating characteristics, gel forming 
capacity, extent of swelling and buoyancy of different polymers like sodium 
starch glycolate, cross carmellose sodium, HPMC K4M, HPMC K100M. Trial 
batch was prepared by using HPMC K4M, HPC LH 11, and POLYOX 303, with 
NaHCO3. These prepared formulations were evaluated mainly for percent weight 
variation, percent drug content, floating lag time, total floating time (TFT) and In 
vitro release pattern.  
After Preformulation study, the formulations of floating tablet containing 
simvastatin/atorvastatin were done by taking into consideration the formulation 
variables like HPMC K4M, HPMC K100M, POLYOX 303, with NaHCO3 using 
“First line of Plackett-burman design”. By applying this design eight formulations 
were prepared and parameters like weight variation, drug content floating lag 
time, total floating time (TFT) and in vitro drug release of prepared floating 
capsule were evaluated. 
The mechanism of release, followed by the above formulations was 
determined by finding the R2 value and release constant for each kinetic model 
viz. Zero-order, First-order, Higuchi, Korsmeyer-Peppas and diffusion coefficient 
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of korsmeyer-peppas model corresponding to the release data of each 
formulation. For most of the simvastatin formulations the R2 value of First order 
and korsmeyer-peppas model is very near to 1 than the R2 values of other kinetic 
models. Thus, it can be inferred that the drug release follows first order and 
korsmeyer-peppas mechanism. The n values of Korsmeyer-Peppas model of all 
formulations are 0.660 to 1.052. It indicate the almost in most cases a non-
Fickian mechanism is dominant. Whereas in atorvastatin formulation R2 value of 
First order and korsmeyer-peppas model is very near to 1 than the R2 values of 
other kinetic models.  Thus it can be inferred that the drug release follows first 
order and korsmeyer-peppas mechanism. The ‘n’ values of Korsmeyer-Peppas 
model of all formulations are 0.687 to 1.143. It indicate the almost in most cases 
a non-Fickian mechanism is dominant. 
The linear model generated for floating lag time was found to be significant with 
an F-value of 1.325 (p<0.05) and R2 value of 0.7681. From the polynomial 
equation of floating lag time of simvastatin floating dosage form concluded that 
the polymer having the significant effect on the Floating lag time (Y1)=-
917.5+11.64X1+7.7X2-12.79X3+18.18X4-21.09X5-28.37X6-191.1X7, From the 
equation HPMC K100M (X1), HPMC K4M (X2), NaHCO3(X4) have positive effect 
on floating lag time, From this NaHCO3(X4) having the maximum effect on the 
Floating lag time and polynomial equation of atorvastatin floating lag time was 
found to be significant with an F-value of 1.81 (p<0.05) and R2 value of 0.8197 
and from the polynomial equation concluded that the polymer having the 
significant effect on the Floating lag time Y1=-732 + 9.62X1 + 6.40X2-
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13.64X3+13.5X4-12.81X5-10.75X6+128.5X7 From the equation HPMC K100M 
(X1), HPMC K4M (X2), NaHCO3(X4) have positive effect on floating lag time.  
From the eight formulation of simvastatin, the formulation number SF8 
was chosen as it has 100% release at 12 hr, Floating lag time 1 to 2 second, and 
total floating time (TFT) 24 hr, which gives the non-fickian drug release. And from 
the eight formulation of Atorvastatin, the formulation number AF1 was chosen as 
it had 83.50% release at 12 hr and near to 99.2% release at 24 hr, Floating lag 
time 78 to 85 second and total floating time (TFT) 26 hr, which gives the first 
order release kinetic.  
The final optimized formulation were kept for stability study at 40ºC / 75% 
RH condition and after every week drug content and drug release were 
estimated. After 3 month of stability data there was no significant change in drug 
content and drug release. 
In vivo study carried out on healthy volunteer, In vivo study showed that 
the optimized tablet formulation was retained in stomach for more than eight 
hours 
High density tablet of simvastatin and atorvastatin 
Initial trials were taken to check the density of tablet, gel forming capacity, 
extent of swelling. Trial batch was prepared by using HPMC K4M, HPMC 
K100M, barium sulphate, Titanium dioxide, POLYOX 303, POLYOX 301, Mg. Al. 
silicate (Veegum), Eudragit RS. These prepared formulations were evaluated 
mainly for percent weight variation, percent drug content and In vitro release 
pattern.  
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After Preformulation study, the formulations of High density tablet 
containing simvastatin/atorvastatin were done by taking into consideration the 
formulation variables like HPMC K4M, HPMC K100M, Titanium dioxide, 
POLYOX 303 using “First line of Plackett-burman design”. By applying this 
design eight formulations were prepared and parameters like weight variation, 
drug content, and in vitro drug release of prepared high density tablet were 
evaluated. 
The mechanism of release, followed by the above formulations was determined 
by finding the R2 value and release constant for each kinetic model viz. Zero-
order, First-order, Higuchi, Korsmeyer-Peppas and diffusion coefficient of 
korsmeyer-peppas model corresponding to the release data of each formulation. 
For most of the simvastatin formulations the R2 value of First order is very near to 
1 than the R2 values of other kinetic models. Thus it can be inferred that the drug 
release follows first order mechanism. The n values of Korsmeyer-Peppas model 
of all formulations are 0.494 to 0.743. It indicate the almost in most cases a non-
Fickian mechanism is dominant. Whereas in atorvastatin formulation R2 value of 
First order and korsmeyer-peppas model is very near to 1 than the R2 values of 
other kinetic models.  Thus it can be inferred that the drug release follows first 
order and korsmeyer-peppas mechanism. The n values of Korsmeyer-Peppas 
model of all formulations are 0.768 to 1.228. It indicate the almost in most cases 
a non-Fickian mechanism is dominant.  
The linear model generated for ‘n’ value of Korsmeyer-Peppas was found to be 
insignificant with an F-value of 88.04 (p<0.05) and R2 value of 0.9954. From the 
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polynomial equation of simvastatin concluded that the polymer having the 
significant effect on the ‘n’ value of Korsmeyer-Peppas constant (Y1) = 1.238-
0.005X1-0.002X2-0.016X3-0.006X4-0.004X5+0.004X6+0.006X7. From the 
equation HPMC K100M (X1), HPMC K4M (X2), POLYOX 303 (X3) and Titanium 
dioxide (X4) had negative effect so that we can conclude that polymers were 
responsible for the diffusion of drug and drug release is by swelling and erosion, 
PVP (X5) have insignificant effect on drug release and polynomial equation of 
atorvastatin for ‘n’ value of Korsmeyer-Peppas was found to be significant with 
an F-value of 2.95 (p<0.05) and R2 value of 0.8807 concluded that the polymer 
having the significant effect on the ‘n’ value of Korsemeyer-Peppas coefficient 
(Y1) = 0.380+0.003X1+0.002X2+0.038X3-0.008X4+0.018X5-0.040X6 +0.077X7. 
From the equation HPMC K100M (X1), HPMC K4M (X2), POLYOX 303 (X3) and 
Titanium dioxide (X4) all the term have insignificant value. 
From the eight formulation of simvastatin, the formulation number SH7 
was chosen as it has 70% release at 12 hr, near to 100% release at 24 hr which 
gives the first order release kinetic and from the eight formulation of Atorvastatin, 
the formulation number AH1 was chosen as it had 44.50% release at 12 hr and 
near to 89.2% release at 24 hr, which gives the first order release kinetic.  
The final optimized formulation were kept for stability study at 40ºC / 75% RH 
condition and after every week drug content and drug release were estimated. 
After 3 month of stability data there was no significant change in drug content 
and drug release.  
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Mucoadhesive tablet of simvastatin and atorvastatin 
Initial trials were taken to check the mucoadhesion strength, gel forming 
capacity, extent of swelling different polymers like HPMC K4M, HPMC K100M, 
POLYOX 303, POLYOX 301, Xanthum gum, Gaur gum, and Carbopol 934P 
based on Mucoadhesion strength trial batches were prepared. Trial batch was 
prepared by using HPMC K4M, HPMC K100M, POLYOX 303, and POLYOX 301. 
These prepared formulations were evaluated mainly for percent weight variation, 
percent drug content, Mucoadhesion strength, Mucoadhesion time and In vitro 
release pattern. 
After Preformulation study, the formulations of Mucoadhesive tablet 
containing simvastatin/atorvastatin were done by taking into consideration the 
formulation variables like, HPMC K100M, POLYOX 303, Carbopol 934P and 
Guar Gum, using “First line of Plackett-burman design”. By applying this design 
eight formulations were prepared and parameters like weight variation, percent 
drug content, Mucoadhesion strength, Mucoadhesion time and In vitro release 
pattern of prepared Mucoadhesive tablet were evaluated. 
 The mechanism of release, followed by the above formulations was 
determined by finding the R2 value for each kinetic model viz. Zero-order, First-
order, Higuchi and Korsmeyer-Peppas corresponding to the release data of each 
formulation. For most of the simvastatin formulations the R2 value of First order 
and korsmeyer-peppas is very near to 1 than the R2 values of other kinetic 
models. Thus it can be inferred that the drug release follows first order 
mechanism. The n values of Korsmeyer-Peppas model of all formulations are 
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0.501 to 0.810. It indicate the almost in most cases a non-Fickian mechanism is 
dominant.  
 Whereas in atorvastatin formulation R2 value of First order and korsmeyer-
peppas model is very near to 1 than the R2 values of other kinetic models.  Thus 
it can be inferred that the drug release follows first order and korsmeyer-peppas 
mechanism. The n values of Korsmeyer-Peppas model of all formulations are 
0.526 to 0.767. It indicate the almost in most cases a non-Fickian mechanism is 
dominant.  
The in-vitro mucoadhesion test showed that the mucoadhesion of tablet of 
all the batches of the plackett burman design, were good enough to adhere to 
gastric mucosa. The linear model generated for mucoadhesion strength was 
found to be significant with an F-value of 5.738 (p<0.05) and R2 value of 0.9348: 
for Simvastatin dosage form Mucoadhesion strength (SIM) = 15.5+0.017X1 
+0.275X2+0.188X3+0.063X4+0.031X5-0.625X6-0.250X7. The linear model 
generated for mucoadhesion strength was found to be significant with an F-value 
of 8.242 (p<0.05) and R2 value of 0.9537: for Atorvastatin dosage form, 
Mucoadhesion strength (ATS) = 14.4 +0.022X1 +0.293X2 +0.189X3+ 0.061X4 
+0.022X5-0.538X6-0.175X7.  
It can be concluded from the above equation that HPMC K4M (X1), POLYOX 
303 (X2), Carbopol 934P (X3), Guar Gum (X4), exhibited positive effect on 
Mucoadhesion strength on increasing the concentration of POLYOX and 
CARBOPOL 934P. In the above polynomial equation showed that the maximum 
mucoadhesion was achieved by the POLYOX 303.  From the results, it can be 
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concluded that some variables have to be minimized and some variables have to 
maximize to have desirable responses. 
From the eight formulation of simvastatin, the formulation number SM5 
was chosen as it has 68.6% release at 12 hr, near to 100% release at 24 hr, 
good mucoadhesive strength and good mucoadhesion time which gives the first 
order release kinetic and from the eight formulation of Atorvastatin, the 
formulation number AM5 was chosen as it had 59.7% release at 12 hr and near 
to 98.3% release at 24 hr, High mucoadhesive strength and high mucoadhesion 
time, which gives the first order release kinetic.  
The final optimized formulation were kept for stability study at 40ºC / 75% 
RH condition and after every week drug content and drug release were 
estimated. After 3 month of stability data there was no significant change in drug 
content and drug release. 
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  7. CONCLUSION 
The main aim the present dissertation was to minimize the liver extraction 
ratio by controlling the release of drug from the dosage form. Thus 
gastroretentive dosage form was formulated to achieve the above aim. These 
systems proved to give better efficacy by minimizing extraction ratio. 
Thus from the data obtained, it can be concluded that:  
 Gastroretentive dosage form of an antihyperlipidemic drug 
simvastatin/atorvastatin formulated as an approach to increase gastric 
residence time and thereby minimizing hepatic extraction ratio. 
 Among the polymers used to improve the gastric residence, cellulose 
polymers HPMC K4M, HPMC K100M, showed better control over drug 
release, and POLYOX 303, Carbopol 934P showed good control on 
mucoadhesive strength.  
 Formulated capsules and tablets gave satisfactory results for various 
physicochemical evaluation for capsules like Weight variation, Floating 
lag time, Content uniformity, Total floating time, Mucoadhesion time, 
mucoadhesive strength and in vitro drug release. 
 Formulated gastroretentive dosage form best fitted to Korsmeyer-
peppas and First-order model rate kinetics.  
 Further it is concluded that, by the application of optimization 
technique,  
Optimized formulation can be obtained with minimum expenditure of 
time and money. 
 In vivo study showed that optimized tablet and capsule formulation 
were retained in stomach for more than eight hours.  
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 Thus the objective of the work of formulating a gastroretentive dosage 
form of Simvastatin and atorvastatin to minimize hepatic extraction has 
been achieved with success.  
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8. SUMMARY 
In the present study Gastroretentive delivery systems of 
simvastatin/atorvastatin has been successfully developed in the form of 
Hydrodynamically Balanced Tablet, Mucoadhesive Tablet, High Density 
Tablet and Hydrodynamically Balanced capsule to improve local action.  
Initial trials were for checking the effect of various ingredients on the 
floating, mucoadhesive characteristics of the dosage form. 
First line of Plackett-burman design is an experimental design 
technique, by which the factors involved and their relative importance can be 
assessed. The tablets and capsule were formulated using different grades of 
polymers (HPMC K4M, HPMC K100M, Cross carmellose sod., Sod Starch 
glycolate, MCC 101, Mg. Al. silicate, Eudragit RS) and effervescing agent 
(NaHCO3), POLYOX 303, carbopol 934P, Guar Gum, for mucoadhesive 
polymer and titanium dioxide for the high density material. 
The evaluation parameters like content uniformity were within the limits 
for various batches formulated. Another most important parameter like in vitro 
drug release was also performed. Formulations subjected to curve fitting 
analysis showed to best fit Korsmeyer-peppas and first order equation. 
Optimized formulations were obtained using constraints on drug 
release at 12 hr (% CDR), at 24 hr (%CDR), Floating lag time, total floating 
time, Mucoadhesive strength and ‘n’ of korsmeyer-peppas coefficient. 
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The optimized formulations were evaluated for the responses. The 
actual response values were in accordance with the predicted values. 
The final optimized formulation were kept for stability study at 40ºC / 
75% RH condition and after every week drug content and drug release were 
estimated. After 3 month of stability data there was no significant change in 
drug content and drug release. 
           Animal study was carried out for the above suitable optimized 
formulation. The Total cholesterol was estimated in treated animal group. 
Animal study data shows the there was significant difference in control and 
formulation treated group but there was no significant difference in pure drug 
and formulation treated group. 
 In vivo buoyancy time for tablet and capsule were evaluated by X-ray 
studies. In vivo study showed that the optimized tablet formulation was 
retained in stomach for more than eight hours. 
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